
<html lang="en"     class="pb-page"  data-request-id="cf1cf09e-18e4-4c1a-af38-dc24cece79d4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-20;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.7b00900;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma" /></meta><meta name="dc.Creator" content="Ken  Yamada" /></meta><meta name="dc.Creator" content="Margaret  Brousseau" /></meta><meta name="dc.Creator" content="Wataru  Honma" /></meta><meta name="dc.Creator" content="Akiko  Iimura" /></meta><meta name="dc.Creator" content="Hidetomo  Imase" /></meta><meta name="dc.Creator" content="Yuki  Iwaki" /></meta><meta name="dc.Creator" content="Toshio  Kawanami" /></meta><meta name="dc.Creator" content="Daniel  LaSala" /></meta><meta name="dc.Creator" content="Guiqing  Liang" /></meta><meta name="dc.Creator" content="Hironobu  Mitani" /></meta><meta name="dc.Creator" content="Kazuhiko  Nonomura" /></meta><meta name="dc.Creator" content="Osamu  Ohmori" /></meta><meta name="dc.Creator" content="Meihui  Pan" /></meta><meta name="dc.Creator" content="Dean F.  Rigel" /></meta><meta name="dc.Creator" content="Ichiro  Umemura" /></meta><meta name="dc.Creator" content="Kayo  Yasoshima" /></meta><meta name="dc.Creator" content="Guoming  Zhu" /></meta><meta name="dc.Creator" content="Muneto  Mogi" /></meta><meta name="dc.Description" content="Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inh..." /></meta><meta name="Description" content="Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inh..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 16, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00900" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00900" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00900" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00900" /></link>
        
    
    

<title>Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00900" /></meta><meta property="og:title" content="Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0013.jpeg" /></meta><meta property="og:description" content="Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound 16 (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase aldosterone secretion in human adrenocortical carcinoma cells nor in chronically cannulated rats. On the basis of its preclinical efficacy and safety profile, the compound was advanced into clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00900"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00900">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00900&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00900&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00900&amp;href=/doi/10.1021/acs.jmedchem.7b00900" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8466-8481</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00847" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00922" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ken++Yamada">Ken Yamada</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-7899-6192" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Margaret++Brousseau">Margaret Brousseau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wataru++Honma">Wataru Honma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akiko++Iimura">Akiko Iimura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hidetomo++Imase">Hidetomo Imase</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuki++Iwaki">Yuki Iwaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshio++Kawanami">Toshio Kawanami</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++LaSala">Daniel LaSala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guiqing++Liang">Guiqing Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hironobu++Mitani">Hironobu Mitani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kazuhiko++Nonomura">Kazuhiko Nonomura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Osamu++Ohmori">Osamu Ohmori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meihui++Pan">Meihui Pan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+F.++Rigel">Dean F. Rigel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>◆</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ichiro++Umemura">Ichiro Umemura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kayo++Yasoshima">Kayo Yasoshima</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guoming++Zhu">Guoming Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muneto++Mogi">Muneto Mogi</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Novartis Institutes for BioMedical Research, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey 07936-1080, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Novartis Institutes for BioMedical Research, Novartis Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div><div class="corresp-info"><strong>*</strong>For K.Y.: phone, 617-871-8826; E-mail, <a href="/cdn-cgi/l/email-protection#bad1dfd494c3dbd7dbdedbfad4d5ccdbc8ced3c994d9d5d7"><span class="__cf_email__" data-cfemail="5c37393272253d313d383d1c32332a3d2e28352f723f3331">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For M.M.: E-mail, <a href="/cdn-cgi/l/email-protection#a5c8d0cbc0d1ca8bc8cac2cce5cbcad3c4d7d1ccd68bc6cac8"><span class="__cf_email__" data-cfemail="81ecf4efe4f5eeafeceee6e8c1efeef7e0f3f5e8f2afe2eeec">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00900&amp;href=/doi/10.1021%2Facs.jmedchem.7b00900" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8466–8481</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 16, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 June 2017</li><li><span class="item_label"><b>Published</b> online</span>16 October 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 October 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00900" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00900</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8466%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKen%2BYamada%252C%2BMargaret%2BBrousseau%252C%2BWataru%2BHonma%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D20%26contentID%3Dacs.jmedchem.7b00900%26title%3DDiscovery%2Bof%2Ba%2BNovel%2BPiperidine-Based%2BInhibitor%2Bof%2BCholesteryl%2BEster%2BTransfer%2BProtein%2B%2528CETP%2529%2BThat%2BRetains%2BActivity%2Bin%2BHypertriglyceridemic%2BPlasma%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8481%26publicationDate%3DOctober%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00900"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1327</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00900" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ken&quot;,&quot;last_name&quot;:&quot;Yamada&quot;},{&quot;first_name&quot;:&quot;Margaret&quot;,&quot;last_name&quot;:&quot;Brousseau&quot;},{&quot;first_name&quot;:&quot;Wataru&quot;,&quot;last_name&quot;:&quot;Honma&quot;},{&quot;first_name&quot;:&quot;Akiko&quot;,&quot;last_name&quot;:&quot;Iimura&quot;},{&quot;first_name&quot;:&quot;Hidetomo&quot;,&quot;last_name&quot;:&quot;Imase&quot;},{&quot;first_name&quot;:&quot;Yuki&quot;,&quot;last_name&quot;:&quot;Iwaki&quot;},{&quot;first_name&quot;:&quot;Toshio&quot;,&quot;last_name&quot;:&quot;Kawanami&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;LaSala&quot;},{&quot;first_name&quot;:&quot;Guiqing&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Hironobu&quot;,&quot;last_name&quot;:&quot;Mitani&quot;},{&quot;first_name&quot;:&quot;Kazuhiko&quot;,&quot;last_name&quot;:&quot;Nonomura&quot;},{&quot;first_name&quot;:&quot;Osamu&quot;,&quot;last_name&quot;:&quot;Ohmori&quot;},{&quot;first_name&quot;:&quot;Meihui&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;F. Rigel&quot;},{&quot;first_name&quot;:&quot;Ichiro&quot;,&quot;last_name&quot;:&quot;Umemura&quot;},{&quot;first_name&quot;:&quot;Kayo&quot;,&quot;last_name&quot;:&quot;Yasoshima&quot;},{&quot;first_name&quot;:&quot;Guoming&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Muneto&quot;,&quot;last_name&quot;:&quot;Mogi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8466-8481&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00900&quot;},&quot;abstract&quot;:&quot;Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound 16 (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00900&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00900" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00900&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00900" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00900&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00900" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00900&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00900&amp;href=/doi/10.1021/acs.jmedchem.7b00900" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00900" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00900" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00900%26sid%3Dliteratum%253Aachs%26pmid%3D29035537%26genre%3Darticle%26aulast%3DYamada%26date%3D2017%26atitle%3DDiscovery%2Bof%2Ba%2BNovel%2BPiperidine-Based%2BInhibitor%2Bof%2BCholesteryl%2BEster%2BTransfer%2BProtein%2B%2528CETP%2529%2BThat%2BRetains%2BActivity%2Bin%2BHypertriglyceridemic%2BPlasma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D20%26spage%3D8466%26epage%3D8481%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291719" title="Redox reactions">Redox reactions</a>,</li><li><a href="/action/doSearch?ConceptID=292224" title="Serum">Serum</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/jmcmar.2017.60.issue-20/20171026/jmcmar.2017.60.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound <b>16</b> (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase aldosterone secretion in human adrenocortical carcinoma cells nor in chronically cannulated rats. On the basis of its preclinical efficacy and safety profile, the compound was advanced into clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Coronary heart disease (CHD) is the leading cause of mortality in the industrialized world. It has long been recognized that plasma low density lipoprotein (LDL) cholesterol levels directly correlate with CHD risk. Pharmacological reduction of LDL cholesterol via 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) reduces CHD risk by approximately 30%. However, considerable residual CHD risk remains.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Several epidemiological studies have also shown that plasma high density lipoprotein (HDL) cholesterol levels inversely correlate with CHD risk although the clinical benefit of increased HDL cholesterol has yet to be demonstrated.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a></div><div class="NLM_p">Cholesteryl ester transfer protein (CETP) is a 74 kD circulating glycoprotein secreted mainly by the liver. CETP mediates the exchange of cholesteryl ester and triglyceride (TG) between plasma lipoproteins, including LDL, very low density lipoprotein (VLDL), and HDL.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> CETP activity has been correlated with CHD risk in several epidemiological studies.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Moreover, CETP polymorphisms that are associated with reduced CETP activity are associated with reduced CHD risk.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a></div><div class="NLM_p">Owing to the promise of its therapeutic potential, multiple CETP inhibitors have been evaluated in clinical trials. Three CETP inhibitors torcetrapib, dalcetrapib, and evacetrapib, have failed in phase 3 cardiovascular outcome trials. In 2006, development of torcetrapib was abruptly terminated based on increased cardiac events and mortality observed in the treatment group of the ILLUMINATE trial.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is now generally accepted that the increased mortality associated with torcetrapib was due to adverse off-target effects, including increased blood pressure and corticosteroid concentrations.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8-11)</a> In contrast, dalcetrapib, which has modest effects on HDL and LDL cholesterol levels, was terminated due to futility.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The ACCELERATE trial for evacetrapib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> was also terminated upon futility analysis despite robust increases in HDL cholesterol and reductions in LDL cholesterol. The last of these trials REVEAL (anacetrapib) was expected to provide the best evidence (i.e., >30000 patients, 5 year follow-up) as to the relevance of pharmacological CETP inhibition for CHD risk reduction.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> It was very recently reported that anacetrapib reduces CHD risk by 9%, while overall mortality was not affected.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The reduction in CHD risk is consistent with the benefit predicted from a 17% reduction in LDL cholesterol, which suggests a limited role of increased HDL, if any, in CHD risk reduction.</div><div class="NLM_p">In our efforts to identify a best-in-class CETP inhibitor, we noted that most clinical CETP inhibitors suffer from high lipophilicity (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), arguably owing to the nature of the binding sites that accommodate highly lipophilic substrates cholesteryl ester (CE) and TG.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The most striking example is anacetrapib, with cLogD<sub>pH7.4</sub> (abbreviated hereafter as cLogD for brevity) of 9.2, which has high distribution to adipose tissue and an exceptionally long terminal elimination half-life in humans.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As for the pressor effects and corticosteroid effects associated with torcetrapib, we hypothesized that structural deviation from the tetrahydroquinoline core that has been associated with the aldosterone risk<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> should mitigate these off-target liabilities. Thus, we set out to identify a structurally distinct, novel CETP inhibitor scaffold with reduced lipophilicity and without the off-target liabilities of torcetrapib.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and cLogD<sub>pH7.4</sub> of CETP inhibitors that have reached phase 3 clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our search for a novel CETP inhibitor that is structurally distinct from torcetrapib, we explored a number of simpler scaffolds to understand the most essential features of various CETP inhibitors known at the time. Among many prototypes prepared, we identified <b>1</b> as a hit (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Although weak in potency (70% inhibition at 100 μM compound concentration), we were intrigued by the unique piperidine scaffold of <b>1</b>, presenting a relatively simple and modular structure with high sp<sup>3</sup> content, which also seemed amenable to an efficient structure–activity relationship (SAR) exploration.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Initial optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We initially explored the synthetically accessible 6-position of the piperidine. Fortuitously, the mere introduction of an ethyl group at this position to give compound <b>2</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) resulted in dramatically improved CETP inhibition, with half-maximum inhibitory concentration (IC<sub>50</sub>) of 1300 nM in human plasma. Further improvement was made through introduction of a benzyl group in place of one of the ethyl groups to give compound <b>3</b> (IC<sub>50</sub> 771 nM). Another boost in potency was achieved via replacement of the methyl carbamate with a pyrimidine to give compound <b>4</b> (IC<sub>50</sub> 160 nM). The active enantiomer (eutomer) of racemic <b>4</b> was determined to be <b>5</b>, whose absolute stereochemistry was confirmed by single compound X-ray crystallography to be 2<i>S</i>,4<i>S</i>,6<i>R</i> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">Figure 3</a>). As expected, compound <b>5</b> was approximately 2-fold more potent than the racemate <b>4</b>, while the inactive enantiomer (distomer) showed no CETP inhibition.</div><div class="NLM_p">Although potent, compound <b>4</b> is highly lipophilic, with a cLogD value exceeding that of anacetrapib (9.7 vs 9.2). Thus, the next phase of our optimization was focused on reducing lipophilicity while maintaining or improving potency, using racemic <b>4</b> as the lead (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). While many attempts were made to replace the bis-trifluoromethyl groups on the <i>N</i>-benzyl substituent, they all resulted in substantial loss in potency, as exemplified by the methoxy group in compound <b>6</b>. The only exception was chlorine (compound <b>7</b>, IC<sub>50</sub> 240 nM), which offered minimal improvement in lipophilicity. Exploration of the piperidine nitrogen capping group was also accompanied by reduced potency, as seen with ethyl urea <b>8</b> and <i>n</i>-butyl amide <b>9</b>. Isopropyl carbamate <b>10</b> (IC<sub>50</sub> 200 nM) was equipotent but, again, with minimal improvement in lipophilicity. The only point of SAR that showed concomitant improvement in potency and reduced lipophilicity was at the 5-position of the pyrimidine. Both 5-methoxypyrimidine compound <b>11</b> and 5-morpholinopyrimidine compound <b>12</b> were potent and slightly less lipophilic (cLogD 9.4 and 9.0, respectively) than compound <b>4</b> (cLogD 9.7).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR of the pyrimidine analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While we did not explicitly use the parameter of lipophilic efficiency (LipE = pIC<sub>50</sub> – cLogP)<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> at the time of our research, it provides a parameter that, in retrospect, illustrates a main aspect of our compound optimization. Because cLogP does not take ionization into account and overestimates the partitioning of ionized molecules to the octanol phase,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> we calculated a modified LipE based on cLogD at pH 7.4 instead of cLogP and refer to the values as LipE<sub>cLogD</sub>. By this analysis, compound <b>4</b> has a relatively poor LipE<sub>cLogD</sub> value of −2.9 and none of the transformations tested in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> resulted in substantial improvement in lipophilic efficiency, perhaps with the marginal exception of the <i>n</i>-butyl amide <b>9</b>. It was only in the final optimization that the issue of lipophilic efficiency was addressed, which indeed resulted in improved pharmacokinetic profiles, as described below.</div><div class="NLM_p">Compound <b>13</b>, the active enantiomer of racemic compound <b>12</b>, showed robust inhibition of CETP activity (IC<sub>50</sub> 60 nM) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). However, pharmacokinetic (PK) studies in Sprague–Dawley (SD) rats showed that compound <b>13</b> had very poor oral availability (3%). Reasoning that we needed a less lipophilic start point, we turned our attention back to the symmetric 2,6-diethylpiperidine compound <b>2</b>, which showed only marginally weaker CETP inhibition than the substantially more lipophilic 2-benzyl-6-ethylpiperidine analogue <b>3</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). We therefore made the 2,6-diethyl analogue of compound <b>13</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Gratifyingly, compound <b>14</b> retained potent inhibition of CETP (IC<sub>50</sub> 60 nM), while for the first time substantially improving lipophilic efficiency relative to 2-benzyl-6-ethylpiperidines such as compound <b>13</b> (LipE<sub>cLogD</sub> −0.3 vs −1.8). In addition, compound <b>14</b> presented a symmetric, achiral molecule, eliminating the need for chiral resolution or asymmetric synthesis. Compound <b>14</b> showed a much improved PK profile in SD rats when dosed at 1 mg/kg iv and 3 mg/kg po, with an area under the curve (AUC) of 2750 nM·h and oral availability of 35%. However, compound <b>14</b> was an inhibitor of CYP3A4 (2.2 μM) and CYP2C9 (6.6 μM), thereby suggesting the risk of drug–drug interaction. This is a particular concern as a CETP inhibitor would likely be coadministered with a statin (i.e., current standard-of-care), many of which are metabolized primarily by either CYP3A4 or CYP2C9.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Final optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As CYP enzymes often have affinity for lipophilic xenobiotics,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> we hypothesized that further reduction in lipophilicity by introduction of a carboxylic acid motif might mitigate this liability. Among several carboxylic acid bearing analogues prepared, we were gratified to find that compound <b>15</b> retained good CETP inhibition (IC<sub>50</sub> 150 nM) and showed a much improved CYP inhibition profile compared to compound <b>14</b> (CYP3A4 midazolam 25 vs 2.2 μM, CYP2C9 > 50 vs 6.6 μM). In addition, the introduction of a carboxylic acid resulted in a dramatically improved rat pharmacokinetic profile with reduced clearance (0.09 L/h/kg), volume of distribution (0.67 L/kg), and increased exposure (AUC 28,500 nM·h) from a 3 mg/kg po dose.</div><div class="NLM_p">Lastly, we screened a variety of capping groups for the pyrimidine, as we were concerned with the potential generation of reactive metabolites from the morpholine motif and wanted a further boost in potency. We found that the methylpyrazole derivative, (1<i>r</i>,4<i>r</i>)-4-(((2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic acid <b>16</b> (TAP311),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> offered the best balance of CETP inhibition (IC<sub>50</sub> 62 nM), selectivity (>170-fold vs CYPs), lipophilicity (cLogD 4.9), and rat pharmacokinetic profile (CL 0.09 L/h/kg, <i>V</i><sub>d</sub> 0.57 L/kg, AUC 27200 nM·h, <i>F</i> 43%) from 1 mg/kg iv and 3 mg/kg po doses. The compound also had the best lipophilic efficiency (LipE<sub>cLogD</sub> 2.4) among all compounds described herein. The protein binding of compound <b>16</b> was determined to be 99.4% in human plasma.</div><div class="NLM_p">The improvement in the pharmacokinetic profile with carboxylic acid bearing carbamates was generally consistent across many analogues. It should be noted that all compounds were tested as an amorphous form and dosed as a simple supension in 0.5% methylcellulose, including compound <b>16</b>. The high bioavailability observed with these compounds makes a sharp contrast to other CETP inhibitors such as torcetrapib and anacetrapib, which in our hands showed bioavailability of approximately 8–9% in the same suspension formulation.</div><div class="NLM_p">Experimental assessment of octanol–water distribution at pH 7.6 revealed a significantly lower distribution coefficient (Log <i>D</i><sub>pH7.6</sub> 5.2) for <b>16</b> compared to the neutral CETP inhibitors dalcetrapib, torcetrapib, and anacetrapib (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In fact, for neutral CETP inhibitors, an accurate experimental log <i>D</i> value could not be determined because compound concentrations in the aqueous phase were below the detection limit in our protocol. On the other hand, the calculated cLogD<sub>pH7.4</sub> for carboxylic acid bearing evacetrapib and <b>16</b> closely matched their experimental Log <i>D</i><sub>pH7.6</sub> values.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Measured Log <i>D</i><sub>pH7.6</sub>, cLogD<sub>pH7.4</sub>, CETP Plasma IC<sub>50</sub>, and LipE<sub>cLogD</sub> of Clinical CETP Inhibitors and Compound <b>16</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">dalcetrapib</th><th class="colsep0 rowsep0" align="center">torcetrapib</th><th class="colsep0 rowsep0" align="center">anacetrapib</th><th class="colsep0 rowsep0" align="center">evacetrapib</th><th class="colsep0 rowsep0" align="center">compd <b>16</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i><sub>pH7.6</sub></td><td class="colsep0 rowsep0" align="center">>6.0<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>5.9<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">5.7</td><td class="colsep0 rowsep0" align="center">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogD<sub>pH7.4</sub></td><td class="colsep0 rowsep0" align="center">7.2</td><td class="colsep0 rowsep0" align="center">7.6</td><td class="colsep0 rowsep0" align="center">9.2</td><td class="colsep0 rowsep0" align="center">5.2</td><td class="colsep0 rowsep0" align="center">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CETP plasma IC<sub>50</sub></td><td class="colsep0 rowsep0" align="center">4100 nM</td><td class="colsep0 rowsep0" align="center">18 nM</td><td class="colsep0 rowsep0" align="center">18 nM</td><td class="colsep0 rowsep0" align="center">110 nM</td><td class="colsep0 rowsep0" align="center">62 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LipE<sub>cLogD</sub></td><td class="colsep0 rowsep0" align="center">–1.7</td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="center">–1.5</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">2.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Concentration in water phase below detection limit.</p></div></div></div><div class="NLM_p">When administered once daily for 2 weeks to chow-fed hamsters, compound <b>16</b> (0.3–10 mg/kg po) showed comparable exposure to anacetrapib at all doses and statistically significant decreases in CETP activity at all doses compared to vehicle, while anacetrapib showed statistically significant decreases in CETP activity at 3 and 10 mg/kg doses compared to vehicle (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,B). Furthermore, robust, dose-dependent increases in HDL cholesterol were observed for <b>16</b> and anacetrapib (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C), along with dose-dependent reductions in LDL cholesterol with maximum reductions of 41% and 33% for <b>16</b> and anacetrapib, respectively (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics and pharmacodynamics of anacetrapib and <b>16</b> in hamsters. Compound (0.3, 1, 3, and 10 mg/kg po) or vehicle (Veh) was dosed once a day for 14 days to hamsters fed a standard chow diet. Blood was withdrawn 24 h post last dose and analyzed for total compound concentrations (A), CETP inhibition (B), HDL-cholesterol levels (C), and LDL-cholesterol levels (D). Values are mean ± SEM of six animals. ** <i>P</i> < 0.01, significant versus the vehicle group (Dunnett’s multiple comparisons test following one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Consistent with a previous report,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> we observed markedly high adipose and adrenal tissue versus plasma drug concentration ratios in chow-fed hamsters treated once daily with anacetrapib (10 mg/kg po) for 14 days (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). In sharp contrast, hamsters treated with <b>16</b> (10 mg/kg po) for the same time period had substantially lower adipose and adrenal tissue versus plasma drug concentration ratios. Liver to plasma drug concentration ratios were similar for <b>16</b> and anacetrapib. These results suggest that, unlike anacetrapib, <b>16</b> does not preferentially distribute to adipose tissue. This could be an important differentiating factor from anacetrapib, which has been detected in the plasma of patients 2–4 years after cessation of dosing.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Others have also reported similar improvements in tissue distribution profile by reducing overall lipophilicity of the CETP inhibitors.<a onclick="showRef(event, 'ref24 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref26">(24, 26)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Distribution profiles of anacetrapib and compound <b>16</b> in various tissues of hamsters administered anacetrapib or compound <b>16</b>. Anacetrapib and compound <b>16</b> were dosed orally once each day for 14 days to hamsters fed a standard chow diet. Blood and tissues were collected 24 h after the final dose and analyzed for compound concentrations. Data represent mean total concentration ± SEM for seven animals per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next evaluated the efficacy of <b>16</b> and anacetrapib in vitro using serum samples from patients having a wide range of TG concentrations. With increasing TG content in this assay, anacetrapib lost efficacy, while <b>16</b> retained efficacy (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). This trend was recapitulated ex vivo when the compounds were dosed orally in hamsters treated with 4-(1,1,3,3-tetramethylbutyl)phenol polymer with formaldehyde and oxirane (Triton WR-1339),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> an inhibitor of lipoprotein lipase activity that results in elevated plasma TG levels.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The inhibitory effect of <b>16</b> on CETP activity in the plasma of the treated hamsters was largely maintained, while this was not the case for anacetrapib (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B). The retained efficacy of <b>16</b> in the setting of high TG is expected to be clinically relevant, as hypertriglyceridemia is observed in a significant portion of dyslipidemic patients. Overall, 31% of the adult US population has an elevated plasma TG level (≥150 mg/dL) and high (≥200 mg/dL) or very high (≥500 mg/dL) fasting TG levels are found in 16.2% and 1.1% of adults, respectively.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Combined with the fact that TG concentrations can increase by more than 100 mg/dL following a high-fat meal,<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> a substantial portion of patients taking a CETP inhibitor may have a TG level where the observed difference between <b>16</b> and anacetrapib may be relevant. Interestingly, anacetrapib showed a trend for greater CHD risk reduction in patients with higher TG concentrations despite a potential decrease in efficacy,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> suggesting that compound <b>16</b> has an opportunity to further impact this patient subpopulation.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of triglyceride level on efficacy of anacetrapib and <b>16</b>. (A) In vitro CETP activity IC<sub>50</sub> values of anacetrapib and <b>16</b> in serum pooled from donors with varying TG levels. Values are the mean of two replicates for each serum pool. (B) Ex vivo inhibition of plasma CETP activity by anacetrapib (Ana) and <b>16</b> dosed orally in hamsters treated with saline or Triton WR-1339 (Veh). Doses of Ana and <b>16</b> were 3 and 1.5 mg/kg, respectively. Plasma samples were collected 24 h post dose. Values are mean ± SEM of five animals. *<i>P</i> < 0.05, **<i>P</i> < 0.01, significant difference from each Veh group (Dunnett’s multiple comparisons test following one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given this observation, we hypothesized that the differential efficacy of <b>16</b> versus anacetrapib in the hypertriglyceridemic setting may be related to the compound distribution profile across different lipoprotein fractions, owing to the marked differences in their lipophilicity. Indeed, when the compounds were spiked into serum from human donors with normal TG levels (TG < 150 mg/dL), <b>16</b> was found predominantly in the HDL and lipoprotein deficient serum (LPDS) fractions (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A), whereas anacetrapib was more evenly distributed among HDL, LDL, and triglyceride rich lipoproteins (TRL) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A). In serum with higher TG content (300–500 and >750 mg/dL), <b>16</b> showed similar distribution among lipoprotein fractions (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B,C), while anacetrapib was predominantly found in TRL fractions (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B,C). Because CETP is mainly associated with HDL in the circulation, these observations corroborate well with the retained potency of <b>16</b> in hypertriglyceridemic plasma.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vitro distribution profile of compound <b>16</b> among serum lipoproteins when spiked into serum from healthy donors with normal (A), high (B), or very high (C) triglyceride levels. The extraction of compound <b>16</b> was done in duplicate for each sample. The absolute mass of <b>16</b> was calculated in each fraction and, as shown in the <i>Y</i> axis, was expressed relative to the total sum of <b>16</b> in all lipoprotein pools (mean ± SEM). One-way ANOVA was performed to compare the percent distribution of <b>16</b> among serum lipoproteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vitro distribution of anacetrapib among serum lipoproteins when spiked into serum from healthy donors with normal (A), high (B), or very high (C) triglyceride levels. Anacetrapib extraction was done in duplicate for each sample. The absolute mass of anacetrapib was calculated in each fraction and, as shown in the <i>Y</i> axis, was expressed relative to the total sum of anacetrapib in all lipoprotein pools (mean ± SEM). One-way ANOVA was performed to compare the percent distribution of anacetrapib among serum lipoproteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Lastly, given the pressor and corticosteroid effects of torcetrapib, we evaluated the effects of <b>16</b> and torcetrapib on aldosterone production in H295R cells (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">Figure 1</a>) and blood pressure and plasma aldosterone levels in chronically cannulated SD rats (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">Figure 2</a>). We observed a marked increase in aldosterone secretion upon treatment of H295R cells with torcetrapib, whereas increases in aldosterone were not observed with <b>16</b> or anacetrapib. In contrast to torcetrapib, <b>16</b> did not increase mean arterial pressure or plasma aldosterone levels in conscious, cannulated SD rats.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While our literature survey for the preparation of various 2,4- and 2,4,6-substituted piperidines revealed several possible synthetic routes, we opted for the sequential functionalization of acylated 4-methoxypyridine that provided a modular synthetic route for a rapid SAR exploration and compound optimization. Thus, a variety of 2,4,6-trisubstituted piperidines were synthesized by 1,4-addition of a Grignard reagent to the acylated or carbamoylated species of 4-methoxypyridine, followed by 1,4-addition of alkyl cuprates to the resultant dihydropiperidones <b>17b</b>,<b>c</b> to give 2,6-disubstituted piperidine-4-ones <b>18b</b>,<b>c</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> We found that, generally, the <i>cis</i>-addition of the cuprate was favored when R<sub>2</sub> was benzyloxy compared to <i>tert</i>-butoxy. Subsequent reductive amination gave the all-<i>cis</i> isomer as the major product. Capping the secondary amines <b>19a</b>–<b>c</b> with methyl chloroformate gave <b>1</b> and <b>2</b>, while further deprotection of <b>20</b> and capping with <i>tert</i>-butoxycarbonyl (BoC) group gave <b>3</b>.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PhOCOCl, EtMgBr, tetrahydrofuran, −40 °C; then <i>t</i>-BuOK (for <b>17b</b>) or BnOCOCl, BnMgBr (for <b>17c</b>); (b) BF<sub>3</sub>·Et<sub>2</sub>O, EtMgBr, CuI, tetrahydrofuran, −78 °C to rt; (c) 3,5-bis(trifluoromethyl)benzylamine, Ti(O<i>i</i>Pr)<sub>4</sub>, MeOH, then NaBH<sub>4</sub>, 0 °C to rt (<b>19a</b>), 3,5-bis(trifluoromethyl)benzylamine, NaBH(OAc)<sub>3</sub>, acetic acid, dichloroethane, 0 °C to rt (<b>19b</b>,<b>c</b>); (d) MeOCOCl, pyridine, 0 °C to rt (for <b>1</b>), or MeOCOCl, 4-dimethylaminopyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt (for <b>2</b>, <b>20</b>); (e) PdCl<sub>2</sub>, Et<sub>3</sub>SiH, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) Boc<sub>2</sub>O, 60 °C, no solvent.</p></p></figure><div class="NLM_p">Pyrimidine capped compounds in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> were accessed in a similar manner via ketone <b>18d</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). We initially investigated the SAR with racemic compounds as shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, resolving selected compounds of interest at the end such as with racemic <b>4</b> and <b>12</b> into eutomers <b>5</b> and <b>13</b>, respectively. Reductive amination of the ketone <b>18d</b> gave all-<i>cis</i> 2,4,6-trisubstituted piperidine <b>21</b>, which was deprotected to give <b>22</b>. Capping the primary amine of <b>22</b> with 5-bromo-2-chloropyrimidine gave <b>23</b>, followed by alkylation with 3,5-disubstituted benzyl bromide to give <b>4</b>, <b>6</b>–<b>7</b>. Deprotection of the Boc group to <b>24</b> was followed by acylation to give <b>8</b>–<b>10</b>. The bromopyrimidine <b>4</b> was converted to the methoxy analogue <b>11</b> and morpholinyl analogues <b>12</b> and <b>13</b> through copper and palladium catalyzed couplings, respectively.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BnNH<sub>2</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, toluene, reflux, NaBH<sub>4</sub>, MeOH, rt; (b) Pd/C, H<sub>2</sub>, EtOH, 55 °C; (c) <i>i</i>-Pr<sub>2</sub>NEt, DMF, 120 °C; (d) NaH, DMF, 0 °C to rt; (e) 4 N HCl in EtOAc, rt; (f) EtNCO, iPr<sub>2</sub>NEt, DMF, rt (for <b>8</b>), or <i>n</i>-PrCOCl, iPr<sub>2</sub>NEt, DMF, rt (for <b>9</b>), or iPrOCOCl, iPr<sub>2</sub>NEt, DMF, rt (for <b>10</b>); (g) NaOMe, CuI, DMF, 85 °C (for <b>11</b>), or Pd<sub>2</sub>(dba)<sub>3</sub>, (2-biphenyl)di<i>tert</i>-butylphosphine, NaOtBu, morpholine, toluene, 100 °C (for <b>12</b>); (h) chiral HPLC.</p></p></figure><div class="NLM_p">The compounds for final optimization (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) were prepared from the aforementioned ketone intermediate <b>18b</b> or the isopropyl analogue <b>18e</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The same sequence of transformation as in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> gave the all-<i>cis</i> intermediates <b>27a</b>,<b>b</b>, which were then elaborated into compounds <b>14</b> and <b>29a</b> through palladium catalyzed coupling with morpholine. In a similar manner, <b>29b</b> was prepared by palladium catalyzed coupling with the pinacol boronate of the methylpyrazole. Deprotection of the Boc group was followed by acylation with chloroformate <b>26</b>, which was prepared by esterification of the acid <b>25</b> followed by treatment with triphosgene and base to form the chloroformate. Finally, hydrolysis of the methyl ester gave <b>15</b> and <b>16</b>. The all-<i>cis</i> configuration of the piperidine substituents of <b>16</b> was confirmed by single compound X-ray crystallography (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">Figure 4</a>).</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C to rt; (b) triphosgene, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) benzylamine, Ti(O-<i>i</i>-Pr)<sub>4,</sub> MeOH, rt, then NaBH<sub>4</sub>, 0 °C to rt; (d) Pd/C, H<sub>2</sub>, EtOH, 60 °C; (e) 2-chloro-5-bromopyrimidine, <i>i</i>-Pr<sub>2</sub>NEt, DMF, 120 °C; (f) 3,5-bis(trifluoromethyl)benzylamine, NaH, DMF, 0 °C to rt; (g) morpholine, Pd<sub>2</sub>(dba)<sub>3</sub>, (2-biphenyl)di-<i>tert</i>-butylphosphine, <i>t</i>-BuONa, toluene, 100 °C (<b>14</b> and <b>29a</b>), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME-H<sub>2</sub>O, 90 °C (<b>29b</b>); (h) 4 N HCl in EtOAc, rt, (i) <b>26</b>, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt; (j) NaOH, tetrahydrofuran–H<sub>2</sub>O, rt.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified <b>16</b> as a novel, piperidine-based CETP inhibitor with excellent pharmacokinetic and efficacy profiles. The compound has a substantially lower log <i>D</i><sub>pH6.8</sub> compared to CETP inhibitors that have entered phase 3 clinical trials to date. On the basis of our preclinical data package, we propose that the lower lipophilicity of compound <b>16</b> contributes to its lack of accumulation in adipose tissue and retained efficacy versus anacetrapib in the setting of high plasma triglycerides. Unlike torcetrapib, compound <b>16</b> does not increase blood pressure or plasma aldosterone levels in vivo. Taken together, our results indicate that compound <b>16</b> is a promising candidate for targeting residual cardiovascular disease risk. On the basis of its preclinical efficacy and safety profile, compound <b>16</b> was advanced into clinical trials.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Methods</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Software</h4><div class="NLM_p last"><a class="ref internalNav" href="#fig5" aria-label="Figures 5">Figures 5</a>–<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> were generated with and statistical analyses were performed using GraphPad Prism version 7.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Calculated Octanol–Water Distribution Coefficient</h4><div class="NLM_p last">Calculated cLogD at pH 7.4 was determined using the following approximation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/jm-2017-00900t_m001.gif" alt="" /></img></span>where cp<i>K</i><sub>a</sub> was determined using FOCUS software<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> with built-in MoKa algorithm.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Lipophilic Efficiency<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a></h4><div class="NLM_p last">LipE<sub>cLogD</sub> = p[CETP human plasma IC<sub>50</sub>] – cLogD<sub>pH7.4</sub>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> CETP IC<sub>50</sub> Determination in Human Plasma</h4><div class="NLM_p last">A pool of ethylenediaminetetraacetic acid (EDTA)–plasma from healthy male donors was obtained from New Drug Development Research Center, Inc. (Hokkaido, Japan). Human dyslipidemic serum (1 lot, lot no. N83376) was obtained from Uniglobe Research Co. (Reseda, CA). To evaluate the effect of compounds, 50 μL of human plasma (final 50% plasma), 35 μL of the assay buffer, and 1 μL of compound dissolved in dimethyl sulfoxide (DMSO, final 1%, Sigma, St. Louis, MO, catalogue no. D2650) were added to each well of a 96-well half-area black, flat bottom polystyrene NBS microplate (Corning, Corning, NY, catalogue no. 3686). The reaction (final volume of 100 μL) was started by the addition of 14 μL of donor solution diluted with the assay buffer. Fluorescence intensities (relative fluorescence unit, RFU) were measured every 30 min at 485 nm (excitation) and 535 nm (emission) for 120 min at 37 °C using ARVO SX+L (PerkinElmer, Wellesley, MA). CETP activity (RFU/min) was determined from the changes in fluorescence intensity from 30 to 90 min. The inhibitory activity of the compound was calculated as % inhibition of enzyme activity using 1 or 10 μM torcetrapib (as positive control) and DMSO as 100% and 0% inhibition, respectively. The IC<sub>50</sub> value of duplicate wells was obtained by logistic equation (<i>Y</i> = bottom + (top – bottom)/(1 + (<i>x</i>/IC<sub>50</sub>)̂Hill slope) using Origin software, version 7.5 SR3 (OriginLab Co., Northampton, MA).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Log <i>D</i> (pH 7.6) Determination</h4><div class="NLM_p">Phosphate buffered saline (pH 7.4) saturated with octanol and 1-octanol saturated with buffer were prepared prior to the start of the log <i>D</i> assay. Aliquots of 10 mM DMSO compound solution along with an internal reference compound were dispensed in triplicate in 96-well polypropylene 2 mL plates. The DMSO was removed using a GeneVac HT4X evaporator for approximately 1 h.</div><div class="NLM_p last">Dried samples were incubated with 300 μL of octanol and 300 μL of buffer and shaken for at least 4 h. Plates were centrifuged for 15 min at 4000 rpm to separate the octanol and buffer layers. Sample preparation and phase separation were automated using liquid handling workstations. Both octanol and buffer phases were quantified using a tandem mass spectrometer. Log <i>D</i> was derived from the ratio of compound peak area responses in each phase, adjusted to the internal standard peak areas. Log <i>P</i> was equivalent to log <i>D</i> when the compound was un-ionized at pH 7.4.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Statement on Animal Welfare</h4><div class="NLM_p last">All procedures were conducted in accordance with approved Novartis Animal Care and Use Committee protocols and the Guide for the Care and Use of Laboratory Animals.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Pharmacokinetic Studies</h4><div class="NLM_p last">The test article was administered intravenously (1 mg/mL/kg bolus, in <i>N</i>-methyl pyrrolidin-2-one/PEG 200) or orally (3 mg/5 mL/kg, suspended in 0.5% aqueous methylcellulose solution) to conscious 7-week old male Sprague–Dawley rats (Charles River, Yokohama, Japan). Blood samples were taken at various time points after administration. The samples were treated with methanol for protein precipitation, and the supernatants were analyzed by liquid chromatography followed by electrospray/tandem mass spectrometric detection. Pharmacokinetic variables were estimated using noncompartmental methods. Animals were fed a standard diet and had free access to tap water throughout the experiment. This work was conducted with the permission of the Novartis Tsukuba Research Institute Animal Welfare Committee (permission no.: AWCJ06054).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Measurement of Human Plasma Protein Binding</h4><div class="NLM_p last">Binding of compound <b>16</b> to human plasma proteins was determined by ultracentrifugation method. Approximately 0.5 mL of human plasma was prepared in Beckman ultracentrifuge tube for each sample after spiking with [<sup>14</sup>C]compound <b>16</b> at multiple concentrations (50–10000 ng/mL). The remaining samples were centrifuged for 3 h at 37 °C at 306000<i>g</i> using a Sorvall RCM120GX microultracentrifuge and 80K rotor. The centrifuge was allowed to stop without using the brake. Aliquots (0.05 mL) of the supernatant were carefully removed without disturbing the separate layers and then transferred to scintillation vials for radioactivity analysis. The fraction of drug bound to plasma proteins equals (<i>T</i><sub>t</sub> – <i>T</i><sub>s</sub>)/<i>T</i><sub>t</sub>, where <i>T</i><sub>t</sub> is the total radioactivity in the uncentrifuged sample and <i>T</i><sub>s</sub> is the radioactivity in the supernatant after ultracentrifugation.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Hamster Efficacy Study</h4><div class="NLM_p">Ten-week-old, male golden Syrian hamsters were purchased from Japan SLC Inc. (Shizuoka, Japan). Animals underwent a one-week acclimation period. Compounds were prepared in a 0.5% methyl cellulose (MC, methyl cellulose 400 cP, catalogue no. 138-05072, Wako Pure Chemical Industries, Osaka, Japan) suspension. Compound <b>16</b> (0.3, 1, 3, and 10 mg/kg), anacetrapib (0.3, 1, 3, and 10 mg/kg), or vehicle (10 mL/kg) was administrated once a day in the morning for 2 weeks by oral gavage. Then 24 h after administration of the last dose (16 h fast), whole blood samples were collected from the abdominal vein by venipuncture under isoflurane (Forane, Abbott Japan Co. Ltd., Tokyo, Japan) inhalant anesthesia. After centrifugation at 15000 rpm (rotor no. AF-2536A, Kubota Co., Tokyo, Japan) for 10 min at 4 °C, heparinized plasma (final concentration about 28.6 U/mL, heparin sodium injection “Ajinomoto”; Ajinomoto, Tokyo, Japan) or EDTA–plasma was prepared and stored at −80 °C until use. It should be noted that some animals in the 0.3 mg/kg anacetrapib group were mistakenly administered a dose of 1 mg/kg (one animal on day 5 and two animals on day 7). Because each of the three animals only received one incorrect dose during the two-week study period, we concluded that the results would not be significantly altered by this error. Therefore, all animals were included in the data analysis. This study was performed according to the approval of the Novartis Tsukuba Research Institute Animal Welfare Committee (permission no. AWCJ06077).</div><div class="NLM_p last">Lipoprotein cholesterol content in the hamster efficacy study was assessed using an HPLC-size exclusion chromatography system with an online enzymatic dual detection system for lipids. Plasma samples were diluted (5-fold) with saline after filtration (0.45 μm, Millipore Co, catalogue no. UFC30HV00) and injected into the HPLC system at a volume of 100 μL (as 20 μL of plasma), every 95 min, using an autosampler. Plasma lipoproteins were separated using a single Superose 6 column and filtered phosphate buffered saline (0.45 μm, Millipore Co., Bedford, MA, catalogue no. SJHVM4710; PBS, Dainippon Pharmaceutical, Osaka, Japan catalogue no. 28-103-05 FN) at a flow rate of 0.5 mL/min. Each enzymatic reagent was pumped at a flow rate of 0.25 mL/min. Both enzymatic reactions proceeded at 37 °C in a reactor coil (Teflon tube, 15 m × 0.4 mm id) in the column oven. The color developed after the enzyme reaction was measured at 580 nm, and the electric signal was monitored (every 0.5 s). A control pooled EDTA-plasma sample was used to standardize lipoprotein cholesterol levels. Cholesterol levels in control hamster plasma were measured manually (cholesterol E-test, catalogue no. 439-17501), and the level was 122 mg/dL. Lipoprotein cholesterol concentrations were calculated using chromatogram areas observed with control hamster plasma samples.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Drug Distribution among Serum Lipoprotein Fractions</h4><div class="NLM_p">Human serum samples were obtained from Uniglobe Research Corporation (Reseda, CA), Bioreclamation (Hicksville, NY) or from the in-house donor program at the Novartis Institute for BioMedical Research. Donors were not fasted before blood collection. Serum was isolated by centrifugation of samples at 2500 rpm for 20 min and stored at −80 °C until use. Three pools of human serum samples were prepared for this study. The mean TG concentration (mg/dL) of each pool were as follows: 122, 347, and 958, respectively, to represent normal, high, and very high levels. Once thawed, serum samples were gently mixed prior to incubation with compound. Two μL of each CETP inhibitor (<b>16</b>, anacetrapib) in dimethyl sulfoxide (2 mg/mL) were added to 4 mL of serum, mixed well, and incubated in a 37 °C water bath for 1 h.</div><div class="NLM_p">Lipoprotein fractions were isolated from serum by density gradient ultracentrifugation, according to Wasan et al.,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> with minor modifications. NaBr (0.36 g/mL) was added to serum containing 500 ng/mL of CETP inhibitor. Samples were mixed by gentle inversion to facilitate the dissolution of salt. Density gradient layers were carefully generated from the bottom of tube as follows: 3 mL serum/CETPi/NaBr (<i>d</i> = 1.28), 2.8 mL NaBr/H<sub>2</sub>O (<i>d</i> = 1.21), 2.8 mL NaBr/H<sub>2</sub>O (<i>d</i> = 1.063), and 2.8 mL NaBr/H<sub>2</sub>O (<i>d</i> = 1.006). Tubes were kept in an ice-bath before centrifugation for 18.5 h at 15 °C, using an SW41 Rotor in an L80 ultracentrifuge (Beckman Coulter, Brea, CA). A fraction recovery system (FRS, Beckman Coulter) was used to collect fractions (∼0.3 mL) from the bottom of each centrifuge tube. The density of fractions, relative to water, was measured to determine fractions for pooling. 2-Propanol was used to recover TRL adhering to the inner wall of the centrifuge tube. Fractions were pooled as follows: Lipoprotein-deficient serum (1.21 < <i>d</i> < 1.30), HDL (1.065<<i>d</i> ≤ 1.21), LDL (1.019<<i>d</i> ≤ 1.065), and TRL (<i>d</i> < 1.019).</div><div class="NLM_p last">For the measurement of lipoprotein drug concentrations, serum and LPDS were diluted 1:3 using saline. Duplicate 50 μL aliquots of undiluted TRL, LDL, or HDL and diluted serum or LPDS were transferred into a 96-well plate (catalogue no. 17P687, Thermo Fisher Scientific) for the determination of CETP inhibitor concentration by LC-MS/MS. All samples were frozen and stored at −20 °C freezer prior to use. Extraction of CETP inhibitor from lipoprotein pools was carried out using an acetonitrile protein precipitation method. A Freedom EVO 150 and a Freedom EVO (Tecan, San Jose, CA) were used in this procedure. Calibration standards, composed of a CETP inhibitor (0–10,000 ng/mL) in 50% acetonitrile, and quality control (QC) samples of a single concentration (50 ng/mL) were prepared. Then 25 μL of each calibration standard or QC or test sample were added to a 1 mL 96-well plate. Then 150 μL of acetonitrile with 50 ng/mL glyburide (ISTD) was added to each well. The mixture was vortexed vigorously, followed by centrifugation at ∼4000 rpm for 5 min. Next, 125 μL of supernatant/well was transferred to a new 1 mL 96-well plate, followed by the addition of 50 μL of water. For each mixed sample, a 10 μL aliquot was injected into the LC-MS/MS system.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Tissue Drug Exposure Analysis</h4><div class="NLM_p last">A ∼100 mg sample of each tissue type (adipose, adrenal, liver) was harvested and placed in a 1.5 mL microcentrifuge tube. All samples were flash frozen and placed at −80 °C for storage. Drug concentrations were determined by LC-MS/MS.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Triton WR-1339 Treated Hamster Study</h4><div class="NLM_p last">The effect of acute hypertriglyceridemia in vivo on the extent of CETP inhibition caused by anacetrapib and <b>16</b> were investigated. Compound or vehicle was administered once by gavage to hamsters fed a standard chow diet. Triton WR-1339 (100 mg/kg) or saline was injected intravenously 5 h after administration of compound. Plasma parameters were measured 3 h after injection of Triton WR-1339. Two doses for each inhibitor were selected: around 55–75% (lower dose) or 75–80% (higher dose) inhibition in CETP activity in the saline group. Plasma CETP activity ex vivo was determined as follows: 50 μL of hamster plasma (final 80% plasma) was mixed with 10 μL of donor solution diluted with assay buffer composed of 50 mM Tris-HCl (pH 7.4) containing 150 mM NaCl and 2 mM EDTA in a 96-well half-area black flat-bottom plate (catalogue no. 3686, Corning, Corning, NY). Fluorescence intensity was measured every 15 min at an excitation wavelength of 485 nm and an emission wavelength of 535 nm for 120 min at 37 °C using ARVO SX+L (PerkinElmer, Wellesley, MA). CETP activity (RFU/min) was defined as the change in fluorescence intensity from 30 to 90 min.</div></div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemical Syntheses</h3><div class="NLM_p">Unless otherwise specified, all solvents and reagents were obtained from commercial sources and used without further purification, including intermediates <b>17c</b>, <b>18a</b>, and <b>25</b>. All reactions were performed under nitrogen atmosphere unless otherwise noted. Normal-phase flash chromatography was performed using Merck silica gel 60 (230–400 mesh). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker DRX or a Bruker AV400 (400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C). Chemical shifts are reported in parts per million (ppm) downfield from tetramethylsilane (0.00 ppm) or residual peaks from the corresponding solvent as an internal standard and coupling constants (<i>J</i>) in Hz. Multiplicity abbreviation are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, app = apparent, br = broad. LC-MS analyses were performed on an HPLC system with a C18 column coupled to a single quad mass spectrometer with electrospray ionization (ESI). High resolution mass spectra were obtained with Acquity Xevo G2 QToF system with UPLC (Acquity UPLC BEH C18 column, 2–98% acetonitrile in water both with 0.1% formic acid) coupled to time-of-flight detection after electrospray ionization. Chemical purity of the compounds were assessed by LCMS and confirmed to have at least 95% purity by UV/ELSD, except compound <b>7</b>, which showed 90% purity by UV.</div><div id="sec5_1_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>rac</i>-<i>tert</i>-Butyl (2<i>R</i>,4<i>R</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethylpiperidine-1-carboxylate (<b>1</b>)</h4><div class="NLM_p last">To a mixture of <i>rac</i>-<i>tert</i>-butyl 2-ethyl-4-oxopiperidine-1-carboxylate (<b>18a</b>) (1 g, 4.4 mmol) and 3,5-bis(trifluoromethyl)benzylamine (technical grade ∼85%, 1.38 g, 4.84 mmol) in MeOH (7.5 mL) and 1,2-dichloroethane (7.5 mL) was added titanium tetraisopropoxide (∼0.15 mL) at rt under nitrogen. The reaction mixture was allowed to stir at the same temperature for 6 h and quenched with saturated aqueous NH<sub>4</sub>Cl. The organic products were extracted twice with EtOAc, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a crude oil (<b>19a</b>). The crude product was dissolved in pyridine (10 mL), and methyl chloroformate (2.0 g, 22 mmol) was added at 0 °C. The mixture was gradually warmed up to rt and stirred for 13.5 h. The reaction was quenched with 1 M aqueous HCl, and the products were extracted with EtOAc, washed with brine, dried, filtered, and concentrated to a crude product which was purified by silica gel column chromatography to afford <i>rac</i>-<i>tert</i>-butyl (2<i>R</i>,4<i>R</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethylpiperidine-1-carboxylate (<b>1</b>) (1.3 g, 58% in 2 steps). ESI-MS <i>m</i>/<i>z</i>: 513 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>2</b>)</h4><div class="NLM_p last">To a mixture of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>19b</b>) (20.8 mg, 0.043 mmol) and DMAP (10.6 mg, 0.086 mmol) in DCM (0.3 mL) was added methyl chloroformate (6.1 μL, 0.086 mmol) at rt under nitrogen. The mixture was stirred overnight and purified by preparative TLC (hexane/EtOAc = 2:1) to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>2</b>) (21.2 mg, 91%). ESI-MS <i>m</i>/<i>z</i>: 541 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-6-ethylpiperidine-1-carboxylate (<b>3</b>)</h4><div class="NLM_p">To a mixture of <i>rac-</i>benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-6-ethylpiperidine-1-carboxylate (<b>20</b>) (710 mg, 1.12 mmol) and PdCl<sub>2</sub> (39 mg, 0.22 mmol) in DCM (11 mL) were added Et<sub>3</sub>N (61.3 μL, 0.44 mmol) and Et<sub>3</sub>SiH (358 μL, 2.24 mmol) at rt under nitrogen. The mixture was allowed to stir for 11.5 h. Additional Et<sub>3</sub>SiH (1.4 mL, 8.76 mmol) was added portionwise over 4.5 h. After stirring for a further 3 h, the reaction mixture was concentrated and purified by silica gel column chromatography (DCM/MeOH/NH<sub>3</sub>(28% in H<sub>2</sub>O) = 300:10:1) to afford <i>rac</i>-methyl ((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-yl)(3,5-bis(trifluoromethyl)benzyl)carbamate (560 mg, 99%). ESI-MS <i>m</i>/<i>z</i>: 503 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A mixture of <i>rac</i>-methyl ((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-yl)(3,5-bis(trifluoromethyl)benzyl)carbamate (560 mg, 1.11 mmol) and Boc<sub>2</sub>O (909 mg, 4.17 mmol) was allowed to stir at 60 °C for 19 h. The mixture was cooled and purified by silica gel column chromatography (EtOAc/heptane = 6:94 to 60:40) to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-6-ethylpiperidine-1-carboxylate (<b>3</b>) (410 mg, 61%). MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i>: 603 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>4</b>)</h4><div class="NLM_p last">To a suspension of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>23</b>) (0.952 g, 2.00 mmol) in DMF (20 mL) was added NaH (60% dispersion in oil, 160 mg, 4.00 mmol) at 0 °C under nitrogen. The mixture was warmed up to rt and stirred for 20 min. To the mixture was added 3,5-bis(trifluoromethyl)benzyl bromide (921 mg, 3.00 mmol) at 0 °C. The reaction mixture was allowed to stir from 0 °C to rt for 4 h and then quenched with H<sub>2</sub>O. The products were extracted with EtOAc, washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The obtained residue was purified by silica gel column chromatography to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>4</b>) (962 mg, 68%). ESI-MS <i>m</i>/<i>z</i>: 701 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Chiral <i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>5</b>)</h4><div class="NLM_p"><i>rac-</i>Benzyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i>cis</i>-racemate) (<i><b>rac</b></i>-<b>18c</b>) (45 g) was purified by two consecutive chiral chromatography runs. The first elution with supercritical carbon dioxide with 5% 2-propanol (isocratic) in a Daicel Chiralcel OD-H column (30 mm × 250 mm) resulted in good separation of the enantiomers but with undesired <i>trans</i>-isomer which coeluted. The second elution with supercritical carbon dioxide with 5% 2-propanol (isocratic) with a Daicel Chiralpak AD-H (30 mm × 250 mm) gave diastereomerically pure enantiomers. The enantiomeric excess of the separated enantiomers were determined by chiral HPLC (Daicel Chiralpak AD-H 0.46 cm × 25 cm, <i>n</i>-heptane:EtOH = 80:20, 1 mL/min, 210 nM). <i>T</i><sub>r</sub> = 6.90 min (<i><b>pro-distomer</b></i>-<b>18c</b>, 98.3% ee); 8.53 min (<i><b>pro-eutomer</b></i>-<b>18c</b>, 95.9% ee).</div><div class="NLM_p last"><i><b>Pro-eutomer</b></i>-<b>18c</b> (absolute configuration unknown at this stage) was converted to compound <b>5</b> and <i><b>pro-distomer</b></i>-<b>18c</b> to its enantiomer using the same sequence of reactions as with racemic <b>4</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, conditions a, b, c, and d). Compound <b>5</b> was shown to be the active enantiomer by inhibition of CETP activity in human plasma. Compound <b>5</b> was then crystallized in tetrahydrofuran–methanol co-solvent and the absolute configuration was determined by X-ray crystallography (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">Figure 3</a>) to be 2<i>S</i>,4<i>S</i>,6<i>R</i>.</div></div><div id="sec5_1_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((5-bromopyrimidin-2-yl)(3-methoxy-5-(trifluoromethyl)benzyl)amino)-6-ethylpiperidine-1-carboxylate (<b>6</b>)</h4><div class="NLM_p last">Compound <b>6</b> was synthesized according to a procedure similar to that described for compound <b>4</b>, using 3-methoxy-5-(trifluoromethyl)benzyl bromide instead of 3,5-bis(trifluoromethyl)benzyl bromide. Yield: 16.4 mg (25%). ESI-MS <i>m</i>/<i>z</i>: 663 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((5-bromopyrimidin-2-yl)(3-chloro-5-(trifluoromethyl)benzyl)amino)-6-ethylpiperidine-1-carboxylate (<b>7</b>)</h4><div class="NLM_p last">Compound <b>7</b> was synthesized according to a procedure similar to that described for compound <b>4</b>, using 3-chloro-5-(trifluoromethyl)benzyl bromide instead of 3,5-bis(trifluoromethyl)benzyl bromide. Yield: 49 mg (73%). ESI-MS <i>m</i>/<i>z</i>: 667 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>rac</i>-(2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-<i>N</i>,6-diethylpiperidine-1-carboxamide (<b>8</b>)</h4><div class="NLM_p last">To a mixture of <i>rac</i>-<i>N</i>-((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-yl)-<i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-5-bromopyrimidin-2-amine hydrochloride (<b>24</b>) (50 mg, 0.078 mmol) in DMF (1 mL) were added ethyl isocyanate (13.7 μL, 0.157 mmol) and DIPEA (41 μL, 0.235 mmol) at rt. The mixture was stirred at rt for 18 h, added to saturated aqueous NaHCO<sub>3</sub>, and extracted with dichloromethane. The combined organic layers were passed through a phase separator and concentrated in vacuo. The residue was purified by preparative HPLC to give <i>rac</i>-(2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-<i>N</i>,6-diethylpiperidine-1-carboxamide (<b>8</b>) (20.5 mg, 39%). ESI-MS <i>m</i>/<i>z</i>: 672 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>rac</i>-1-((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidin-1-yl)butan-1-one (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was synthesized according to a procedure similar to that described for compound <b>8</b>, using butyryl chloride instead of ethyl isocyanate. Yield: 21 mg (40%). ESI-MS <i>m</i>/<i>z</i>: 671 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>rac</i>-Isopropyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was synthesized according to a procedure similar to that described for compound <b>8</b>, using isopropyl chloroformate instead of ethyl isocyanate. Yield: 20 mg (37%). ESI-MS <i>m</i>/<i>z</i>: 687 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-methoxypyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>11</b>)</h4><div class="NLM_p last">A mixture of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>4</b>) (114 mg, 0.16 mmol), sodium methoxide (25 wt % in methanol, 111 μL, 0.48 mmol), and copper iodide (I) (62 mg, 0.32 mmol) in DMF (1.5 mL) was stirred at 85 °C for 2.5 h and then allowed to cool to rt. The mixture was diluted with water and ethyl acetate and then passed through a Celite pad. The filtrate was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained residue was purified by preparative HPLC to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-methoxypyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>11</b>) (26 mg, 25%). ESI-MS <i>m</i>/<i>z</i>: 653 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>12</b>)</h4><div class="NLM_p last">To <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>4</b>) (0.038 mmol, 27 mg) in a flask purged with N<sub>2</sub> were added Pd<sub>2</sub>(dba)<sub>3</sub> (0.0077 mmol, 7 mg), 2-(di-<i>tert</i>-butylphosphino)biphenyl (0.0154 mmol, 4.6 mg), sodium <i>tert</i>-butoxide (0.154 mmol, 14.8 mg), and morpholine (0.077 mmol, 7 μL). The flask was purged again with N<sub>2</sub>, toluene (0.4 mL) was added, and the mixture was heated to 100 °C for 4 h. The mixture was cooled, quenched with silica gel, and the slurry subjected to silica gel column chromatography to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>12</b>) (13.37 mg, 50%). ESI-MS <i>m</i>/<i>z</i>: 708 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Chiral <i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>13</b>)</h4><div class="NLM_p last">The chiral separation of <i>rac</i>-<b>12</b> was carried out by chiral HPLC (Daicel Chiralpak AD-H 5 cm × 50 cm, <i>n</i>-hexane:<i>i</i>-PrOH = 95:5, 1 mL/min, 220 nm) to afford compound <b>13</b> and the distomer. The enantiomeric excess was determined by chiral HPLC (Daicel Chiralpak AD-H 0.46 cm × 25 cm, <i>n</i>-hexane:<i>i</i>-PrOH = 95:5, 1 mL/min, 220 nm). <i>T</i><sub>r</sub> = 8.22 min (compound <b>13</b>, >99% ee); 11.00 min (the distomer, >99% ee)</div></div><div id="sec5_1_13_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Isopropyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>14</b>)</h4><div class="NLM_p last">To a solution of isopropyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>28b</b>) (250 mg, 0.40 mmol) and morpholine (39 μL, 0.44 mmol) in toluene (5 mL) were added Pd<sub>2</sub>(dba)<sub>3</sub> (36.6 mg, 0.04 mmol), 2-(di-<i>tert</i>-butylphosphino)biphenyl (12 mg, 0.04 mmol), and sodium <i>tert</i>-butoxide (42 mg, 0.44 mmol). The reaction mixture was allowed to stir at 70 °C for 1.5 h under nitrogen and then allowed to cool to rt. The mixture was diluted with brine and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography eluting with ethyl acetate/heptane to afford isopropyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>14</b>) (126 mg, 0.20 mmol. 50%) as a white powder. ESI-MS <i>m</i>/<i>z</i>: 632.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1<i>r</i>,4<i>r</i>)-4-(((2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic Acid (<b>15</b>)</h4><div class="NLM_p">A solution of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29a</b>) (250 mg, 0.38 mmol) in 4 M HCl in ethyl acetate (3 mL) was allowed to stir from 0 °C to rt for 3 h. The reaction mixture was poured into saturated aqueous NaHCO<sub>3</sub> and extracted with ethyl acetate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford <i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-<i>N</i>-((2<i>R</i>,4<i>r</i>,6<i>S</i>)-2,6-diethylpiperidin-4-yl)-5-morpholinopyrimidin-2-amine (195 mg). The obtained product was used in the next step without further purification.</div><div class="NLM_p">To a solution of <i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-<i>N</i>-((2<i>R</i>,4<i>r</i>,6<i>S</i>)-2,6-diethylpiperidin-4-yl)-5-morpholinopyrimidin-2-amine (95 mg, 0.17 mmol) in DMF (0.1 mL) were added methyl (1<i>r</i>,4<i>r</i>)-4-((chlorocarbonyl)oxy)cyclohexane-1-carboxylate (<b>26</b>) (76 mg, 0.35 mmol) and diisopropylethylamine (68 μL, 0.52 mmol) at rt. The reaction mixture was allowed to stir at rt for 3 h and then diluted with DCM and water. The product was extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with EtOAc/heptane to afford (1<i>r</i>,4<i>r</i>)-4-(methoxycarbonyl)cyclohexyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (53 mg).</div><div class="NLM_p last">To a solution of (1<i>r</i>,4<i>r</i>)-4-(methoxycarbonyl)cyclohexyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (53 mg, 0.073 mmol) in THF (0.7 mL) and MeOH (0.3 mL) was added 1 M aqueous LiOH (0.37 mL, 0.37 mL) at rt. The reaction mixture was allowed to stir at rt for 17 h and then quenched with 1 M aqueous HCl. The mixture was further diluted with water. The product was extracted with DCM. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained crude product was purified by silica gel column chromatography eluting with MeOH/DCM to afford (1<i>r</i>,4<i>r</i>)-4-(((2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic acid (<b>15</b>) (33 mg, 0.046 mmol, 63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 0. 84 (t, <i>J</i> = 7.45 Hz, 6H), 1.35–1.53 (m, 6H), 1.55–1.67 (m, 2H) 1.74–1.83 (m, 2H) 2.03–2.18 (m, 6H), 2.30–2.40 (m, 1H), 2.99–3.05 (m, 4H), 3.83–3.87 (m, 4H), 4.10–4.19 (m, 2H), 4.62–4.76 (m, 2H), 4.79 (s, 2H), 7.69 (s, 2H), 7.73 (s, 1H), 8.09 (s, 2H). ESI-MS <i>m</i>/<i>z</i>: 716.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1<i>r</i>,4<i>r</i>)-4-(((2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic Acid (<b>16</b>)</h4><div class="NLM_p">To a mixture of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29b</b>) (24.6 g) in ethyl acetate (60 mL) was added dropwise 4 M HCl in ethyl acetate (200 mL) over 15 min, and the mixture was stirred at rt for 2 h. Precipitates were collected by filtration and then dissolved in a mixture of saturated NaHCO<sub>3</sub> and EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford <i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-<i>N</i>-((2<i>R</i>,4<i>r</i>,6<i>S</i>)-2,6-diethylpiperidin-4-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (18.5 g) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.87 (t, 6H), 1.18–1.28 (m, 2H), 1.37–1.45 (m, 4H), 1.63 (bs, 2H), 1.79 (d, 2H), 2.61–2.67 (m, 2H), 3.95 (s, 3H), 4.88 (s, 3H), 7.52 (s, 1H), 7.65 (s, 1H), 7.68 (s, 2H), 7.72 (s, 1H), 8.43 (s, 2H).</div><div class="NLM_p">To a mixture of <i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-<i>N</i>-((2<i>R</i>,4<i>r</i>,6<i>S</i>)-2,6-diethylpiperidin-4-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (15.0 g, 27.7 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (38.0 mL, 218 mmol) in DMF (19 mL) was added a solution of methyl (1<i>r</i>,4<i>r</i>)-4-((chlorocarbonyl)oxy)cyclohexane-1-carboxylate (<b>26</b>) (12.2 g, 55.1 mmol) in DMF (1 mL). The mixture was stirred for 1 h at room temperature, then another portion of <b>26</b> (2.94 g, 13.3 mmol) was added. The mixture was stirred for 1 h at rt, and then another portion of <b>26</b> (3.13 g, 14.2 mmol) was added. After the mixture was stirred for 30 min, the reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (gradient from 12% to 80% ethyl acetate in hexane) to afford (1<i>r</i>,4<i>r</i>)-4-(methoxycarbonyl)cyclohexyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (21.3 g). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.85 (t, 6H), 1.24–1.27 (m, 1H), 1.34–1.46 (m, 4H), 1.47–1.65 (m, 9H), 1.74–1.84 (m, 2H), 2.01–2.19 (m, 7H), 2.26–2.33 (m, 1H), 3.67 (s, 3H), 3.95 (s, 3H), 4.09–4.20 (m, 2H), 4.61–4.67 (m, 1H), 4.76–4.82 (m, 1H), 4.86 (s, 2H), 7.53 (s, 1H), 7.66 (s, 1H), 7.70 (s, 2H), 7.75 (s, 1H), 8.43 (s, 2H).</div><div class="NLM_p last">To a mixture (1<i>r</i>,4<i>r</i>)-4-(methoxycarbonyl)cyclohexyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (15.4 g, 21.2 mmol) in THF (100 mL) and MeOH (100 mL) was added aqueous 2 M NaOH (45 mL) at 0 °C. The mixture was stirred at rt for 24 h, cooled to 0 °C, and aqueous 1 M HCl (90 mL) was added dropwise. The mixture was concentrated and extracted with EtOAc. The organic layer was washed with water followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained solid was dissolved in a mixture of ethyl acetate (15 mL) and diisopropyl ether (135 mL) at 80 °C, then gradually cooled to rt. The crystalline solid was collected by filtration, washed with diisopropyl ether, and then dried under vacuum at 50 °C to afford (1<i>r</i>,4<i>r</i>)-4-(((2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carbonyl)oxy)cyclohexane-1-carboxylic acid (<b>16</b>) (10.9 g). HRMS calculated exact mass 711.30880, observed 711.30908 [M + H]<sup>+</sup> (Δ0.4 ppm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.85 (t, 6 H) 1.36–1.70 (m, 7 H) 1.75–1.85 (m, 3H) 2.03–2.20 (m, 6 H) 2.31–2.41 (m, 1 H) 3.95 (s, 3 H) 4.11–4.22 (m, 2 H) 4.61–4.71 (m, 1 H) 4.76–4.88 (m, 1 H) 4.86 (s, 2 H) 7.53 (s, 1 H) 7.66 (s, 1 H) 7.70 (s, 2 H) 7.75 (s, 1 H) 8.43 (s, 2 H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>), δ (ppm): 10.7, 12.14, 26.3, 30.4, 30.6, 31.1, 38.7, 40.9, 45.6, 49.3, 52.7, 72.2, 116, 116.3, 120.3, 123.3, 126.8, 127.5, 130.1, 135.4, 144.5, 154.5, 155.1, 159.7, 176.2. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>), δ (ppm): −61.3.</div></div><div id="sec5_1_13_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>rac</i>-<i>tert</i>-Butyl 2-Ethyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17b</b>)</h4><div class="NLM_p last">To a solution of 4-methoxypyridine (15.6 g, 143 mmol) in dry THF (1 L) cooled to −35 °C was added phenyl chloroformate (22.7 g, 144 mmol). After stirring for 1 h, 1 M ethyl magnesium bromide in THF (150 mL, 150 mmol) was added slowly over 30 min. The mixture was warmed to 10 °C over 2 h and then quenched with water. The reaction mixture was extracted twice with Et<sub>2</sub>O (1 L). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. To a solution of the resulting colorless oil in dry THF (500 mL) at −78 °C was added potassium <i>tert</i>-butoxide (64 g, 572 mmol). The reaction mixture was stirred from −78 °C to rt overnight. The reaction mixture was diluted with Et<sub>2</sub>O and then quenched with ice. The organic layer was separated, washed three times with 1.5 M aqueous NaOH, and then with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo to afford <i>rac</i>-<i>tert</i>-butyl 2-ethyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17b</b>) as a pale-yellow oil (27.8 g, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.92 (t, 3H), 1.55 (s, 9H), 1.57–1.75 (m, 3H), 2.44 (d, 1H), 2.80 (dd, 1H), 4.55 (d, 1H), 5.26 (d, 1H), 7.74 (d, 1H). ESI-MS <i>m</i>/<i>z</i>: 226 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>tert</i>-Butyl (2<i>R</i>,6<i>S</i>)-2,6-Diethyl-4-oxopiperidine-1-carboxylate (<b>18b</b>)</h4><div class="NLM_p last">To copper(I) iodide (0.82 mmol, 156 mg) in a flask purged with nitrogen was added 1 M EtMgBr in THF (0.82 mmol, 0.82 mL) at −78 °C. After stirring for 30 min, BF<sub>3</sub>·Et<sub>2</sub>O (0.41 mmol, 57.9 mg) was added, and the mixture was stirred for 10 min at the same temperature. To the suspension was added a solution of <i>rac</i>-<i>tert</i>-butyl 2-ethyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17b</b>) (0.41 mmol, 92.7 mg) in tetrahydrofuran (3.3 mL) at −78 °C. The mixture was allowed to stir at the same temperature for 1.5 h and then at −40 °C for 2 h. This mixture was warmed to rt, quenched with saturated aqueous NH<sub>4</sub>Cl, and extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered, concentrated in vacuo, and purified by silica gel column chromatography (hexane/EtOAc = 10:1) to afford <i>tert</i>-butyl (2<i>R</i>,6<i>S</i>)-2,6-diethyl-4-oxopiperidine-1-carboxylate (<b>18b</b>) (50 mg, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.91 (t, 6H), 1.44–1.53 (m, 11H), 1.65–1.70 (m, 2H), 2.35 (dd, 2H), 2.64–2.68 (m, 2H), 4.48 (bs, 2H). ESI-MS <i>m</i>/<i>z</i>: 200 (M<sup>+</sup> – <i>t</i>Bu + 2).</div></div><div id="sec5_1_13_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>rac</i>-Benzyl (2<i>S</i>,6<i>R</i>)-2-Benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i><b>rac</b></i>-<b>18c</b>)</h4><div class="NLM_p last">To copper(I) iodide (2.29 g, 12 mmol) in a flask was added 1 M EtMgBr in THF (14 mL, 14 mmol) at −78 °C under nitrogen followed by addition of BF<sub>3</sub>·Et<sub>2</sub>O (0.75 mL, 6 mmol). After stirring for 20 min at the same temperature, a solution of <i>rac</i>-benzyl 2-benzyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (<b>17c</b>) (1.93 g, 6 mmol) in THF (40 mL) was added portionwise at the same temperature. The mixture was gradually warmed up to rt, stirred for 12 h, and then quenched with saturated aqueous NH<sub>4</sub>Cl. The products were extracted with EtOAc, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography to afford a mixture of <i>rac</i>-benzyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i>cis</i>-racemate) (<i><b>rac</b></i>-<b>18c</b>) and the corresponding <i>trans</i>-racemate in a 10:1 ratio (1.60 g, 76%).</div></div><div id="sec5_1_13_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,6<i>R</i>)-2-Benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i><b>rac</b></i>-<b>18d</b>)</h4><div class="NLM_p">A suspension of a 10:1 mixture of <i>rac</i>-benzyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i><b>rac</b></i>-<b>18c</b>) (<i>cis</i>-racemate) and the <i>trans</i>-racemate, and 10% Pd/C (850 mg) in MeOH (170 mL) was allowed to stir at rt under hydrogen until complete consumption of the substrate (monitored by TLC). The reaction mixture was filtered and concentrated to give a crude product. The crude product was purified by silica gel column chromatography (hexane/EtOAc) to afford <i>rac</i>-(2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-one (3.88 g, 74%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i>: 218 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A mixture of <i>rac</i>-(2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-one (3.86 g, 17.8 mmol) and Boc<sub>2</sub>O (7.84 g, 35.9 mmol) was allowed to stir at 60 °C for 2 h. The mixture was cooled to rt and purified by silica gel column chromatography (hexane/EtOAc) to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i><b>rac</b></i>-<b>18d</b>) (5.37 g, 95%) as a pale-yellow oil. ESI-MS <i>m</i>/<i>z</i>: 262 (M – <i>t</i>Bu + 2H)<sup>+</sup>.</div></div><div id="sec5_1_13_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Isopropyl (2<i>R</i>,6<i>S</i>)-2,6-Diethyl-4-oxopiperidine-1-carboxylate (<b>18e</b>)</h4><div class="NLM_p">Into a solution of 4-methoxypyridine (53.7 g, 0.492 mol) in THF (1150 mL) were added isopropyl chloroformate (62 mL, 0.542 mol) and then EtMgBr (1 M in THF, 517 mL, 517 mmol) at −50 °C. This reaction mixture was stirred for 1 h, warming toward rt. The reaction mixture was diluted with water (100 mL) at 5 °C and then filtered. The filter cake was washed with EtOAc, and the filtrate was extracted with EtOAc. The combined organic layers were washed with 1 M aqueous HCl and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford isopropyl 2-ethyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (102.1 g), which was used in the next step without further purification.</div><div class="NLM_p last">To a suspension of copper(I) iodide (37 g, 195.3 mmol) in THF (100 mL) cooled to −65 °C were added EtMgBr (195.3 mL, 195.3 mmol), BF<sub>3</sub>·Et<sub>2</sub>O (12.2 mL, 97.65 mmol), and isopropyl 2-ethyl-4-oxo-3,4-dihydropyridine-1(2<i>H</i>)-carboxylate (22 g, 97.65 mmol) in THF (100 mL) at −65 °C in this order. This reaction mixture was stirred for 16 h, warming to rt. The reaction mixture was diluted with half-saturated aqueous NH<sub>4</sub>Cl and EtOAc and extracted with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with ethyl acetate/hexane to afford isopropyl (2<i>R</i>,6<i>S</i>)-2,6-diethyl-4-oxopiperidine-1-carboxylate (<b>18e</b>) (10 g, 30.65 mmol, 40%).</div></div><div id="sec5_1_13_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>19b</b>)</h4><div class="NLM_p last">To a mixture of <i>tert</i>-butyl (2<i>R</i>,6<i>S</i>)-2,6-diethyl-4-oxopiperidine-1-carboxylate (<b>18b</b>) (53 mg, 0.21 mmol), 3,5-bis(trifluoromethyl)benzylamine (technical grade ∼85%, 61.3 mg, 0.25 mmol), and acetic acid (14 μL, 0.25 mmol) in 1,2-dichloroethane (0.5 mL) was added NaBH(OAc)<sub>3</sub> (89 mg, 0.42 mmol) at rt under nitrogen. The mixture was stirred for 20 h and then quenched with 1 M aqueous NaOH. The organic products were extracted with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by preparative TLC (hexane/EtOAc = 2:1) to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>19b</b>) (21.2 mg, 20%). ESI-MS <i>m</i>/<i>z</i>: 483 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>rac</i>-Benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)amino)-6-ethylpiperidine-1-carboxylate (<b>19c</b>)</h4><div class="NLM_p last">To a 10:1 mixture of <i>rac</i>-benzyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i>cis</i>-racemate) (<i><b>rac</b></i>-<b>18c</b>) and <i>rac</i>-benzyl (2<i>R</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i>trans</i>-racemate) (1.60 g, 4.55 mmol), 3,5-bis(trifluoromethyl)benzylamine (technical grade ∼85%, 1.55 g, 6.37 mmol), and acetic acid (348 μL, 6.37 mmol) in 1,2-dichloroethane (10 mL) was added NaBH(OAc)<sub>3</sub> (1.93 g, 9.1 mmol) at rt. The mixture was stirred for 13 h and then quenched with 1 M aqueous NaOH. The organic products were extracted with DCM. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (DCM/EtOAc) to afford <i>rac</i>-benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)amino)-6-ethylpiperidine-1-carboxylate (<b>19c</b>) (990 mg, 38%). ESI-MS <i>m</i>/<i>z</i>: 579 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>rac-</i>Benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-6-ethylpiperidine-1-carboxylate (<b>20</b>)</h4><div class="NLM_p last">To a mixture of <i>rac</i>-benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)amino)-6-ethylpiperidine-1-carboxylate (<b>19c</b>) (990 mg, 1.71 mmol) and DMAP (420 mg, 3.42 mmol) in DCM (20 mL) was added methyl chloroformate (304 μL, 4.28 mmol) at rt under nitrogen, The mixture was stirred for 3 h and quenched with brine. The organic layer was separated and purified by silica gel column chromatography (DCM/EtOAc) to afford <i>rac</i>-benzyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-6-ethylpiperidine-1-carboxylate (<b>20</b>) (710 mg, 65%). ESI-MS <i>m</i>/<i>z</i>: 637.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-(benzylamino)-6-ethylpiperidine-1-carboxylate (<b>21</b>)</h4><div class="NLM_p last">A mixture of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,6<i>R</i>)-2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate (<i><b>rac</b></i>-<b>18d</b>) (5.36 g, 16.8 mmol), benzylamine (2.00 mL, 18.3 mmol) and BF<sub>3</sub>·Et<sub>2</sub>O (10 μL) in toluene (200 mL) was refluxed in a Dean–Stark apparatus for 20 min. The reaction mixture was cooled to rt and concentrated to give a crude oil. The crude product was dissolved in MeOH (200 mL), and then NaBH<sub>4</sub> (393 mg, 10.4 mmol) was added portionwise at rt. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl and then concentrated. The residue was diluted with water and extracted with dichloromethane. The organic layer was washed with saturated aqueous NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH) to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-(benzylamino)-6-ethylpiperidine-1-carboxylate (<b>21</b>) (4.18 g, 61%) as a pale-yellow oil. ESI-MS <i>m</i>/<i>z</i> 409: (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,<i>4S,</i>6<i>R</i>)-4-Amino-2-benzyl-6-ethylpiperidine-1-carboxylate (<b>22</b>)</h4><div class="NLM_p last">A mixture of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-(benzylamino)-6-ethylpiperidine-1-carboxylate (<b>21</b>) (2.89 g, 7 mmol) and 10% Pd/C (100 mg, 0.09 mmol) in EtOH (80 mL) was allowed to stir at 40 °C under hydrogen until complete consumption of the substrate. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH) to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-4-amino-2-benzyl-6-ethylpiperidine-1-carboxylate (<b>22</b>) (1.85 g, 83%). ESI-MS <i>m</i>/<i>z</i>: 319 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_13_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>rac</i>-<i>tert</i>-Butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-4-((5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>23</b>)</h4><div class="NLM_p last">A mixture of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-4-amino-2-benzyl-6-ethylpiperidine-1-carboxylate (<b>22</b>) (1.75 g, 5.5 mmol), 5-bromo-2-chloropyridine (1.6 g, 8.25 mmol), and DIPEA (1.92 mL, 11 mmol) in DMF (16.5 mL) was heated at 120 °C for 4 h under nitrogen. The mixture was cooled to rt and diluted with brine. The products were extracted with EtOAc. The organic layer was washed with saturated aqueous NH<sub>4</sub>Cl and water and then concentrated to give a brown solid. The solid was triturated with diisopropyl ether to afford <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate as a colorless solid (<b>23</b>) (1.52 g, 58%).</div></div><div id="sec5_1_13_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>rac</i>-<i>N</i>-((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-Benzyl-6-ethylpiperidin-4-yl)-<i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-5-bromopyrimidin-2-amine Hydrochloride (<b>24</b>)</h4><div class="NLM_p last">A mixture of <i>rac</i>-<i>tert</i>-butyl (2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-6-ethylpiperidine-1-carboxylate (<b>4</b>) (1.29 mmol, 900 mg) and a solution of 4 M HCl in EtOAc was stirred for 4 h at rt, then concentrated in vacuo. To the obtained residue was added Et<sub>2</sub>O, and the solid was collected by filtration to give <i>rac</i>-<i>N</i>-((2<i>S</i>,4<i>S</i>,6<i>R</i>)-2-benzyl-6-ethylpiperidin-4-yl)-<i>N</i>-(3,5-bis(trifluoromethyl)benzyl)-5-bromopyrimidin-2-amine hydrochloride (<b>24</b>) (1.2 mmol, 771 mg, 94% as HCl salt). ESI-MS <i>m</i>/<i>z</i>: 601 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Methyl (1<i>r</i>,4<i>r</i>)-4-Hydroxycyclohexane-1-carboxylate (<b>25</b>)</h4><div class="NLM_p last">To a solution of (1<i>r</i>,4<i>r</i>)-4-hydroxycyclohexane-1-carboxylic acid (2.12 g, 14.7 mmol) in DMF (15 mL) were added potassium carbonate (2.44 g, 17.6 mmol) and methyl iodide (1.1 mL, 17.6 mmol) at 0 °C. The reaction mixture was allowed to stir from 0 °C to rt for 2 h. The reaction mixture was diluted with water and EtOAc. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford methyl (1<i>r</i>,4<i>r</i>)-4-hydroxycyclohexane-1-carboxylate (<b>25</b>) (1.62 g, 10.29 mmol, 70%). <sup>1</sup>H NMR (400 MHz, CDCl3), δ (ppm): 1.23–1.33 (m, 2H), 1.48–1.56 (m, 2H), 1.99–2.05 (m, 4H), 2.22–2.30 (m, 1H), 3.58–3.64 (m, 1H), 3.67 (s, 3H).</div></div><div id="sec5_1_13_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Methyl (1<i>r</i>,4<i>r</i>)-4-((Chlorocarbonyl)oxy)cyclohexane-1-carboxylate (<b>26</b>)</h4><div class="NLM_p last">To a solution of triphosgene (1.52 g, 5.12 mmol) in DCM (15 mL) were added a solution of pyridine (870 μL, 10.8 mmol) in DCM (5 mL) and methyl (1<i>r</i>,4<i>r</i>)-4-hydroxycyclohexane-1-carboxylate (<b>25</b>) (1.62 g, 10.29 mmol) at 0 °C. The reaction mixture was allowed to stir from 0 °C to rt for 3 h. The reaction mixture was diluted with aqueous NH<sub>4</sub>Cl. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford methyl (1<i>r</i>,4<i>r</i>)-4-((chlorocarbonyl)oxy)cyclohexane-1-carboxylate (<b>26</b>) (1.77 g, 3.63 mmol, 78%). <sup>1</sup>H NMR (400 MHz, CDCl3), δ (ppm): 1.53–1.64 (m, 4H), 2.05–2.18 (m, 4H), 2.30–2.37 (m, 1H), 3.68 (m, 3H), 4.77–4.83 (m, 1H).</div></div><div id="sec5_1_13_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((5-Bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>27a</b>)</h4><div class="NLM_p">To a mixture of <i>tert</i>-butyl (2<i>R</i>,6<i>S</i>)-2,6-diethyl-4-oxopiperidine-1-carboxylate (<b>18b</b>) (11.1 g, 44 mmol) in MeOH (150 mL) were added benzylamine (7.1 mL, 65 mmol) and titanium tetraisopropoxide (26 mL, 87 mmol) at 0 °C, and the mixture was stirred overnight at rt. After addition of sodium borohydride (2.5 g, 65 mmol), the mixture was stirred for an additional 1 h at rt. H<sub>2</sub>O and EtOAc were added to the mixture, and the resulting precipitate was removed by filtration. The filtrate was washed sequentially with saturated aqueous NaHCO<sub>3</sub> and brine. The product was extracted from the aqueous layer with EtOAc, and the combined organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to obtain <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-(benzylamino)-2,6-diethylpiperidine-1-carboxylate as a clear oil (13.9 g, 92%). The diastereomeric ratio was typically 10:1 (<i>cis</i>:<i>trans</i>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.87 (t, 6H), 1.17–1.23 (m, 2H), 1.45 (s, 9H), 1.46–1.50 (m, 3H), 1.73–1.80 (m, 2H), 2.22–2.28 (m, 2H), 2.67–2.71 (m, 1H), 3.78 (s, 2H), 3.98–4.03 (m, 2H).</div><div class="NLM_p">A mixture of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-(benzylamino)-2,6-diethylpiperidine-1-carboxylate (4.0 g, 11.4 mmol) and 10% Pd/C (400 mg) in EtOH (80 mL) was stirred for 5 h at 55 °C under hydrogen. After removal of the catalyst by filtration through a pad of Celite, the filtrate was concentrated in vacuo to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-amino-2,6-diethylpiperidine-1-carboxylate as clear oil (2.9 g, 99%), which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.90 (t, 6H), 1.06–1.12 (m, 3H), 1.38–1.50 (m, 12H), 1.71–1.77 (m, 2H), 2.15–2.21 (m, 2H), 2.84 (m, 1H), 4.00–4.04 (m, 2H).</div><div class="NLM_p last">A mixture of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-amino-2,6-diethylpiperidine-1-carboxylate (21.1 g, 82.3 mmol), 5-bromo-2-chloropyrimidine (17.1 g, 88.5 mmol), and diisopropylethylamine (28.0 mL, 161 mmol) in DMF (220 mL) was stirred at 120 °C for 3.5 h. After cooling to rt, the mixture was diluted with water (300 mL) and extracted with EtOAc (200 mL × 2). The combined organic layers were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. To the obtained solid was added diisopropyl ether (65 mL), and the solid was dissolved under reflux. The resulting solution was cooled to rt, then <i>n</i>-hexane (65 mL) was added. Precipitates were collected by filtration and washed with diisopropyl ether to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>27a</b>) (12.4 g, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.89 (t, 6H), 1.19–1.27 (m, 2H), 1.39–1.44 (m, 3H), 1.45 (s, 9H), 1.73–1.84 (m, 2H), 2.39–2.45 (m, 2H), 3.83–3.92 (m, 1H), 4.09–4.17 (m, 2H), 4.94 (d, 1H), 8.27 (s, 2H).</div></div><div id="sec5_1_13_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Isopropyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((5-Bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>27b</b>)</h4><div class="NLM_p last">Compound <b>27b</b> was synthesized according to a procedure similar to that described for compound <b>23</b>, using compound <b>18e</b> in 30% yield in three steps.</div></div><div id="sec5_1_13_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>28a</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>27a</b>) (6.05 g, 14.6 mmol) in DMF (60 mL) was added NaH (60% in oil, 0.70 g, 17.6 mmol) at 0 °C. After the solution was stirred for 1 h, 3,5-bis(trifluoromethyl)benzyl bromide (3.23 mL, 17.6 mmol) was added, and the reaction mixture was warmed to rt and stirred for 20 min. After the reaction was quenched with H<sub>2</sub>O at 0 °C, the mixture was extracted with ethyl acetate, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>28a</b>) (8.02 g, 86%) as yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.84 (t, 6H), 1.37–1.56 (m, 5H), 1.47 (s, 9H), 1.73–1.84 (m, 2H), 2.09–2.15 (m, 2H), 4.10 (p, 2H), 4.63–4.74 (m, 1H), 4.81 (s, 2H), 7.66 (s, 2H), 7.75 (s, 1H), 8.32 (s, 2H). ESI-MS <i>m</i>/<i>z</i>: 639.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Isopropyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>28b</b>)</h4><div class="NLM_p last">Compound <b>28b</b> was synthesized according to a procedure similar to that described for compound <b>28a</b>, using compound <b>27b</b> in 74% yield.</div></div><div id="sec5_1_13_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29a</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate <b>28a</b> (300 mg, 0.47 mmol) and morpholine (82 μL, 0.94 mmol) in toluene (5 mL) were added Pd<sub>2</sub>(dba)<sub>3</sub> (86 mg, 0.09 mmol), 2-(di-<i>t</i>-butylphosphiphino)biphenyl (56 mg, 0.19 mmol), and <i>t</i>-BuONa (180 mg, 1.88 mmol). The reaction mixture was allowed to stir at 100 °C for 3 h under nitrogen and then allowed to cool to rt. The mixture was diluted with brine and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography eluting with EtOAc/heptane to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r,</i>6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-morpholinopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29a</b>) (250 mg, 0.38 mmol. 81%) as a white powder. ESI-MS <i>m</i>/<i>z</i>: 646 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>tert</i>-Butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-Bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29b</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-bromopyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>28a</b>) (28.2 g, 44.0 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (11.0 g, 53.0 mmol), and Na<sub>2</sub>CO<sub>3</sub> (6.99 g, 66.0 mmol) in dimethoxyethane (340 mL) and H<sub>2</sub>O (33 mL) was purged with N<sub>2</sub>, then Pd(PPh<sub>3</sub>)<sub>4</sub> (2.54 g, 2.2 mmol) was added. The mixture was stirred at 90 °C for 4 h, and then additional amounts of Pd(PPh<sub>3</sub>)<sub>4</sub> (2.00 g, 1.7 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1<i>H</i>-pyrazole (3.68 g, 18.0 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.39 g, 23.0 mmol), and H<sub>2</sub>O (11 mL) were added. The mixture was stirred at 90 °C for a further 16 h, then cooled to rt, and H<sub>2</sub>O (400 mL) was added. The product was extracted with EtOAc (200 mL × 2), and the combined organic layers were washed with water followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (gradient from 12% to 60% EtOAc in hexane) to afford <i>tert</i>-butyl (2<i>R</i>,4<i>r</i>,6<i>S</i>)-4-((3,5-bis(trifluoromethyl)benzyl)(5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-yl)amino)-2,6-diethylpiperidine-1-carboxylate (<b>29b</b>) (ca. 25 g), which was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), δ (ppm): 0.84 (t, 6H), 1.38–1.55 (m, 5H), 1.46 (s, 9H), 1.74–1.85 (m, 2H), 2.11–2.19 (m, 2H), 3.90 (s, 3H), 4.08–4.16 (m, 2H), 4.75–4.87 (m, 3H), 7.52 (s, 1H), 7.65 (s, 1H), 7.71 (s, 2H), 7.76 (s, 1H), 8.42 (s, 2H). ESI-MS <i>m</i>/<i>z</i>: 641.6 [M + H]<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00900">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00900" class="ext-link">10.1021/acs.jmedchem.7b00900</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Aldosterone and pressor effects of torcetrapib, anacetrapib, and compound <b>16</b>; single compound X-ray crystallography for the confirmation of relative stereochemistry of compound <b>16</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf">jm7b00900_si_001.pdf (495.35 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00900" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken Yamada</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7899-6192" title="Orcid link">http://orcid.org/0000-0001-7899-6192</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9cf7f9f2b2e5fdf1fdf8fddcf2f3eafdeee8f5efb2fff3f1"><span class="__cf_email__" data-cfemail="761d1318580f171b171217361819001704021f055815191b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muneto Mogi</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2548504b40514a0b484a424c654b4a534457514c560b464a48"><span class="__cf_email__" data-cfemail="2449514a41504b0a494b434d644a4b524556504d570a474b49">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margaret Brousseau</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wataru Honma</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akiko Iimura</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hidetomo Imase</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuki Iwaki</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshio Kawanami</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel LaSala</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey 07936-1080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiqing Liang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hironobu Mitani</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazuhiko Nonomura</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Osamu Ohmori</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meihui Pan</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean F. Rigel</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey 07936-1080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ichiro Umemura</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kayo Yasoshima</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Novartis
Pharma K.K., Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guoming Zhu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139-4133, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>K. Yamada and M.B. prepared the manuscript. M.M., K. Yamada, O.O., K. Yasoshima, T.K., I.U., Y.I., and H.I. designed and synthesized the compounds, K.N. and G.Z. developed the human plasma CETP assay, A.I. and H.M. developed and performed hamster PD studies, W.H. developed and performed CYP assays, M.P. and D.L. developed and performed aldosterone secretion assay in H295R cells, M.P. performed plasma lipoprotein distribution studies, G.L. performed pharmacokinetic and tissue distribution studies, D.F.R. developed and supervised cannulated SD rat studies, and M.M., H.M., and M.B. directed the discovery program.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All research was fully funded by Novartis.<br /></br></div></li></ul></div><div class="ack" id="ACK-d165e4744-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Dr. J. M. Elliott for careful review and advice on this manuscript, Dr. M. Kato for modeling support, Dr. H. Qin for chemical synthesis support, Drs. T. Miyake, E. Kawahara, M. Kishida, J. Levell, T. Fujita, K. Konishi, L. McQuire, and R. Sun for the insights from exploration of alternative chemotypes, T. Hayashi and S. Raghavan for performing human plasma CETP assays, Y. Arai and Y. Murakami for performing hamster PD studies, Dr. H. Fukaya for supporting PK studies, Dr. L. Shah for formulation support, Drs. A. Jeng and K. DiPetrillo for the supporting H295R aldosterone secretion assay, W. Chen, F. Fu, M. Beil, and J. Liu for conducting the cannulated SD rat studies, J. Leung-Chu and C.-W. Hu for ex vivo analyses of PAC and PCC from the rat studies, P. Piechon, Drs. I. Dix and B. Wagner for X-ray crystallography of compound <b>16</b>, and Dr. S. Skolnik and L. Yang for determining experimental Log <i>D</i> values. We also acknowledge Drs. G. Iwasaki and A. B. Jones for their guidance on medicinal chemistry strategy.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i66" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i66"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i67" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i67"> Abbreviations Used</h2><tr><td class="NLM_term">CETP</td><td class="NLM_def"><p class="first last">cholesteryl ester transfer protein</p></td></tr><tr><td class="NLM_term">LDL</td><td class="NLM_def"><p class="first last">low density lipoprotein</p></td></tr><tr><td class="NLM_term">HDL</td><td class="NLM_def"><p class="first last">high density lipoprotein</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">CHD</td><td class="NLM_def"><p class="first last">coronary heart disease</p></td></tr><tr><td class="NLM_term">HMGCoA</td><td class="NLM_def"><p class="first last">3-hydroxy-3-methylglutaryl-coenzyme A</p></td></tr><tr><td class="NLM_term">TG</td><td class="NLM_def"><p class="first last">triglyceride</p></td></tr><tr><td class="NLM_term">VLDL</td><td class="NLM_def"><p class="first last">very low density lipoprotein</p></td></tr><tr><td class="NLM_term">TG</td><td class="NLM_def"><p class="first last">triglycerides</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LPDS</td><td class="NLM_def"><p class="first last">lipoprotein deficient serum</p></td></tr><tr><td class="NLM_term">TRL</td><td class="NLM_def"><p class="first last">triglyceride rich lipoproteins</p></td></tr><tr><td class="NLM_term">SD rats</td><td class="NLM_def"><p class="first last">Sprague–Dawley rats</p></td></tr><tr><td class="NLM_term">H295R cells</td><td class="NLM_def"><p class="first last">human adrenal corticocarcinoma cells</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emberson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMets, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacMahon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulter, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preiss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandercock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeeth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span> </span><span class="NLM_article-title">Interpretation of the evidence for the efficacy and safety of statin therapy</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2561</span><span class="refDoi"> DOI: 10.1016/S0140-6736(16)31357-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2FS0140-6736%2816%2931357-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=27616593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2gsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2532-2561&author=R.+Collinsauthor=C.+Reithauthor=J.+Embersonauthor=J.+Armitageauthor=C.+Baigentauthor=L.+Blackwellauthor=R.+Blumenthalauthor=J.+Daneshauthor=G.+D.+Smithauthor=D.+DeMetsauthor=S.+Evansauthor=M.+Lawauthor=S.+MacMahonauthor=S.+Martinauthor=B.+Nealauthor=N.+Poulterauthor=D.+Preissauthor=P.+Ridkerauthor=I.+Robertsauthor=A.+Rodgersauthor=P.+Sandercockauthor=K.+Schulzauthor=P.+Severauthor=J.+Simesauthor=L.+Smeethauthor=N.+Waldauthor=S.+Yusufauthor=R.+Peto&title=Interpretation+of+the+evidence+for+the+efficacy+and+safety+of+statin+therapy&doi=10.1016%2FS0140-6736%2816%2931357-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretation of the evidence for the efficacy and safety of statin therapy</span></div><div class="casAuthors">Collins, Rory; Reith, Christina; Emberson, Jonathan; Armitage, Jane; Baigent, Colin; Blackwell, Lisa; Blumenthal, Roger; Danesh, John; Davey Smith, George; DeMets, David; Evans, Stephen; Law, Malcolm; MacMahon, Stephen; Martin, Seth; Neal, Bruce; Poulter, Neil; Preiss, David; Ridker, Paul; Roberts, Ian; Rodgers, Anthony; Sandercock, Peter; Schulz, Kenneth; Sever, Peter; Simes, John; Smeeth, Liam; Wald, Nicholas; Yusuf, Salim; Peto, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10059</span>),
    <span class="NLM_cas:pages">2532-2561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes.  It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy.  In addn., it discusses how claims that statins commonly cause adverse effects reflect a failure to recognize the limitations of other sources of evidence about the effects of treatment.  Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L redn. in LDL cholesterol during each year (after the first) that it continues to be taken.  The abs. benefits of statin therapy depend on an individual's abs. risk of occlusive vascular events and the abs. redn. in LDL cholesterol that is achieved.  For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per mo) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% abs. benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% abs. benefit) who are at increased risk but have not yet had a vascular event (primary prevention).  Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger abs. benefits would accrue with more prolonged therapy, and these benefits persist long term.  The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concns. of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke.  Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes.  However, any adverse impact of these side-effects on major vascular events has already been taken into account in the ests. of the abs. benefits.  Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% abs. harm) per 10 000 treated for 5 years.  However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution).  The large-scale evidence available from randomised trials also indicates that it is unlikely that large abs. excesses in other serious adverse events still await discovery.  Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms.  It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events.  For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtn_rGxpXyT7Vg90H21EOLACvtfcHk0lgFVXmREFEVYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2gsr3E&md5=33303c53c45813e3bc564c1142c32854</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2931357-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252931357-5%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DReith%26aufirst%3DC.%26aulast%3DEmberson%26aufirst%3DJ.%26aulast%3DArmitage%26aufirst%3DJ.%26aulast%3DBaigent%26aufirst%3DC.%26aulast%3DBlackwell%26aufirst%3DL.%26aulast%3DBlumenthal%26aufirst%3DR.%26aulast%3DDanesh%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DDeMets%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DM.%26aulast%3DMacMahon%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNeal%26aufirst%3DB.%26aulast%3DPoulter%26aufirst%3DN.%26aulast%3DPreiss%26aufirst%3DD.%26aulast%3DRidker%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DI.%26aulast%3DRodgers%26aufirst%3DA.%26aulast%3DSandercock%26aufirst%3DP.%26aulast%3DSchulz%26aufirst%3DK.%26aulast%3DSever%26aufirst%3DP.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DSmeeth%26aufirst%3DL.%26aulast%3DWald%26aufirst%3DN.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DPeto%26aufirst%3DR.%26atitle%3DInterpretation%2520of%2520the%2520evidence%2520for%2520the%2520efficacy%2520and%2520safety%2520of%2520statin%2520therapy%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D2532%26epage%3D2561%26doi%3D10.1016%2FS0140-6736%2816%2931357-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Gordon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjortland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawber, T. R.</span><span> </span><span class="NLM_article-title">High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/0002-9343(77)90874-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2F0002-9343%2877%2990874-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=193398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1977&pages=707-714&author=T.+Gordonauthor=W.+P.+Castelliauthor=M.+C.+Hjortlandauthor=W.+B.+Kannelauthor=T.+R.+Dawber&title=High+density+lipoprotein+as+a+protective+factor+against+coronary+heart+disease.+The+Framingham+Study&doi=10.1016%2F0002-9343%2877%2990874-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">High density lipoprotein as a protective factor against coronary heart disease.  The framingham study</span></div><div class="casAuthors">Gordon, Tavia; Castelli, William P.; Hjortland, Marthana C.; Kannel, William B.; Dawber, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">707-14</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Lipid and lipoprotein values, including fasting triglycerides and high d. lipoproteins (HDL), low d. lipoproteins (LDL), and total cholesterol levels, were obtained on 2815 men and women aged 49-82 years chiefly between 1969 and 1971 at Framingham.  In the ∼4 years following the characterization of lipids, coronary heart disease developed in 79 of the 1025 men and 63 of the 1445 women free of coronary heart diseases.  At these older ages the major potent lipid risk factor was HDL cholesterol.  This lipid was assocd. with each major manifestation of coronary heart disease.  Triglycerides were assocd. with the incidence of coronary heart disease only in women and then only when the level of other lipids was not taken into account.  At these ages total cholesterol was not assocd. with the risk of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd43DXOPo8vrVg90H21EOLACvtfcHk0lgFVXmREFEVYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D&md5=4627db810c609ea43992d8f508b7ec08</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2877%2990874-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252877%252990874-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DT.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DHjortland%26aufirst%3DM.%2BC.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26aulast%3DDawber%26aufirst%3DT.%2BR.%26atitle%3DHigh%2520density%2520lipoprotein%2520as%2520a%2520protective%2520factor%2520against%2520coronary%2520heart%2520disease.%2520The%2520Framingham%2520Study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1977%26volume%3D62%26spage%3D707%26epage%3D714%26doi%3D10.1016%2F0002-9343%2877%2990874-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gordon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probstfield, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neaton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoke, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, D. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bangdiwala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyroler, H. A.</span><span> </span><span class="NLM_article-title">High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1161/01.CIR.79.1.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2F01.CIR.79.1.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1989&pages=8-15&author=D.+J.+Gordonauthor=J.+L.+Probstfieldauthor=R.+J.+Garrisonauthor=J.+D.+Neatonauthor=W.+P.+Castelliauthor=J.+D.+Knokeauthor=D.+R.+Jacobsauthor=S.+Bangdiwalaauthor=H.+A.+Tyroler&title=High-density+lipoprotein+cholesterol+and+cardiovascular+disease.+Four+prospective+American+studies&doi=10.1161%2F01.CIR.79.1.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.79.1.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.79.1.8%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BJ.%26aulast%3DProbstfield%26aufirst%3DJ.%2BL.%26aulast%3DGarrison%26aufirst%3DR.%2BJ.%26aulast%3DNeaton%26aufirst%3DJ.%2BD.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DKnoke%26aufirst%3DJ.%2BD.%26aulast%3DJacobs%26aufirst%3DD.%2BR.%26aulast%3DBangdiwala%26aufirst%3DS.%26aulast%3DTyroler%26aufirst%3DH.%2BA.%26atitle%3DHigh-density%2520lipoprotein%2520cholesterol%2520and%2520cardiovascular%2520disease.%2520Four%2520prospective%2520American%2520studies%26jtitle%3DCirculation%26date%3D1989%26volume%3D79%26spage%3D8%26epage%3D15%26doi%3D10.1161%2F01.CIR.79.1.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1161/01.ATV.0000054658.91146.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2F01.ATV.0000054658.91146.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=12588754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=160-167&author=P.+J.+Barterauthor=H.+B.+Brewerauthor=M.+J.+Chapmanauthor=C.+H.+Hennekensauthor=D.+J.+Raderauthor=A.+R.+Tall&title=Cholesteryl+ester+transfer+protein%3A+a+novel+target+for+raising+HDL+and+inhibiting+atherosclerosis&doi=10.1161%2F01.ATV.0000054658.91146.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein</span></div><div class="casAuthors">Barter, Philip J.; Brewer, H. Bryan; Chapman, M. John; Hennekens, Charles H.; Rader, Daniel J.; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)-contg. lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs.  A deficiency of CETP is assocd. with increased HDL levels and decreased LDL levels, a profile that is typically antiatherogenic.  Studies in rabbits, a species with naturally high levels of CETP, support the therapeutic potential of CETP inhibition as an approach to retarding atherogenesis.  Studies in mice, a species that lacks CETP activity, have provided mixed results.  Human subjects with heterozygous CETP deficiency and an HDL cholesterol level >60 mg/dL have a reduced risk of coronary heart disease.  Evidence that atherosclerosis may be increased in CETP-deficient subjects whose HDL levels are not increased is difficult to interpret and may reflect confounding or bias.  Small-mol. inhibitors of CETP have now been tested in human subjects and shown to increase the concn. of HDL cholesterol while decreasing that of LDL cholesterol and apoB.  Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacol. inhibition of CETP retards the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBGX_CUbamrVg90H21EOLACvtfcHk0liqGHdkL3yCTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D&md5=1cf83327815b82a906915c61e355e891</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000054658.91146.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000054658.91146.64%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%253A%2520a%2520novel%2520target%2520for%2520raising%2520HDL%2520and%2520inhibiting%2520atherosclerosis%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D160%26epage%3D167%26doi%3D10.1161%2F01.ATV.0000054658.91146.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Angelantonio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarwar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erqou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleheen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dullaart, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keavney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span> </span><span class="NLM_article-title">Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">2777</span><span class="NLM_x">–</span> <span class="NLM_lpage">2788</span><span class="refDoi"> DOI: 10.1001/jama.299.23.2777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1001%2Fjama.299.23.2777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18560005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Sktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2008&pages=2777-2788&author=A.+Thompsonauthor=E.+Di+Angelantonioauthor=N.+Sarwarauthor=S.+Erqouauthor=D.+Saleheenauthor=R.+P.+Dullaartauthor=B.+Keavneyauthor=Z.+Yeauthor=J.+Danesh&title=Association+of+cholesteryl+ester+transfer+protein+genotypes+with+CETP+mass+and+activity%2C+lipid+levels%2C+and+coronary+risk&doi=10.1001%2Fjama.299.23.2777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk</span></div><div class="casAuthors">Thompson, Alexander; Di Angelantonio, Emanuele; Sarwar, Nadeem; Erqou, Sebhat; Saleheen, Danish; Dullaart, Robin P. F.; Keavney, Bernard; Ye, Zheng; Danesh, John</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2777-2788</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The importance of the cholesteryl ester transfer protein (CETP) pathway in coronary disease is uncertain.  Study of CETP genotypes can help better understand the relevance of this pathway to lipid metab. and disease risk.  Objective was to assess assocns. of CETP genotypes with CETP phenotypes, lipid levels, and coronary risk.  Data Sources Studies published between Jan. 1970 and Jan. 1980 were identified through computer-based and manual searches using MEDLINE, EMBASE, BIOSIS, Science Citation Index, and the Chinese National Knowledge Infrastructure Database.  Previously unreported studies were sought through correspondence with investigators.  Selection Relevant studies related principally to 3 common (TaqlB[rs708272], I405V [rs5882], and - 629C > A[rs1800775]) and 3 uncommon (D442G[rs2303790], - 631C > A[rs1800776], and R451Q [rs1800777]) CETP polymorphisms.  Extn. Information on CETP genotypes, CETP Phenotypes, lipid levels, coronary disease, and study characteristics was abstracted from publications, supplied by investigators, or both.  Ninety-two studies had data on CETP phenotypes, lipid levels, or both in 113833 healthy participants, and 46 studies had data on 27 196 coronary cases and 55 338 controls.  For each A allele inherited, individuals with the TaqlB polymorphism had lower mean CETP mass (- 9.7%; 95% confidence interval [CI], - 11.7% tp - 7.8%), lower mean CETP activity (- 8.6%; 95% Cl, - 13.0% to - 4.1%), higher mean high-d. lipoprotein cholesterol (HDL-C) concns. (4.5%; 95% Cl, 3.8%-5.2%), and higher mean apolipoprotein A-I concns. (2.4%; 95% Cl, 1.6%-3.2%).  The pattern of findings was very similar with the I405V and - 629C > A polymorphisms.  The combined per-allele odds ratios (ORs) for coronary disease were 0.95 (95% Cl, 0.92-0.99) for TaqlB, 0.94 (95% Cl, 0.89-1.00) for I405V, and 0.95 (95% Cl, 0.91-1.00) for - 629C > A.  Three CETP genotypes that are assocd. with moderate inhibition of CETP activity (and, therefore, modestly higher HDL-C levels) show weakly inversely assocns. with coronary risk.  The ORs for coronary disease were compatible with the expected redns. in risk for equiv. increases in HDL-C concn. in available prospective studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBUEuoJ3vytLVg90H21EOLACvtfcHk0liqGHdkL3yCTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Sktb4%253D&md5=f828480566c595b6e3aca85eeff05c41</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.299.23.2777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.299.23.2777%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DSarwar%26aufirst%3DN.%26aulast%3DErqou%26aufirst%3DS.%26aulast%3DSaleheen%26aufirst%3DD.%26aulast%3DDullaart%26aufirst%3DR.%2BP.%26aulast%3DKeavney%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DDanesh%26aufirst%3DJ.%26atitle%3DAssociation%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520genotypes%2520with%2520CETP%2520mass%2520and%2520activity%252C%2520lipid%2520levels%252C%2520and%2520coronary%2520risk%26jtitle%3DJAMA%26date%3D2008%26volume%3D299%26spage%3D2777%26epage%3D2788%26doi%3D10.1001%2Fjama.299.23.2777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Johannsen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frikke-Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordestgaard, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tybjaerg-Hansen, A.</span><span> </span><span class="NLM_article-title">Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2048</span><span class="refDoi"> DOI: 10.1016/j.jacc.2012.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.jacc.2012.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=23083790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=2041-2048&author=T.+H.+Johannsenauthor=R.+Frikke-Schmidtauthor=J.+Schouauthor=B.+G.+Nordestgaardauthor=A.+Tybjaerg-Hansen&title=Genetic+inhibition+of+CETP%2C+ischemic+vascular+disease+and+mortality%2C+and+possible+adverse+effects&doi=10.1016%2Fj.jacc.2012.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects</span></div><div class="casAuthors">Johannsen, Trine Holm; Frikke-Schmidt, Ruth; Schou, Jesper; Nordestgaard, Borge G.; Tybjaerg-Hansen, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2041-2048</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objectives: This study tested whether genetic variation in the CETP gene is consistent with a protective effect of cholesteryl ester transfer protein (CETP) inhibition on risk of ischemic events and on total mortality, without the adverse effects reported for torcetrapib.  Background: Torcetrapib, an inhibitor of CETP, increased risk of death and ischemic cardiovascular disease of those randomized to the drug, despite improving the lipid profile.  Methods: The Copenhagen City Heart Study is a prospective cohort study of 10,261 individuals, aged 20 to 93 years, who were followed for up to 34 years (1976 to 2010).  Of these, 2,087 developed ischemic heart disease, 1,064 developed ischemic cerebrovascular disease, and 3,807 died during follow-up.  We selected 2 common genetic variants in CETP previously assocd. with redns. in CETP activity, thus mimicking the effect of pharmacol. CETP inhibition.  Results: In individuals carrying 4 vs. 0 high-d. lipoprotein cholesterol-increasing alleles, there was an increase in levels of high-d. lipoprotein cholesterol of up to 14% (0.2 mmol/l), and concomitant decreases in triglycerides, low-d. lipoprotein cholesterol, and non-high-d. lipoprotein cholesterol of, resp., 6% (0.1 mmol/l), 3% (0.1 mmol/l), and 4% (0.2 mmol/l) (p for trend 0.004 to <0.001).  Corresponding hazard ratios were 0.76 (95% confidence interval [CI]: 0.68 to 0.85) for any ischemic vascular event, 0.74 (95% CI: 0.65 to 0.85) for ischemic heart disease, 0.65 (95% CI: 0.54 to 0.79) for myocardial infarction, 0.77 (95% CI: 0.65 to 0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for ischemic stroke, and 0.88 (95% CI: 0.80 to 0.97) for total mortality.  CETP genotypes did not assoc. with variation in markers of possible side effects previously reported for torcetrapib.  Conclusions: Genetic CETP inhibition assocs. with redns. in risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a corresponding antiatherogenic lipid profile, and with increased longevity, without adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Pu5WBKmjErVg90H21EOLACvtfcHk0li_23PiSWag1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnM&md5=b9960b97887b3b10c1a3e5b3b4c92b5a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohannsen%26aufirst%3DT.%2BH.%26aulast%3DFrikke-Schmidt%26aufirst%3DR.%26aulast%3DSchou%26aufirst%3DJ.%26aulast%3DNordestgaard%26aufirst%3DB.%2BG.%26aulast%3DTybjaerg-Hansen%26aufirst%3DA.%26atitle%3DGenetic%2520inhibition%2520of%2520CETP%252C%2520ischemic%2520vascular%2520disease%2520and%2520mortality%252C%2520and%2520possible%2520adverse%2520effects%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2012%26volume%3D60%26spage%3D2041%26epage%3D2048%26doi%3D10.1016%2Fj.jacc.2012.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Sendon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shear, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revkin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, B.</span><span> </span><span class="NLM_article-title">Investigators, I. Effects of torcetrapib in patients at high risk for coronary events</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">–</span> <span class="NLM_lpage">2122</span><span class="refDoi"> DOI: 10.1056/NEJMoa0706628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa0706628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=17984165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2109-2122&author=P.+J.+Barterauthor=M.+Caulfieldauthor=M.+Erikssonauthor=S.+M.+Grundyauthor=J.+J.+Kasteleinauthor=M.+Komajdaauthor=J.+Lopez-Sendonauthor=L.+Moscaauthor=J.+C.+Tardifauthor=D.+D.+Watersauthor=C.+L.+Shearauthor=J.+H.+Revkinauthor=K.+A.+Buhrauthor=M.+R.+Fisherauthor=A.+R.+Tallauthor=B.+Brewer&title=Investigators%2C+I.+Effects+of+torcetrapib+in+patients+at+high+risk+for+coronary+events&doi=10.1056%2FNEJMoa0706628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of torcetrapib in patients at high risk for coronary events</span></div><div class="casAuthors">Barter, Philip J.; Caulfield, Mark; Eriksson, Mats; Grundy, Scott M.; Kastelein, John J. P.; Komajda, Michel; Lopez-Sendon, Jose; Mosca, Lori; Tardif, Jean-Claude; Waters, David D.; Shear, Charles L.; Revkin, James H.; Buhr, Kevin A.; Fisher, Marian R.; Tall, Alan R.; Brewer, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2109-2122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels.  We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events.  The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.  Methods: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk.  The patients received either torcetrapib plus atorvastatin or atorvastatin alone.  The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.  Results: At 12 mo in patients who received torcetrapib, there was an increase of 72.1% in high-d. lipoprotein cholesterol and a decrease of 24.9% in low-d. lipoprotein cholesterol, as compared with baseline (P < 0.001 for both comparisons), in addn. to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P < 0.001 for all comparisons).  There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P = 0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P = 0.006).  Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose redn. in potassium or increase in bicarbonate was greater than the median change.  Conclusions: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism.  Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjJJlK3IwJbVg90H21EOLACvtfcHk0li_23PiSWag1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL&md5=36913112326b0998658eaf6ea95b3ff9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706628%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DCaulfield%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DM.%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%26aulast%3DMosca%26aufirst%3DL.%26aulast%3DTardif%26aufirst%3DJ.%2BC.%26aulast%3DWaters%26aufirst%3DD.%2BD.%26aulast%3DShear%26aufirst%3DC.%2BL.%26aulast%3DRevkin%26aufirst%3DJ.%2BH.%26aulast%3DBuhr%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BR.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DBrewer%26aufirst%3DB.%26atitle%3DInvestigators%252C%2520I.%2520Effects%2520of%2520torcetrapib%2520in%2520patients%2520at%2520high%2520risk%2520for%2520coronary%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2109%26epage%3D2122%26doi%3D10.1056%2FNEJMoa0706628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briscoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparrow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woltmann, R. F.</span><span> </span><span class="NLM_article-title">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span><span class="refDoi"> DOI: 10.1038/bjp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fbjp.2008.229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18536749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1465-1473&author=M.+J.+Forrestauthor=D.+Bloomfieldauthor=R.+J.+Briscoeauthor=P.+N.+Brownauthor=A.+M.+Cumiskeyauthor=J.+Ehrhartauthor=J.+C.+Hersheyauthor=W.+J.+Kellerauthor=X.+Maauthor=H.+E.+McPhersonauthor=E.+Messinaauthor=L.+B.+Petersonauthor=W.+Sharif-Rodriguezauthor=P.+K.+Sieglauthor=P.+J.+Sinclairauthor=C.+P.+Sparrowauthor=A.+S.+Stevensonauthor=S.+Y.+Sunauthor=C.+Tsaiauthor=H.+Vargasauthor=M.+Walkerauthor=S.+H.+Westauthor=V.+Whiteauthor=R.+F.+Woltmann&title=Torcetrapib-induced+blood+pressure+elevation+is+independent+of+CETP+inhibition+and+is+accompanied+by+increased+circulating+levels+of+aldosterone&doi=10.1038%2Fbjp.2008.229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span></div><div class="casAuthors">Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1473</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high d. lipoprotein (HDL) cholesterol levels but is assocd. with increased blood pressure.  In a phase 3 clin. study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib.  The studies reported herein sought to evaluate off-target effects of torcetrapib.  Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models.  Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was obsd. with anacetrapib.  The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists.  Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator.  Treatment with torcetrapib was assocd. with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells.  Increased adrenal steroid levels were not obsd. with anacetrapib.  Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats.  Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids.  The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhvVtQh2IkLVg90H21EOLACvtfcHk0li_23PiSWag1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D&md5=c24fd90f9cbd9e8c2ab9c7994f8b21c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DBloomfield%26aufirst%3DD.%26aulast%3DBriscoe%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DHershey%26aufirst%3DJ.%2BC.%26aulast%3DKeller%26aufirst%3DW.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMcPherson%26aufirst%3DH.%2BE.%26aulast%3DMessina%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSinclair%26aufirst%3DP.%2BJ.%26aulast%3DSparrow%26aufirst%3DC.%2BP.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DWoltmann%26aufirst%3DR.%2BF.%26atitle%3DTorcetrapib-induced%2520blood%2520pressure%2520elevation%2520is%2520independent%2520of%2520CETP%2520inhibition%2520and%2520is%2520accompanied%2520by%2520increased%2520circulating%2520levels%2520of%2520aldosterone%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1465%26epage%3D1473%26doi%3D10.1038%2Fbjp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Stroes, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benardeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clerc, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesor, E. J.</span><span> </span><span class="NLM_article-title">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">–</span> <span class="NLM_lpage">1770</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00460.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1111%2Fj.1476-5381.2009.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=19917065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1763-1770&author=E.+S.+Stroesauthor=J.+J.+Kasteleinauthor=A.+Benardeauauthor=O.+Kuhlmannauthor=D.+Blumauthor=L.+A.+Camposauthor=R.+G.+Clercauthor=E.+J.+Niesor&title=Dalcetrapib%3A+no+off-target+toxicity+on+blood+pressure+or+on+genes+related+to+the+renin-angiotensin-aldosterone+system+in+rats&doi=10.1111%2Fj.1476-5381.2009.00460.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span></div><div class="casAuthors">Stroes, E. S. G.; Kastelein, J. J. P.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1763-1770</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The assocn. between torcetrapib and its off-target effects on blood pressure suggested a possible class-specific effect.  The effects of dalcetrapib (RO4607381/JTT-705) and torcetrapib on haemodynamics and the renin-angiotensin-aldosterone system (RAAS) were therefore assessed in a rat model.  Arterial pressure (AP) and heart rate were measured by telemetry in normotensive and spontaneously hypertensive rats (SHR) receiving torcetrapib 10, 40, or 80 mg/kg-1/day-1; dalcetrapib 100, 300, or 500 mg-1/kg/day-1; or vehicle (placebo) for 5 days.  Expression of RAAS genes in adrenal gland, kidney, aorta and lung from normotensive rats following 5 days' treatment with torcetrapib 40 mg/kg-1/day-1, dalcetrapib 500 mg/kg-1/day-1 or vehicle was measured by quant. polymerase chain reaction.  Torcetrapib transiently increased mean AP in normotensive rats (+3.7 ± 0.1 mmHg), whereas treatment in SHR resulted in a dose-dependent and sustained increase [+6.5 ± 0.6 mmHg with 40 mg/kg-1/day-1 at day 1 (P < 0.05 vs. placebo)], which lasted over the treatment period.  No changes in AP or heart rate were obsd. with dalcetrapib.  Torcetrapib, but not dalcetrapib, increased RAAS-related mRNAs in adrenal glands and aortas.  In contrast to torcetrapib, dalcetrapib did not increase blood pressure or RAAS-related gene expression in rats, suggesting that the off-target effects of torcetrapib are not a common feature of all compds. acting on cholesteryl ester transfer protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SJRkg9vZAbVg90H21EOLACvtfcHk0ljT3nGr81Uy8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL&md5=f907da070f24a4fe86e1398869c86de8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DStroes%26aufirst%3DE.%2BS.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DBenardeau%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DO.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DCampos%26aufirst%3DL.%2BA.%26aulast%3DClerc%26aufirst%3DR.%2BG.%26aulast%3DNiesor%26aufirst%3DE.%2BJ.%26atitle%3DDalcetrapib%253A%2520no%2520off-target%2520toxicity%2520on%2520blood%2520pressure%2520or%2520on%2520genes%2520related%2520to%2520the%2520renin-angiotensin-aldosterone%2520system%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1763%26epage%3D1770%26doi%3D10.1111%2Fj.1476-5381.2009.00460.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span> </span><span class="NLM_article-title">Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1210/en.2008-1512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1210%2Fen.2008-1512" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2009&pages=2211-2219&author=X.+Huauthor=J.+D.+Dietzauthor=C.+Xiaauthor=D.+R.+Knightauthor=W.+T.+Logingauthor=A.+H.+Smithauthor=H.+Yuanauthor=D.+A.+Perryauthor=J.+Keiser&title=Torcetrapib+induces+aldosterone+and+cortisol+production+by+an+intracellular+calcium-mediated+mechanism+independently+of+cholesteryl+ester+transfer+protein+inhibition&doi=10.1210%2Fen.2008-1512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1210%2Fen.2008-1512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2008-1512%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDietz%26aufirst%3DJ.%2BD.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DD.%2BR.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DSmith%26aufirst%3DA.%2BH.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DJ.%26atitle%3DTorcetrapib%2520induces%2520aldosterone%2520and%2520cortisol%2520production%2520by%2520an%2520intracellular%2520calcium-mediated%2520mechanism%2520independently%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%26jtitle%3DEndocrinology%26date%3D2009%26volume%3D150%26spage%3D2211%26epage%3D2219%26doi%3D10.1210%2Fen.2008-1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Johns, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.2165/11599310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.2165%2F11599310-000000000-00000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=491-507&author=D.+G.+Johnsauthor=J.+Duffyauthor=T.+Fisherauthor=B.+K.+Hubbardauthor=M.+J.+Forrest&title=On-+and+off-target+pharmacology+of+torcetrapib%3A+current+understanding+and+implications+for+the+structure+activity+relationships+%28SAR%29%2C+discovery+and+development+of+cholesteryl+ester-transfer+protein+%28CETP%29+inhibitors&doi=10.2165%2F11599310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2165%2F11599310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DJohns%26aufirst%3DD.%2BG.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DT.%26aulast%3DHubbard%26aufirst%3DB.%2BK.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DOn-%2520and%2520off-target%2520pharmacology%2520of%2520torcetrapib%253A%2520current%2520understanding%2520and%2520implications%2520for%2520the%2520structure%2520activity%2520relationships%2520%2528SAR%2529%252C%2520discovery%2520and%2520development%2520of%2520cholesteryl%2520ester-transfer%2520protein%2520%2528CETP%2529%2520inhibitors%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D491%26epage%3D507%26doi%3D10.2165%2F11599310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Schwartz, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaitman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallend, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitersdorf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dal-OUTCOMES Investigators</span><span> </span><span class="NLM_article-title">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2089</span><span class="NLM_x">–</span> <span class="NLM_lpage">2099</span><span class="refDoi"> DOI: 10.1056/NEJMoa1206797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa1206797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=23126252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2089-2099&author=G.+G.+Schwartzauthor=A.+G.+Olssonauthor=M.+Abtauthor=C.+M.+Ballantyneauthor=P.+J.+Barterauthor=J.+Brummauthor=B.+R.+Chaitmanauthor=I.+M.+Holmeauthor=D.+Kallendauthor=L.+A.+Leiterauthor=E.+Leitersdorfauthor=J.+J.+McMurrayauthor=H.+Mundlauthor=S.+J.+Nichollsauthor=P.+K.+Shahauthor=J.+C.+Tardifauthor=R.+S.+Wrightauthor=dal-OUTCOMES+Investigators&title=Effects+of+dalcetrapib+in+patients+with+a+recent+acute+coronary+syndrome&doi=10.1056%2FNEJMoa1206797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span></div><div class="casAuthors">Schwartz, Gregory G.; Olsson, Anders G.; Abt, Markus; Ballantyne, Christie M.; Barter, Philip J.; Brumm, Jochen; Chaitman, Bernard R.; Holme, Ingar M.; Kallend, David; Leiter, Lawrence A.; Leitersdorf, Eran; McMurray, John J. V.; Mundl, Hardi; Nicholls, Stephen J.; Shah, Prediman K.; Tardif, Jean-Claude; Wright, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2089-2099</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: In observational analyses, higher levels of high-d. lipoprotein (HDL) cholesterol have been assocd. with a lower risk of coronary heart disease events.  However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain.  Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.  Methods: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addn. to the best available evidence-based care.  The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.  Results: At the time of randomization, the mean HDL cholesterol level was 42 mg per dL (1.1 mmol per L), and the mean low-d. lipoprotein (LDL) cholesterol level was 76 mg per dL (2.0 mmol per L).  Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group.  Dalcetrapib had a minimal effect on LDL cholesterol levels.  Patients were followed for a median of 31 mo.  At a prespecified interim anal. that included 1135 primary end-point events (71% of the projected total no.), the independent data and safety monitoring board recommended termination of the trial for futility.  As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, resp.; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality.  The median C-reactive protein level was 0.2 mg per L higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons).  Conclusions: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppAqt1S8zjbVg90H21EOLACvtfcHk0ljT3nGr81Uy8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK&md5=a9bcd3b77461ed5ef7e14fdbd8101a7b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1206797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1206797%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BG.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DAbt%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrumm%26aufirst%3DJ.%26aulast%3DChaitman%26aufirst%3DB.%2BR.%26aulast%3DHolme%26aufirst%3DI.%2BM.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DLeitersdorf%26aufirst%3DE.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DMundl%26aufirst%3DH.%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DTardif%26aufirst%3DJ.%2BC.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3D%26atitle%3DEffects%2520of%2520dalcetrapib%2520in%2520patients%2520with%2520a%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2089%26epage%3D2099%26doi%3D10.1056%2FNEJMoa1206797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoff, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grainger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riesmeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangerow, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruotolo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerakkody, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissen, S. E.</span><span> </span><span class="NLM_article-title">Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1069</span><span class="refDoi"> DOI: 10.1016/j.ahj.2015.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.ahj.2015.09.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=1061-1069&author=S.+J.+Nichollsauthor=A.+M.+Lincoffauthor=P.+J.+Barterauthor=H.+B.+Brewerauthor=K.+A.+Foxauthor=C.+M.+Gibsonauthor=C.+Graingerauthor=V.+Menonauthor=G.+Montalescotauthor=D.+Raderauthor=A.+R.+Tallauthor=E.+McErleanauthor=J.+Riesmeyerauthor=B.+Vangerowauthor=G.+Ruotoloauthor=G.+J.+Weerakkodyauthor=S.+E.+Nissen&title=Assessment+of+the+clinical+effects+of+cholesteryl+ester+transfer+protein+inhibition+with+evacetrapib+in+patients+at+high-risk+for+vascular+outcomes%3A+Rationale+and+design+of+the+ACCELERATE+trial&doi=10.1016%2Fj.ahj.2015.09.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2015.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2015.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DGrainger%26aufirst%3DC.%26aulast%3DMenon%26aufirst%3DV.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DRader%26aufirst%3DD.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DMcErlean%26aufirst%3DE.%26aulast%3DRiesmeyer%26aufirst%3DJ.%26aulast%3DVangerow%26aufirst%3DB.%26aulast%3DRuotolo%26aufirst%3DG.%26aulast%3DWeerakkody%26aufirst%3DG.%2BJ.%26aulast%3DNissen%26aufirst%3DS.%2BE.%26atitle%3DAssessment%2520of%2520the%2520clinical%2520effects%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%2520with%2520evacetrapib%2520in%2520patients%2520at%2520high-risk%2520for%2520vascular%2520outcomes%253A%2520Rationale%2520and%2520design%2520of%2520the%2520ACCELERATE%2520trial%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2015%26volume%3D170%26spage%3D1061%26epage%3D1069%26doi%3D10.1016%2Fj.ahj.2015.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rye, K. A.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein inhibition is not yet dead – <i>Pro</i></span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1161/ATVBAHA.115.306879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2FATVBAHA.115.306879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26848159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVKlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=439-441&author=P.+J.+Barterauthor=K.+A.+Rye&title=Cholesteryl+ester+transfer+protein+inhibition+is+not+yet+dead+%E2%80%93+Pro&doi=10.1161%2FATVBAHA.115.306879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead-Pro</span></div><div class="casAuthors">Barter, Philip J.; Rye, Kerry-Anne</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-441</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from nonatherogenic high-d. lipoproteins to potentially proatherogenic non-high-d. lipoprotein fractions.  Human genetic studies and human cohort studies have concluded that CETP gene polymorphisms assocd. with decreased CETP activity are accompanied by a significantly lower risk of atherosclerotic cardiovascular disease.  Inhibition of CETP in rabbits reduces development of diet-induced atherosclerosis.  Inhibition of CETP in humans reduces non-high-d. lipoprotein cholesterol while increasing high-d. lipoproteins cholesterol, consistent with a reduced risk of having an atherosclerotic cardiovascular disease event.  The failure of randomized human clin. outcome trials with 3 different CETP inhibitors may have been the consequence of either off-target adverse effects of the drug used or problems with the design of the trials.  The hypothesis that CETP inhibition reduces atherosclerotic cardiovascular disease risk is still untested.  The future of CETP inhibition as a cardio-protective strategy will depend on the outcome of the ongoing Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial with the CETP inhibitor, anacetrapib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8ECU0zUIUsLVg90H21EOLACvtfcHk0liu6kiXpQrdBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVKlsr0%253D&md5=d7f9341fac058369561b5c706e4e5e1e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.115.306879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.115.306879%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DRye%26aufirst%3DK.%2BA.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%2520inhibition%2520is%2520not%2520yet%2520dead%2520%25E2%2580%2593%2520Pro%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D439%26epage%3D441%26doi%3D10.1161%2FATVBAHA.115.306879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">HPS3/TIMI55-REVEAL Collaborative Group</span><span> </span><span class="NLM_article-title">Effects of anacetrapib in patients with atherosclerotic vascular disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span><span class="refDoi"> DOI: 10.1056/NEJMoa1706444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa1706444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=28847206" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1217-1227&author=HPS3%2FTIMI55-REVEAL+Collaborative+Group&title=Effects+of+anacetrapib+in+patients+with+atherosclerotic+vascular+disease&doi=10.1056%2FNEJMoa1706444"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706444%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEffects%2520of%2520anacetrapib%2520in%2520patients%2520with%2520atherosclerotic%2520vascular%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1217%26epage%3D1227%26doi%3D10.1056%2FNEJMoa1706444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, X.</span><span> </span><span class="NLM_article-title">Crystal structures of cholesteryl ester transfer protein in complex with inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">37321</span><span class="NLM_x">–</span> <span class="NLM_lpage">37329</span><span class="refDoi"> DOI: 10.1074/jbc.M112.380063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1074%2Fjbc.M112.380063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=22961980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37321-37329&author=S.+Liuauthor=A.+Mistryauthor=J.+M.+Reynoldsauthor=D.+B.+Lloydauthor=M.+C.+Grifforauthor=D.+A.+Perryauthor=R.+B.+Ruggeriauthor=R.+W.+Clarkauthor=X.+Qiu&title=Crystal+structures+of+cholesteryl+ester+transfer+protein+in+complex+with+inhibitors&doi=10.1074%2Fjbc.M112.380063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors</span></div><div class="casAuthors">Liu, Shenping; Mistry, Anil; Reynolds, Jennifer M.; Lloyd, David B.; Griffor, Matthew C.; Perry, David A.; Ruggeri, Roger B.; Clark, Ronald W.; Qiu, Xiayang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37321-37329</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human plasma cholesteryl ester transfer protein (CETP) transports cholesteryl ester from the antiatherogenic high-d. lipoproteins (HDL) to the proatherogenic low-d. and very low-d. lipoproteins (LDL and VLDL).  Inhibition of CETP has been shown to raise human plasma HDL cholesterol (HDL-C) levels and is potentially a novel approach for the prevention of cardiovascular diseases.  Here, we report the crystal structures of CETP in complex with torcetrapib, a CETP inhibitor that has been tested in phase 3 clin. trials, and compd. 2, an analog from a structurally distinct inhibitor series.  In both crystal structures, the inhibitors are buried deeply within the protein, shifting the bound cholesteryl ester in the N-terminal pocket of the long hydrophobic tunnel and displacing the phospholipid from that pocket.  The lipids in the C-terminal pocket of the hydrophobic tunnel remain unchanged.  The inhibitors are positioned near the narrowing neck of the hydrophobic tunnel of CETP and thus block the connection between the N- and C-terminal pockets.  These structures illuminate the unusual inhibition mechanism of these compds. and support the tunnel mechanism for neutral lipid transfer by CETP.  These highly lipophilic inhibitors bind mainly through extensive hydrophobic interactions with the protein and the shifted cholesteryl ester mol.  However, polar residues, such as Ser-230 and His-232, are also found in the inhibitor binding site.  An enhanced understanding of the inhibitor binding site may provide opportunities to design novel CETP inhibitors possessing more drug-like phys. properties, distinct modes of action, or alternative pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnCzSbL7tPrVg90H21EOLACvtfcHk0liu6kiXpQrdBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs7zJ&md5=04e3f7a33d893f05fadada46ad6deb9d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.380063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.380063%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DLloyd%26aufirst%3DD.%2BB.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DQiu%26aufirst%3DX.%26atitle%3DCrystal%2520structures%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37321%26epage%3D37329%26doi%3D10.1074%2Fjbc.M112.380063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panebianco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoydonck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laethem, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez-Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilliard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bortel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Huniti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykstra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span> </span><span class="NLM_article-title">Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2009.03465.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1111%2Fj.1365-2125.2009.03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=19843057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyis73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=535-545&author=R.+Krishnaauthor=A.+Gargauthor=D.+Panebiancoauthor=J.+Coteauthor=A.+J.+Bergmanauthor=P.+Van+Hoydonckauthor=T.+Laethemauthor=K.+Van+Dyckauthor=J.+Chenauthor=C.+Chavez-Engauthor=L.+Archerauthor=R.+Lutzauthor=D.+Hilliardauthor=K.+Snyderauthor=B.+Jinauthor=L.+Van+Bortelauthor=K.+C.+Lasseterauthor=N.+Al-Hunitiauthor=K.+Dykstraauthor=K.+Gottesdienerauthor=J.+A.+Wagner&title=Single-dose+pharmacokinetics+and+pharmacodynamics+of+anacetrapib%2C+a+potent+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitor%2C+in+healthy+subjects&doi=10.1111%2Fj.1365-2125.2009.03465.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects</span></div><div class="casAuthors">Krishna, Rajesh; Garg, Amit; Panebianco, Deborah; Cote, Josee; Bergman, Arthur J.; Van Hoydonck, Pascale; Laethem, Tine; Van Dyck, Kristien; Chen, Jingjing; Chavez-Eng, Cynthia; Archer, Laura; Lutz, Ryan; Hilliard, Deborah; Snyder, Karen; Jin, Bo; Van Bortel, Luc; Lasseter, Kenneth C.; Al-Huniti, Nidal; Dykstra, Kevin; Gottesdiener, Keith; Wagner, John A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-545</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS Anacetrapib is an orally active and potent inhibitor of CETP in development for the treatment of dyslipidemia.  These studies endeavoured to establish the safety, tolerability, pharmacokinetics and pharmacodynamics of rising single doses of anacetrapib, administered in fasted or fed conditions, and to preliminarily assess the effect of food, age, gender and obesity on the single-dose pharmacokinetics and pharmacodynamics of anacetrapib.  METHODS Safety, tolerability, anacetrapib concns. and CETP activity were evaluated.  RESULTS Anacetrapib was rapidly absorbed, with peak concns. occurring at ∼4 h post-dose and an apparent terminal half-life ranging from ∼9 to 62 h in the fasted state and from ∼42 to ∼83 h in the fed state.  Plasma AUC and Cmax appeared to increase in a less than approx. dose-dependent manner in the fasted state, with an apparent plateau in absorption at higher doses.  Single doses of anacetrapib markedly and dose-dependently inhibited serum CETP activity with peak effects of ∼90% inhibition at tmax and ∼58% inhibition at 24 h post-dose.  An Emax model best described the plasma anacetrapib concn. vs CETP activity relationship with an EC50 of ∼22 nM.  Food increased exposure to anacetrapib; up to ∼two-three-fold with a low-fat meal and by up to ∼six-eight fold with a high-fat meal.  Anacetrapib pharmacokinetics and pharmacodynamics were similar in elderly vs young adults, women vs men, and obese vs non-obese young adults.  Anacetrapib was well tolerated and was not assocd. with any meaningful increase in blood pressure.  CONCLUSIONS Whereas food increased exposure to anacetrapib significantly, age, gender and obese status did not meaningfully influence anacetrapib pharmacokinetics and pharmacodynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCk8KUowPfKLVg90H21EOLACvtfcHk0lgJl-UtbPP9bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyis73J&md5=b8e576da068c883896816f910ef48549</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2009.03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2009.03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DGarg%26aufirst%3DA.%26aulast%3DPanebianco%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DA.%2BJ.%26aulast%3DVan%2BHoydonck%26aufirst%3DP.%26aulast%3DLaethem%26aufirst%3DT.%26aulast%3DVan%2BDyck%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChavez-Eng%26aufirst%3DC.%26aulast%3DArcher%26aufirst%3DL.%26aulast%3DLutz%26aufirst%3DR.%26aulast%3DHilliard%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DK.%26aulast%3DJin%26aufirst%3DB.%26aulast%3DVan%2BBortel%26aufirst%3DL.%26aulast%3DLasseter%26aufirst%3DK.%2BC.%26aulast%3DAl-Huniti%26aufirst%3DN.%26aulast%3DDykstra%26aufirst%3DK.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26atitle%3DSingle-dose%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520anacetrapib%252C%2520a%2520potent%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitor%252C%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D68%26spage%3D535%26epage%3D545%26doi%3D10.1111%2Fj.1365-2125.2009.03465.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lgJl-UtbPP9bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lgJl-UtbPP9bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, C. D.</span><span> </span><span class="NLM_article-title">LogD: lipophilicity for ionisable compounds</span> <span class="citation_source-journal">Chemosphere</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1408</span><span class="refDoi"> DOI: 10.1016/j.chemosphere.2008.04.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.chemosphere.2008.04.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18565570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=1401-1408&author=M.+Kahauthor=C.+D.+Brown&title=LogD%3A+lipophilicity+for+ionisable+compounds&doi=10.1016%2Fj.chemosphere.2008.04.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Log D: Lipophilicity for ionizable compounds</span></div><div class="casAuthors">Kah, Melanie; Brown, Colin D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemosphere</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1401-1408</span>CODEN:
                <span class="NLM_cas:coden">CMSHAF</span>;
        ISSN:<span class="NLM_cas:issn">0045-6535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  The octanol/water partition coeff. (Kow) for org. compds. is widely used in predictive environmental studies.  A significant proportion of contaminants of surface and ground water are ionizable (e.g. many pesticides, pharmaceuticals, metabolites).  Such compds. may be partially ionized dependent on the pH.  Since the neutral and ionic species exhibit different polarities, the Kow value of ionizable pesticides is pH dependent.  It is therefore essential to det. Kow values over the full range of pH that occurs in the environment in order to get appropriate predictors.  Numerous methods are available to measure lipophilicity but only a few are appropriate for ionizable pesticides (e.g. pH metric and filter probe methods).  Parameters such as pH and ionic strength need to be carefully controlled when working with ionizable compds.  Variation of these factors probably explains why literature can yield Kow values that differ by more than one order of magnitude for some compds.  In this article, Kow values obtained for six acidic pesticides with three different methods are compared as well (data from the literature, measured by pH metric method and calcd. with five computer programs).  The values used in predictive regression equations needs to be either measured with a suitable method or selected from the literature with great care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovGJvDX2SsPrVg90H21EOLACvtfcHk0liv1J1MiUE8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGmsLw%253D&md5=e35b5073cc61d6cdae39efb5881c8ad7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chemosphere.2008.04.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemosphere.2008.04.074%26sid%3Dliteratum%253Aachs%26aulast%3DKah%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26atitle%3DLogD%253A%2520lipophilicity%2520for%2520ionisable%2520compounds%26jtitle%3DChemosphere%26date%3D2008%26volume%3D72%26spage%3D1401%26epage%3D1408%26doi%3D10.1016%2Fj.chemosphere.2008.04.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Hirota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ieiri, I.</span><span> </span><span class="NLM_article-title">Drug-drug interactions that interfere with statin metabolism</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1435</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span><span class="refDoi"> DOI: 10.1517/17425255.2015.1056149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1517%2F17425255.2015.1056149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26058399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1435-1447&author=T.+Hirotaauthor=I.+Ieiri&title=Drug-drug+interactions+that+interfere+with+statin+metabolism&doi=10.1517%2F17425255.2015.1056149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions that interfere with statin metabolism</span></div><div class="casAuthors">Hirota, Takeshi; Ieiri, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1447</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Lipid-lowering drugs, esp. hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases.  The benefits of statins are well documented.  However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been assocd. with the use of statins.  In some cases, this toxicity is assocd. with pharmacokinetic alterations.  Potent inhibitors of CYP 3A4 significantly increase plasma concns. of the active forms of simvastatin, lovastatin and atorvastatin.  Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.  This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metab. of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.  An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions.  Quant. analyzed information for the low-d. lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-G_q1DYD7ALVg90H21EOLACvtfcHk0liv1J1MiUE8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntLvO&md5=9ec84303e67b64049feaaa0722fb6001</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1056149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1056149%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DT.%26aulast%3DIeiri%26aufirst%3DI.%26atitle%3DDrug-drug%2520interactions%2520that%2520interfere%2520with%2520statin%2520metabolism%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26spage%3D1435%26epage%3D1447%26doi%3D10.1517%2F17425255.2015.1056149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lewis, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span> </span><span class="NLM_article-title">Quantitative structure-activity relationships (QSars) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding</span> <span class="citation_source-journal">J. Enzyme Inhib. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1080/14756360500532747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1080%2F14756360500532747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=16789425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1ajtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=127-132&author=D.+F.+Lewisauthor=B.+G.+Lakeauthor=M.+Dickins&title=Quantitative+structure-activity+relationships+%28QSars%29+in+CYP3A4+inhibitors%3A+the+importance+of+lipophilic+character+and+hydrogen+bonding&doi=10.1080%2F14756360500532747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding</span></div><div class="casAuthors">Lewis, David F. V.; Lake, Brian G.; Dickins, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The results of Quant. Structure-Activity Relationship (QSAR) analyses on three series of CYP3A4 inhibitors are reported for enzyme inhibition expressed as Ki values.  These include a small series of structurally related statins and two larger groupings of structurally diverse compds., some of which display competitive inhibition of CYP3A4 whereas others act via heme iron ligation.  In all cases, however, it is apparent that there are lipophilicity relationships assocd. with CYP3A4 inhibitory activity in the total of 46 compds. investigated.  This is evidenced by linear correlations between inhibition of CYP3A4 and the octanol-water partition coeff. (P value) when expressed logarithmically (ie., log P).  In the case of the statins, however, the distribution coeff. (D) at pH 7 is used due to the effect of compd. ionization.  Conversion of equil. consts. (ie. Ki and P) to the corresponding free energy changes (ΔG values) facilitates exploration of the likely intermol. forces of interaction between the inhibitors and the active site region of CYP3A4.  In this respect, there appears to be good agreement between QSAR analyses and mol. modeling of the CYP3A4 enzyme itself, and both are consistent with the known mechanisms of inhibition displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMt4lAzR-aILVg90H21EOLACvtfcHk0lhY5AdAbVDTdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1ajtLc%253D&md5=07c8373b6900504588cb076f4c96644e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F14756360500532747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360500532747%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BF.%26aulast%3DLake%26aufirst%3DB.%2BG.%26aulast%3DDickins%26aufirst%3DM.%26atitle%3DQuantitative%2520structure-activity%2520relationships%2520%2528QSars%2529%2520in%2520CYP3A4%2520inhibitors%253A%2520the%2520importance%2520of%2520lipophilic%2520character%2520and%2520hydrogen%2520bonding%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2006%26volume%3D21%26spage%3D127%26epage%3D132%26doi%3D10.1080%2F14756360500532747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Mogi, M.; Yamada, K.; Yasoshima, K.; Kawanami, T.; Umemura, I.; Iwaki, Y.; Qin, H.; Imase, H.</span><span> </span><span class="NLM_article-title">4-Benzylamino-1-carboxyacyl-piperidine Derivatives as CETP Inhibitors Useful for the Treatment of Diseases Such as Hyperlipidemia or Arteriosclerosis</span>. WIPO PCT WO 2009/059943A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Mogi&author=K.+Yamada&author=K.+Yasoshima&author=T.+Kawanami&author=I.+Umemura&author=Y.+Iwaki&author=H.+Qin&author=H.+Imase&title=4-Benzylamino-1-carboxyacyl-piperidine+Derivatives+as+CETP+Inhibitors+Useful+for+the+Treatment+of+Diseases+Such+as+Hyperlipidemia+or+Arteriosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DM.%26atitle%3D4-Benzylamino-1-carboxyacyl-piperidine%2520Derivatives%2520as%2520CETP%2520Inhibitors%2520Useful%2520for%2520the%2520Treatment%2520of%2520Diseases%2520Such%2520as%2520Hyperlipidemia%2520or%2520Arteriosclerosis%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Trieselmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamprecht, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremonesi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streicher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luippold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span> </span><span class="NLM_article-title">Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1′-spiro-substituted hexahydrofuroquinoline derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8766</span><span class="NLM_x">–</span> <span class="NLM_lpage">8776</span><span class="refDoi"> DOI: 10.1021/jm500431d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500431d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8766-8776&author=T.+Trieselmannauthor=H.+Wagnerauthor=K.+Fuchsauthor=D.+Hamprechtauthor=D.+Bertaauthor=P.+Cremonesiauthor=R.+Streicherauthor=G.+Luippoldauthor=A.+Volzauthor=M.+Markertauthor=H.+Nar&title=Potent+cholesteryl+ester+transfer+protein+inhibitors+of+reduced+lipophilicity%3A+1%2C1%E2%80%B2-spiro-substituted+hexahydrofuroquinoline+derivatives&doi=10.1021%2Fjm500431d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm500431d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500431d%26sid%3Dliteratum%253Aachs%26aulast%3DTrieselmann%26aufirst%3DT.%26aulast%3DWagner%26aufirst%3DH.%26aulast%3DFuchs%26aufirst%3DK.%26aulast%3DHamprecht%26aufirst%3DD.%26aulast%3DBerta%26aufirst%3DD.%26aulast%3DCremonesi%26aufirst%3DP.%26aulast%3DStreicher%26aufirst%3DR.%26aulast%3DLuippold%26aufirst%3DG.%26aulast%3DVolz%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26atitle%3DPotent%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%2520of%2520reduced%2520lipophilicity%253A%25201%252C1%25E2%2580%25B2-spiro-substituted%2520hexahydrofuroquinoline%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8766%26epage%3D8776%26doi%3D10.1021%2Fjm500431d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Gotto, A. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansky, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DEFINE Investigators</span><span> </span><span class="NLM_article-title">Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1016/j.amjcard.2013.08.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.amjcard.2013.08.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24188894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslajsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2014&pages=76-83&author=A.+M.+Gottoauthor=C.+P.+Cannonauthor=X.+S.+Liauthor=S.+Vaidyaauthor=U.+Kherauthor=E.+A.+Brintonauthor=M.+Davidsonauthor=J.+E.+Moonauthor=S.+Shahauthor=H.+M.+Danskyauthor=Y.+Mitchelauthor=P.+Barterauthor=DEFINE+Investigators&title=Evaluation+of+lipids%2C+drug+concentration%2C+and+safety+parameters+following+cessation+of+treatment+with+the+cholesteryl+ester+transfer+protein+inhibitor+anacetrapib+in+patients+with+or+at+high+risk+for+coronary+heart+disease&doi=10.1016%2Fj.amjcard.2013.08.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease</span></div><div class="casAuthors">Gotto, Antonio M.; Cannon, Christopher P.; Li, Xiujiang Susie; Vaidya, Sanskruti; Kher, Uma; Brinton, Eliot A.; Davidson, Michael; Moon, Jennifer E.; Shah, Sukrut; Dansky, Hayes M.; Mitchel, Yale; Barter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-83</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this study was to assess the effects on lipids and safety during a 12-wk reversal period after 18 mo of treatment with anacetrapib.  The cholesteryl ester transfer protein inhibitor anacetrapib was previously shown to reduce low-d. lipoprotein cholesterol by 39.8% (estd. using the Friedewald equation) and increase high-d. lipoprotein (HDL) cholesterol by 138.1%, with an acceptable side-effect profile, in patients with or at high risk for coronary heart disease in the Detg. the Efficacy and Tolerability of CETP Inhibition With Anacetrapib (DEFINE) trial.  A total of 1,398 patients entered the 12-wk reversal-phase study, either after completion of the active-treatment phase or after early discontinuation of the study medication.  In patients allocated to anacetrapib, placebo-adjusted mean percentage decreases from baseline were obsd. at 12 wk off the study drug for Friedewald-calcd. low-d. lipoprotein cholesterol (18.6%), non-HDL cholesterol (17.6%), and apolipoprotein B (10.2%); placebo-adjusted mean percentage increases were obsd. for HDL cholesterol (73.0%) and apolipoprotein A-I (24.5%).  Residual plasma anacetrapib levels (about 40% of on-treatment apparent steady-state trough levels) were also detected 12 wk after cessation of anacetrapib.  No clin. important elevations in liver enzymes, blood pressure, electrolytes, or adverse experiences were obsd. during the reversal phase.  Preliminary data from a small cohort (n = 30) revealed the presence of low concns. of anacetrapib in plasma 2.5 to 4 years after the last anacetrapib dose.  In conclusion, after the cessation of active treatment, anacetrapib plasma lipid changes and drug levels decreased to approx. 40% of on-treatment trough levels at 12 wk after dosing, but modest HDL cholesterol elevations and low drug concns. were still detectable 2 to 4 years after the last dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iSQ6XmMyZbVg90H21EOLACvtfcHk0ljVn8oi17P_KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslajsLzN&md5=fa70e20a5a463a78c9df31c4bf66f588</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2013.08.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2013.08.041%26sid%3Dliteratum%253Aachs%26aulast%3DGotto%26aufirst%3DA.%2BM.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%2BS.%26aulast%3DVaidya%26aufirst%3DS.%26aulast%3DKher%26aufirst%3DU.%26aulast%3DBrinton%26aufirst%3DE.%2BA.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DMoon%26aufirst%3DJ.%2BE.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DDansky%26aufirst%3DH.%2BM.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DBarter%26aufirst%3DP.%26aulast%3D%26atitle%3DEvaluation%2520of%2520lipids%252C%2520drug%2520concentration%252C%2520and%2520safety%2520parameters%2520following%2520cessation%2520of%2520treatment%2520with%2520the%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitor%2520anacetrapib%2520in%2520patients%2520with%2520or%2520at%2520high%2520risk%2520for%2520coronary%2520heart%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2014%26volume%3D113%26spage%3D76%26epage%3D83%26doi%3D10.1016%2Fj.amjcard.2013.08.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garigipati, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefker, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morehouse, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francone, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span> </span><span class="NLM_article-title">Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span><span class="refDoi"> DOI: 10.3109/00498254.2013.874611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.3109%2F00498254.2013.874611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24380613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Wjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=591-605&author=A.+S.+Kalgutkarauthor=K.+S.+Frederickauthor=H.+L.+Hatchauthor=C.+M.+Amblerauthor=D.+A.+Perryauthor=R.+S.+Garigipatiauthor=G.+C.+Changauthor=B.+A.+Lefkerauthor=R.+W.+Clarkauthor=L.+A.+Morehouseauthor=O.+Franconeauthor=X.+Hu&title=Identification+of+a+novel%2C+non-tetrahydroquinoline+variant+of+the+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitor+torcetrapib%2C+with+improved+aqueous+solubility&doi=10.3109%2F00498254.2013.874611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility</span></div><div class="casAuthors">Kalgutkar, Amit S.; Frederick, Kosea S.; Hatch, Heather L.; Ambler, Catherine M.; Perry, David A.; Garigipati, Ravi S.; Chang, George C.; Lefker, Bruce A.; Clark, Ronald W.; Morehouse, Lee A.; Francone, Omar; Hu, Xiao</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. Elaborate studies of cholesteryl ester transfer protein (CETP) polymorphisms and genetic deficiency in humans suggest direct links between CETP, high-d. lipoprotein cholesterol (HDL-c) levels and coronary heart diseases.  The hypothesis that CETP inhibition by small mol. inhibitors raises HDL-c has been validated clin. with structurally-diverse CETP inhibitors such as torcetrapib, anacetrapib, dalcetrapib and evacetrapib.  2. Despite promising phase 2 results with respect to HDL-c elevation, torcetrapib was discontinued in phase 3 trials due to increased mortality rates in the cardiovascular outcomes study.  Emerging evidence for the adverse effects hints at off-target chemotype-specific cardiovascular toxicity, possibly related to the pressor effects of torcetrapib, since structurally diverse CETP inhibitors such as anacetrapib, evacetrapib and dalcetrapib are not assocd. with blood pressure increases in humans.  Nonclin. follow-up studies showed that torcetrapib induces aldosterone biosynthesis and secretion in vivo and in vitro, an effect which is not obsd. with other CETP inhibitors in clin. development.  3. As part of ongoing efforts to identify novel CETP inhibitors devoid of pressor effects, strategies were implemented towards the design of compds., which lack the 1,2,3,4-tetrahydroquinoline (THQ) scaffold present in torcetrapib.  In this article, we disclose results of structure-activity relationship studies for a series of novel non-THQ CETP inhibitors, which resulted in the identification of a novel isonipecotic acid deriv. 10 (also referred to as PF-04445597) with vastly improved oral pharmacokinetic properties mainly as a result of improved aq. soly.  This feature is attractive in that, it bypasses significant investments needed to develop compatible solubilizing formulation(s) for oral drug delivery of highly lipophilic and poorly sol. compds.; attributes, which are usually assocd. with small mol. CETP inhibitors.  PF-04445597 was also devoid of aldosterone secretion in human H295R adrenal carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigP90-90on7Vg90H21EOLACvtfcHk0ljVn8oi17P_KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Wjsbg%253D&md5=a6986b98ad2edf52eef2f33bb3fd366c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3109%2F00498254.2013.874611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2013.874611%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DHatch%26aufirst%3DH.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DGarigipati%26aufirst%3DR.%2BS.%26aulast%3DChang%26aufirst%3DG.%2BC.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DMorehouse%26aufirst%3DL.%2BA.%26aulast%3DFrancone%26aufirst%3DO.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520a%2520novel%252C%2520non-tetrahydroquinoline%2520variant%2520of%2520the%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitor%2520torcetrapib%252C%2520with%2520improved%2520aqueous%2520solubility%26jtitle%3DXenobiotica%26date%3D2014%26volume%3D44%26spage%3D591%26epage%3D605%26doi%3D10.3109%2F00498254.2013.874611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Borensztajn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rone, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlar, T. J.</span><span> </span><span class="NLM_article-title">The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span><span class="refDoi"> DOI: 10.1042/bj1560539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1042%2Fbj1560539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1976&pages=539-543&author=J.+Borensztajnauthor=M.+S.+Roneauthor=T.+J.+Kotlar&title=The+inhibition+in+vivo+of+lipoprotein+lipase+%28clearing-factor+lipase%29+activity+by+triton+WR-1339&doi=10.1042%2Fbj1560539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1042%2Fbj1560539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj1560539%26sid%3Dliteratum%253Aachs%26aulast%3DBorensztajn%26aufirst%3DJ.%26aulast%3DRone%26aufirst%3DM.%2BS.%26aulast%3DKotlar%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520inhibition%2520in%2520vivo%2520of%2520lipoprotein%2520lipase%2520%2528clearing-factor%2520lipase%2529%2520activity%2520by%2520triton%2520WR-1339%26jtitle%3DBiochem.%2520J.%26date%3D1976%26volume%3D156%26spage%3D539%26epage%3D543%26doi%3D10.1042%2Fbj1560539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ugawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakuta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shikama, H.</span><span> </span><span class="NLM_article-title">YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0705229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fsj.bjp.0705229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=12746232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Ghs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2003&pages=140-146&author=T.+Ugawaauthor=H.+Kakutaauthor=H.+Moritaniauthor=O.+Inagakiauthor=H.+Shikama&title=YM-53601%2C+a+novel+squalene+synthase+inhibitor%2C+suppresses+lipogenic+biosynthesis+and+lipid+secretion+in+rodents&doi=10.1038%2Fsj.bjp.0705229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents</span></div><div class="casAuthors">Ugawa, Tohru; Kakuta, Hirotoshi; Moritani, Hiroshi; Inagaki, Osamu; Shikama, Hisataka</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-146</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To better understand how it decreases plasma cholesterol and triglyceride levels, we evaluated the effect of (E)-2-[2-fluoro-2-(quinuclidin-3-ylidene)ethoxy]-9H-carbazole monohydrochloride (YM-53601) on lipogenic biosynthesis in the liver and lipid secretion from the liver in rats and hamsters.  Single administration of YM-53601 in cholestyramine-treated rats inhibited triglyceride and free fatty acid (FFA) biosynthesis at a similar dose range to that at which it inhibited cholesterol biosynthesis.  YM-53601 inhibited both triglyceride and FFA biosynthesis in hamsters treated with cholestyramine.  YM-53601 by single oral administration decreased the enhanced plasma triglyceride levels in hamsters induced by an injection of protamine sulfate, which inhibits lipoprotein lipase (LPL) and consequently increases plasma very low-d. lipoprotein (VLDL) triglyceride levels.  YM-53601 also decreased the enhanced plasma triglyceride and cholesterol levels in hamsters treated with Triton WR1339, which also inhibits the degrdn. of VLDL.  Plasma cholesterol was significantly decreased as soon as 1 h after single administration of YM-53601 in hamsters fed a normal diet.  This is the first report that a squalene synthase inhibitor suppresses lipogenic biosynthesis in the liver and cholesterol and triglyceride secretion from the liver in vivo.  We therefore suggest that the mechanism by which YM-53601 decreases plasma triglyceride might include these effects.  The finding that YM-53601 rapidly decreased plasma cholesterol suggests that this compd. may be effective in decreasing plasma cholesterol levels early in the course of treatment of hypercholesterolemia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciODXXK8Q7LVg90H21EOLACvtfcHk0lg68ODtzv0rgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Ghs7o%253D&md5=6dfff3133d8723b6c2ac9c44982e78e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705229%26sid%3Dliteratum%253Aachs%26aulast%3DUgawa%26aufirst%3DT.%26aulast%3DKakuta%26aufirst%3DH.%26aulast%3DMoritani%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DO.%26aulast%3DShikama%26aufirst%3DH.%26atitle%3DYM-53601%252C%2520a%2520novel%2520squalene%2520synthase%2520inhibitor%252C%2520suppresses%2520lipogenic%2520biosynthesis%2520and%2520lipid%2520secretion%2520in%2520rodents%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D139%26spage%3D140%26epage%3D146%26doi%3D10.1038%2Fsj.bjp.0705229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Carroll, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kit, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shero, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mussolino, M. E.</span><span> </span><span class="NLM_article-title">Trends in lipids and lipoproteins in US adults, 1988–2010</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1545</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1001/jama.2012.13260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1001%2Fjama.2012.13260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1545-1554&author=M.+D.+Carrollauthor=B.+K.+Kitauthor=D.+A.+Lacherauthor=S.+T.+Sheroauthor=M.+E.+Mussolino&title=Trends+in+lipids+and+lipoproteins+in+US+adults%2C+1988%E2%80%932010&doi=10.1001%2Fjama.2012.13260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.13260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.13260%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DM.%2BD.%26aulast%3DKit%26aufirst%3DB.%2BK.%26aulast%3DLacher%26aufirst%3DD.%2BA.%26aulast%3DShero%26aufirst%3DS.%2BT.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26atitle%3DTrends%2520in%2520lipids%2520and%2520lipoproteins%2520in%2520US%2520adults%252C%25201988%25E2%2580%25932010%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1545%26epage%3D1554%26doi%3D10.1001%2Fjama.2012.13260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yunoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span> </span><span class="NLM_article-title">Postprandial hyperlipidemia as a potential residual risk factor</span> <span class="citation_source-journal">J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1016/j.jjcc.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.jjcc.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26744235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A280%3ADC%252BC28rotlCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=335-339&author=K.+Nakamuraauthor=T.+Miyoshiauthor=K.+Yunokiauthor=H.+Ito&title=Postprandial+hyperlipidemia+as+a+potential+residual+risk+factor&doi=10.1016%2Fj.jjcc.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Postprandial hyperlipidemia as a potential residual risk factor</span></div><div class="casAuthors">Nakamura Kazufumi; Miyoshi Toru; Ito Hiroshi; Yunoki Kei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Statin therapy targeting reduction of low-density lipoprotein cholesterol (LDL-C) decreases the risk of coronary heart disease (CHD) and all-cause mortality.  However, a substantial number of cases of CHD are not prevented and residual risk factors remain unsettled.  A high triglyceride (TG) level is considered to be an important and residual risk factor.  Postprandial hyperlipidemia is a condition in which TG-rich chylomicron remnants are increased during the postprandial period and hypertriglycedemia is protracted.  Postprandial hyperlipidemia evokes atherogenesis during the postprandial period.  Several prospective studies have revealed that nonfasting serum TG levels predict the incidence of CHD.  Values of TG, remnant lipoprotein cholesterol, and remnant lipoprotein TG after fat loading were significantly higher in diabetes patients with insulin resistance than in diabetes patients without insulin resistance.  Endothelial dysfunction is an initial process of atherogenesis and it contributes to the pathogenesis of CHD.  Postprandial hyperlipidemia (postprandial hypertriglyceridemia) is involved in the production of proinflammatory cytokines, recruitment of neutrophils, and generation of oxidative stress, resulting in endothelial dysfunction in healthy subjects, hypertriglyceridemic patients, or type 2 diabetic patients.  Effective treatment has not been established till date.  Ezetimibe or omega-3 fatty acids significantly decrease postprandial TG elevation and postprandial endothelial dysfunction.  Ezetimibe or omega-3 fatty acids added to statin therapy reduce serum TG levels and result in good outcomes in patients with CHD.  In conclusion, postprandial hyperlipidemia is an important and residual risk factor especially in patients with insulin resistance syndrome (metabolic syndrome) and diabetes mellitus.  Further studies are needed to establish effective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRN_Yn6hKKU5f3jf77P2BG3fW6udTcc2eY1emnC1SCn9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rotlCnug%253D%253D&md5=84590c36e8a97aba740ef3d5dd89a156</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jjcc.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jjcc.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DYunoki%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPostprandial%2520hyperlipidemia%2520as%2520a%2520potential%2520residual%2520risk%2520factor%26jtitle%3DJ.%2520Cardiol.%26date%3D2016%26volume%3D67%26spage%3D335%26epage%3D339%26doi%3D10.1016%2Fj.jjcc.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Wojczynski, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parnell, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feitosa, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier-Wood, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslibekyan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Province, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiwari, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordovas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuldiner, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnett, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borecki, I. B.</span><span> </span><span class="NLM_article-title">Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)</span> <span class="citation_source-journal">Metab., Clin. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1016/j.metabol.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.metabol.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26256467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12rs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1359-1371&author=M.+K.+Wojczynskiauthor=L.+D.+Parnellauthor=T.+I.+Pollinauthor=C.+Q.+Laiauthor=M.+F.+Feitosaauthor=J.+R.+O%E2%80%99Connellauthor=A.+C.+Frazier-Woodauthor=Q.+Gibsonauthor=S.+Aslibekyanauthor=K.+A.+Ryanauthor=M.+A.+Provinceauthor=H.+K.+Tiwariauthor=J.+M.+Ordovasauthor=A.+R.+Shuldinerauthor=D.+K.+Arnettauthor=I.+B.+Borecki&title=Genome-wide+association+study+of+triglyceride+response+to+a+high-fat+meal+among+participants+of+the+NHLBI+Genetics+of+Lipid+Lowering+Drugs+and+Diet+Network+%28GOLDN%29&doi=10.1016%2Fj.metabol.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)</span></div><div class="casAuthors">Wojczynski, Mary K.; Parnell, Laurence D.; Pollin, Toni I.; Lai, Chao Q.; Feitosa, Mary F.; O'Connell, Jeff R.; Frazier-Wood, Alexis C.; Gibson, Quince; Aslibekyan, Stella; Ryan, Kathy A.; Province, Michael A.; Tiwari, Hemant K.; Ordovas, Jose M.; Shuldiner, Alan R.; Arnett, Donna K.; Borecki, Ingrid B.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1359-1371</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The triglyceride (TG) response to a high-fat meal (postprandial lipemia, PPL) affects cardiovascular disease risk and is influenced by genes and environment.  Genes involved in lipid metab. have dominated genetic studies of PPL TG response.  We sought to elucidate common genetic variants through a genome-wide assocn. (GWA) study in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN).  The GOLDN GWAS discovery sample consisted of 872 participants within families of European ancestry.  Genotypes for 2,543,887 variants were measured or imputed from HapMap.  Replication of our top results was performed in the Heredity and Phenotype Intervention (HAPI) Heart Study (n = 843).  PPL TG response phenotypes were constructed from plasma TG measured at baseline (fasting, 0 h), 3.5 and 6 h after a high-fat meal, using a random coeff. regression model.  Assocn. analyses were adjusted for covariates and principal components, as necessary, in a linear mixed model using the kinship matrix; addnl. models further adjusted for fasting TG were also performed.  Meta-anal. of the discovery and replication studies (n = 1715) was performed on the top SNPs from GOLDN.  GOLDN revealed 111 suggestive (p < 1E-05) assocns., with two SNPs meeting GWA significance level (p < 5E-08).  Of the two significant SNPs, rs964184 demonstrated evidence of replication (p = 1.20E-03) in the HAPI Heart Study and in a joint anal., was GWA significant (p = 1.26E-09).  Rs964184 has been assocd. with fasting lipids (TG and HDL) and is near ZPR1 (formerly ZNF259), close to the APOA1/C3/A4/A5 cluster.  This assocn. was attenuated upon addnl. adjustment for fasting TG.  This is the first report of a genome-wide significant assocn. with replication for a novel phenotype, namely PPL TG response.  Future investigation into response phenotypes is warranted using pathway analyses, or newer genetic technologies such as metabolomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiwAZ-D6B3tLVg90H21EOLACvtfcHk0lg68ODtzv0rgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12rs77L&md5=e33e07aa6ea324c40530a54a4d0dee09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWojczynski%26aufirst%3DM.%2BK.%26aulast%3DParnell%26aufirst%3DL.%2BD.%26aulast%3DPollin%26aufirst%3DT.%2BI.%26aulast%3DLai%26aufirst%3DC.%2BQ.%26aulast%3DFeitosa%26aufirst%3DM.%2BF.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BR.%26aulast%3DFrazier-Wood%26aufirst%3DA.%2BC.%26aulast%3DGibson%26aufirst%3DQ.%26aulast%3DAslibekyan%26aufirst%3DS.%26aulast%3DRyan%26aufirst%3DK.%2BA.%26aulast%3DProvince%26aufirst%3DM.%2BA.%26aulast%3DTiwari%26aufirst%3DH.%2BK.%26aulast%3DOrdovas%26aufirst%3DJ.%2BM.%26aulast%3DShuldiner%26aufirst%3DA.%2BR.%26aulast%3DArnett%26aufirst%3DD.%2BK.%26aulast%3DBorecki%26aufirst%3DI.%2BB.%26atitle%3DGenome-wide%2520association%2520study%2520of%2520triglyceride%2520response%2520to%2520a%2520high-fat%2520meal%2520among%2520participants%2520of%2520the%2520NHLBI%2520Genetics%2520of%2520Lipid%2520Lowering%2520Drugs%2520and%2520Diet%2520Network%2520%2528GOLDN%2529%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2015%26volume%3D64%26spage%3D1359%26epage%3D1371%26doi%3D10.1016%2Fj.metabol.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Comins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamunyon, D. H.</span><span> </span><span class="NLM_article-title">Preparation of 1-(tert-butoxycarbonyl)-2,6-dialkyl-2,3-dihydro-4-pyridones – a stereocontrolled synthesis of (±)-myrtine</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">5053</span><span class="NLM_x">–</span> <span class="NLM_lpage">5056</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)93445-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2FS0040-4039%2801%2993445-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1989&pages=5053-5056&author=D.+L.+Cominsauthor=D.+H.+Lamunyon&title=Preparation+of+1-%28tert-butoxycarbonyl%29-2%2C6-dialkyl-2%2C3-dihydro-4-pyridones+%E2%80%93+a+stereocontrolled+synthesis+of+%28%C2%B1%29-myrtine&doi=10.1016%2FS0040-4039%2801%2993445-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2993445-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252993445-8%26sid%3Dliteratum%253Aachs%26aulast%3DComins%26aufirst%3DD.%2BL.%26aulast%3DLamunyon%26aufirst%3DD.%2BH.%26atitle%3DPreparation%2520of%25201-%2528tert-butoxycarbonyl%2529-2%252C6-dialkyl-2%252C3-dihydro-4-pyridones%2520%25E2%2580%2593%2520a%2520stereocontrolled%2520synthesis%2520of%2520%2528%25C2%25B1%2529-myrtine%26jtitle%3DTetrahedron%2520Lett.%26date%3D1989%26volume%3D30%26spage%3D5053%26epage%3D5056%26doi%3D10.1016%2FS0040-4039%2801%2993445-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients</span>. ClinicalTrials.gov; <span class="NLM_series">NCT01487460</span>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://clinicaltrials.gov/ct2/show/NCT01487460?term=tap311&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01487460?term=tap311&rank=1</a> (accessed Sep 22, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability%2C+Pharmacokinetics+and+Pharmacodynamics+of+TAP311+in+Healthy+Subjects+and+Dyslipidemic+Patients.+ClinicalTrials.gov%3B+NCT01487460%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2011%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01487460%3Fterm%3Dtap311%26rank%3D1+%28accessed+Sep+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520TAP311%2520in%2520Healthy%2520Subjects%2520and%2520Dyslipidemic%2520Patients%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Stiefl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buenemann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Drie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totrov, M.</span><span> </span><span class="NLM_article-title">FOCUS--Development of a global communication and modeling platform for applied and computational medicinal chemists</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span><span class="refDoi"> DOI: 10.1021/ci500598e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500598e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVShtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=896-908&author=N.+Stieflauthor=P.+Gedeckauthor=D.+Chinauthor=P.+Huntauthor=M.+Lindvallauthor=K.+Spiegelauthor=C.+Springerauthor=S.+Billerauthor=C.+Buenemannauthor=T.+Kanazawaauthor=M.+Katoauthor=R.+Lewisauthor=E.+Martinauthor=V.+Polyakovauthor=R.+Tommasiauthor=J.+van+Drieauthor=B.+Vashauthor=L.+Whiteheadauthor=Y.+Xuauthor=R.+Abagyanauthor=E.+Raushauthor=M.+Totrov&title=FOCUS%2D%2DDevelopment+of+a+global+communication+and+modeling+platform+for+applied+and+computational+medicinal+chemists&doi=10.1021%2Fci500598e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">FOCUS - Development of a Global Communication and Modeling Platform for Applied and Computational Medicinal Chemists</span></div><div class="casAuthors">Stiefl, Nikolaus; Gedeck, Peter; Chin, Donovan; Hunt, Peter; Lindvall, Mika; Spiegel, Katrin; Springer, Clayton; Biller, Scott; Buenemann, Christoph; Kanazawa, Takanori; Kato, Mitsunori; Lewis, Richard; Martin, Eric; Polyakov, Valery; Tommasi, Ruben; van Drie, John; Vash, Brian; Whitehead, Lewis; Xu, Yongjin; Abagyan, Ruben; Raush, Eugene; Totrov, Max</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">896-908</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Communication of data and ideas within a medicinal chem. project on a global as well as local level is a crucial aspect in the drug design cycle.  Over a time frame of eight years, we built and optimized FOCUS, a platform to produce, visualize, and share information on various aspects of a drug discovery project such as cheminformatics, data anal., structural information, and design.  FOCUS is tightly integrated with internal services that involve-among others-data retrieval systems and in-silico models and provides easy access to automated modeling procedures such as pharmacophore searches, R-group anal., and similarity searches.  In addn., an interactive 3D editor was developed to assist users in the generation and docking of close analogs of a known lead.  In this paper, we will specifically conc. on issues we faced during development, deployment, and maintenance of the software and how we continually adapted the software in order to improve usability.  We will provide usage examples to highlight the functionality as well as limitations of FOCUS at the various stages of the development process.  We aim to make the discussion as independent of the software platform as possible, so that our experiences can be of more general value to the drug discovery community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozGiXPjxVBHrVg90H21EOLACvtfcHk0liq8u7Z-aU2gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVShtr8%253D&md5=00541e43a6212701678a400e36996caf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fci500598e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500598e%26sid%3Dliteratum%253Aachs%26aulast%3DStiefl%26aufirst%3DN.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DChin%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DK.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DBuenemann%26aufirst%3DC.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3Dvan%2BDrie%26aufirst%3DJ.%26aulast%3DVash%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DRaush%26aufirst%3DE.%26aulast%3DTotrov%26aufirst%3DM.%26atitle%3DFOCUS--Development%2520of%2520a%2520global%2520communication%2520and%2520modeling%2520platform%2520for%2520applied%2520and%2520computational%2520medicinal%2520chemists%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D896%26epage%3D908%26doi%3D10.1021%2Fci500598e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original pKa prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span><span class="refDoi"> DOI: 10.1021/ci700018y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields&doi=10.1021%2Fci700018y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0liq8u7Z-aU2gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181%26doi%3D10.1021%2Fci700018y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wasan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. Y.</span><span> </span><span class="NLM_article-title">A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1023/A:1011951602894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1023%2FA%3A1011951602894" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=165-169&author=K.+M.+Wasanauthor=S.+M.+Cassidyauthor=M.+Ramaswamyauthor=A.+Kennedyauthor=F.+W.+Strobelauthor=S.+P.+Ngauthor=T.+Y.+Lee&title=A+comparison+of+step-gradient+and+sequential+density+ultracentrifugation+and+the+use+of+lipoprotein+deficient+plasma+controls+in+determining+the+plasma+lipoprotein+distribution+of+lipid-associated+nystatin+and+cyclosporine&doi=10.1023%2FA%3A1011951602894"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011951602894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011951602894%26sid%3Dliteratum%253Aachs%26aulast%3DWasan%26aufirst%3DK.%2BM.%26aulast%3DCassidy%26aufirst%3DS.%2BM.%26aulast%3DRamaswamy%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DStrobel%26aufirst%3DF.%2BW.%26aulast%3DNg%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DT.%2BY.%26atitle%3DA%2520comparison%2520of%2520step-gradient%2520and%2520sequential%2520density%2520ultracentrifugation%2520and%2520the%2520use%2520of%2520lipoprotein%2520deficient%2520plasma%2520controls%2520in%2520determining%2520the%2520plasma%2520lipoprotein%2520distribution%2520of%2520lipid-associated%2520nystatin%2520and%2520cyclosporine%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D165%26epage%3D169%26doi%3D10.1023%2FA%3A1011951602894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Silva</span>, <span class="hlFld-ContribAuthor ">Helge  Stray</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Ould Metidji</span>, <span class="hlFld-ContribAuthor ">Tor  Bjørnstad</span>. </span><span class="cited-content_cbyCitation_article-title">Thermal stability and interactions with sedimentary rocks under typical reservoir conditions of selected pyridines investigated as phase partitioning tracers. </span><span class="cited-content_cbyCitation_journal-name">Upstream Oil and Gas Technology</span><span> <strong>2021,</strong> <em>6 </em>, 100033. <a href="https://doi.org/10.1016/j.upstre.2021.100033" title="DOI URL">https://doi.org/10.1016/j.upstre.2021.100033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.upstre.2021.100033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.upstre.2021.100033%26sid%3Dliteratum%253Aachs%26jtitle%3DUpstream%2520Oil%2520and%2520Gas%2520Technology%26atitle%3DThermal%252Bstability%252Band%252Binteractions%252Bwith%252Bsedimentary%252Brocks%252Bunder%252Btypical%252Breservoir%252Bconditions%252Bof%252Bselected%252Bpyridines%252Binvestigated%252Bas%252Bphase%252Bpartitioning%252Btracers%26aulast%3DSilva%26aufirst%3DMario%26date%3D2021%26volume%3D6%26spage%3D100033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonia  de Castro</span>, <span class="hlFld-ContribAuthor ">Tiziana  Ginex</span>, <span class="hlFld-ContribAuthor ">Evelien  Vanderlinden</span>, <span class="hlFld-ContribAuthor ">Manon  Laporte</span>, <span class="hlFld-ContribAuthor ">Annelies  Stevaert</span>, <span class="hlFld-ContribAuthor ">José  Cumella</span>, <span class="hlFld-ContribAuthor ">Federico  Gago</span>, <span class="hlFld-ContribAuthor ">María José  Camarasa</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Lieve  Naesens</span>, <span class="hlFld-ContribAuthor ">Sonsoles  Velazquez</span>. </span><span class="cited-content_cbyCitation_article-title">N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>194 </em>, 112223. <a href="https://doi.org/10.1016/j.ejmech.2020.112223" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112223%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-benzyl%252B4%25252C4-disubstituted%252Bpiperidines%252Bas%252Ba%252Bpotent%252Bclass%252Bof%252Binfluenza%252BH1N1%252Bvirus%252Binhibitors%252Bshowing%252Ba%252Bnovel%252Bmechanism%252Bof%252Bhemagglutinin%252Bfusion%252Bpeptide%252Binteraction%26aulast%3Dde%2BCastro%26aufirst%3DSonia%26date%3D2020%26volume%3D194%26spage%3D112223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinran  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Lijuan  Hao</span>, <span class="hlFld-ContribAuthor ">Honglei  Xie</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Chunchi  Liu</span>, <span class="hlFld-ContribAuthor ">Wenyan  Li</span>, <span class="hlFld-ContribAuthor ">Xuqiong  Xiong</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">The therapeutic potential of CETP inhibitors: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2018,</strong> <em>28 </em>
                                    (4)
                                     , 331-340. <a href="https://doi.org/10.1080/13543776.2018.1439476" title="DOI URL">https://doi.org/10.1080/13543776.2018.1439476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2018.1439476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2018.1439476%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DThe%252Btherapeutic%252Bpotential%252Bof%252BCETP%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%26aulast%3DWang%26aufirst%3DXinran%26date%3D2018%26date%3D2018%26volume%3D28%26issue%3D4%26spage%3D331%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and cLogD<sub>pH7.4</sub> of CETP inhibitors that have reached phase 3 clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Initial optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR of the pyrimidine analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Final optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics and pharmacodynamics of anacetrapib and <b>16</b> in hamsters. Compound (0.3, 1, 3, and 10 mg/kg po) or vehicle (Veh) was dosed once a day for 14 days to hamsters fed a standard chow diet. Blood was withdrawn 24 h post last dose and analyzed for total compound concentrations (A), CETP inhibition (B), HDL-cholesterol levels (C), and LDL-cholesterol levels (D). Values are mean ± SEM of six animals. ** <i>P</i> < 0.01, significant versus the vehicle group (Dunnett’s multiple comparisons test following one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Distribution profiles of anacetrapib and compound <b>16</b> in various tissues of hamsters administered anacetrapib or compound <b>16</b>. Anacetrapib and compound <b>16</b> were dosed orally once each day for 14 days to hamsters fed a standard chow diet. Blood and tissues were collected 24 h after the final dose and analyzed for compound concentrations. Data represent mean total concentration ± SEM for seven animals per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of triglyceride level on efficacy of anacetrapib and <b>16</b>. (A) In vitro CETP activity IC<sub>50</sub> values of anacetrapib and <b>16</b> in serum pooled from donors with varying TG levels. Values are the mean of two replicates for each serum pool. (B) Ex vivo inhibition of plasma CETP activity by anacetrapib (Ana) and <b>16</b> dosed orally in hamsters treated with saline or Triton WR-1339 (Veh). Doses of Ana and <b>16</b> were 3 and 1.5 mg/kg, respectively. Plasma samples were collected 24 h post dose. Values are mean ± SEM of five animals. *<i>P</i> < 0.05, **<i>P</i> < 0.01, significant difference from each Veh group (Dunnett’s multiple comparisons test following one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vitro distribution profile of compound <b>16</b> among serum lipoproteins when spiked into serum from healthy donors with normal (A), high (B), or very high (C) triglyceride levels. The extraction of compound <b>16</b> was done in duplicate for each sample. The absolute mass of <b>16</b> was calculated in each fraction and, as shown in the <i>Y</i> axis, was expressed relative to the total sum of <b>16</b> in all lipoprotein pools (mean ± SEM). One-way ANOVA was performed to compare the percent distribution of <b>16</b> among serum lipoproteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vitro distribution of anacetrapib among serum lipoproteins when spiked into serum from healthy donors with normal (A), high (B), or very high (C) triglyceride levels. Anacetrapib extraction was done in duplicate for each sample. The absolute mass of anacetrapib was calculated in each fraction and, as shown in the <i>Y</i> axis, was expressed relative to the total sum of anacetrapib in all lipoprotein pools (mean ± SEM). One-way ANOVA was performed to compare the percent distribution of anacetrapib among serum lipoproteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PhOCOCl, EtMgBr, tetrahydrofuran, −40 °C; then <i>t</i>-BuOK (for <b>17b</b>) or BnOCOCl, BnMgBr (for <b>17c</b>); (b) BF<sub>3</sub>·Et<sub>2</sub>O, EtMgBr, CuI, tetrahydrofuran, −78 °C to rt; (c) 3,5-bis(trifluoromethyl)benzylamine, Ti(O<i>i</i>Pr)<sub>4</sub>, MeOH, then NaBH<sub>4</sub>, 0 °C to rt (<b>19a</b>), 3,5-bis(trifluoromethyl)benzylamine, NaBH(OAc)<sub>3</sub>, acetic acid, dichloroethane, 0 °C to rt (<b>19b</b>,<b>c</b>); (d) MeOCOCl, pyridine, 0 °C to rt (for <b>1</b>), or MeOCOCl, 4-dimethylaminopyridine, CH<sub>2</sub>Cl<sub>2</sub>, rt (for <b>2</b>, <b>20</b>); (e) PdCl<sub>2</sub>, Et<sub>3</sub>SiH, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt; (f) Boc<sub>2</sub>O, 60 °C, no solvent.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BnNH<sub>2</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, toluene, reflux, NaBH<sub>4</sub>, MeOH, rt; (b) Pd/C, H<sub>2</sub>, EtOH, 55 °C; (c) <i>i</i>-Pr<sub>2</sub>NEt, DMF, 120 °C; (d) NaH, DMF, 0 °C to rt; (e) 4 N HCl in EtOAc, rt; (f) EtNCO, iPr<sub>2</sub>NEt, DMF, rt (for <b>8</b>), or <i>n</i>-PrCOCl, iPr<sub>2</sub>NEt, DMF, rt (for <b>9</b>), or iPrOCOCl, iPr<sub>2</sub>NEt, DMF, rt (for <b>10</b>); (g) NaOMe, CuI, DMF, 85 °C (for <b>11</b>), or Pd<sub>2</sub>(dba)<sub>3</sub>, (2-biphenyl)di<i>tert</i>-butylphosphine, NaOtBu, morpholine, toluene, 100 °C (for <b>12</b>); (h) chiral HPLC.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/medium/jm-2017-00900t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-20/acs.jmedchem.7b00900/20171020/images/large/jm-2017-00900t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00900&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C to rt; (b) triphosgene, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) benzylamine, Ti(O-<i>i</i>-Pr)<sub>4,</sub> MeOH, rt, then NaBH<sub>4</sub>, 0 °C to rt; (d) Pd/C, H<sub>2</sub>, EtOH, 60 °C; (e) 2-chloro-5-bromopyrimidine, <i>i</i>-Pr<sub>2</sub>NEt, DMF, 120 °C; (f) 3,5-bis(trifluoromethyl)benzylamine, NaH, DMF, 0 °C to rt; (g) morpholine, Pd<sub>2</sub>(dba)<sub>3</sub>, (2-biphenyl)di-<i>tert</i>-butylphosphine, <i>t</i>-BuONa, toluene, 100 °C (<b>14</b> and <b>29a</b>), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME-H<sub>2</sub>O, 90 °C (<b>29b</b>); (h) 4 N HCl in EtOAc, rt, (i) <b>26</b>, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt; (j) NaOH, tetrahydrofuran–H<sub>2</sub>O, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i68">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emberson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armitage, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenthal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMets, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacMahon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulter, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preiss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandercock, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeeth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wald, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span> </span><span class="NLM_article-title">Interpretation of the evidence for the efficacy and safety of statin therapy</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2561</span><span class="refDoi"> DOI: 10.1016/S0140-6736(16)31357-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2FS0140-6736%2816%2931357-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=27616593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2gsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2532-2561&author=R.+Collinsauthor=C.+Reithauthor=J.+Embersonauthor=J.+Armitageauthor=C.+Baigentauthor=L.+Blackwellauthor=R.+Blumenthalauthor=J.+Daneshauthor=G.+D.+Smithauthor=D.+DeMetsauthor=S.+Evansauthor=M.+Lawauthor=S.+MacMahonauthor=S.+Martinauthor=B.+Nealauthor=N.+Poulterauthor=D.+Preissauthor=P.+Ridkerauthor=I.+Robertsauthor=A.+Rodgersauthor=P.+Sandercockauthor=K.+Schulzauthor=P.+Severauthor=J.+Simesauthor=L.+Smeethauthor=N.+Waldauthor=S.+Yusufauthor=R.+Peto&title=Interpretation+of+the+evidence+for+the+efficacy+and+safety+of+statin+therapy&doi=10.1016%2FS0140-6736%2816%2931357-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretation of the evidence for the efficacy and safety of statin therapy</span></div><div class="casAuthors">Collins, Rory; Reith, Christina; Emberson, Jonathan; Armitage, Jane; Baigent, Colin; Blackwell, Lisa; Blumenthal, Roger; Danesh, John; Davey Smith, George; DeMets, David; Evans, Stephen; Law, Malcolm; MacMahon, Stephen; Martin, Seth; Neal, Bruce; Poulter, Neil; Preiss, David; Ridker, Paul; Roberts, Ian; Rodgers, Anthony; Sandercock, Peter; Schulz, Kenneth; Sever, Peter; Simes, John; Smeeth, Liam; Wald, Nicholas; Yusuf, Salim; Peto, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10059</span>),
    <span class="NLM_cas:pages">2532-2561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes.  It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy.  In addn., it discusses how claims that statins commonly cause adverse effects reflect a failure to recognize the limitations of other sources of evidence about the effects of treatment.  Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L redn. in LDL cholesterol during each year (after the first) that it continues to be taken.  The abs. benefits of statin therapy depend on an individual's abs. risk of occlusive vascular events and the abs. redn. in LDL cholesterol that is achieved.  For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per mo) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% abs. benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% abs. benefit) who are at increased risk but have not yet had a vascular event (primary prevention).  Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger abs. benefits would accrue with more prolonged therapy, and these benefits persist long term.  The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concns. of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke.  Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes.  However, any adverse impact of these side-effects on major vascular events has already been taken into account in the ests. of the abs. benefits.  Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% abs. harm) per 10 000 treated for 5 years.  However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution).  The large-scale evidence available from randomised trials also indicates that it is unlikely that large abs. excesses in other serious adverse events still await discovery.  Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms.  It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events.  For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtn_rGxpXyT7Vg90H21EOLACvtfcHk0ljtSBNZWYYUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2gsr3E&md5=33303c53c45813e3bc564c1142c32854</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2931357-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252931357-5%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DReith%26aufirst%3DC.%26aulast%3DEmberson%26aufirst%3DJ.%26aulast%3DArmitage%26aufirst%3DJ.%26aulast%3DBaigent%26aufirst%3DC.%26aulast%3DBlackwell%26aufirst%3DL.%26aulast%3DBlumenthal%26aufirst%3DR.%26aulast%3DDanesh%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BD.%26aulast%3DDeMets%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DS.%26aulast%3DLaw%26aufirst%3DM.%26aulast%3DMacMahon%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNeal%26aufirst%3DB.%26aulast%3DPoulter%26aufirst%3DN.%26aulast%3DPreiss%26aufirst%3DD.%26aulast%3DRidker%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DI.%26aulast%3DRodgers%26aufirst%3DA.%26aulast%3DSandercock%26aufirst%3DP.%26aulast%3DSchulz%26aufirst%3DK.%26aulast%3DSever%26aufirst%3DP.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DSmeeth%26aufirst%3DL.%26aulast%3DWald%26aufirst%3DN.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DPeto%26aufirst%3DR.%26atitle%3DInterpretation%2520of%2520the%2520evidence%2520for%2520the%2520efficacy%2520and%2520safety%2520of%2520statin%2520therapy%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D2532%26epage%3D2561%26doi%3D10.1016%2FS0140-6736%2816%2931357-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Gordon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjortland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannel, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawber, T. R.</span><span> </span><span class="NLM_article-title">High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/0002-9343(77)90874-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2F0002-9343%2877%2990874-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=193398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1977&pages=707-714&author=T.+Gordonauthor=W.+P.+Castelliauthor=M.+C.+Hjortlandauthor=W.+B.+Kannelauthor=T.+R.+Dawber&title=High+density+lipoprotein+as+a+protective+factor+against+coronary+heart+disease.+The+Framingham+Study&doi=10.1016%2F0002-9343%2877%2990874-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">High density lipoprotein as a protective factor against coronary heart disease.  The framingham study</span></div><div class="casAuthors">Gordon, Tavia; Castelli, William P.; Hjortland, Marthana C.; Kannel, William B.; Dawber, Thomas R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">707-14</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">Lipid and lipoprotein values, including fasting triglycerides and high d. lipoproteins (HDL), low d. lipoproteins (LDL), and total cholesterol levels, were obtained on 2815 men and women aged 49-82 years chiefly between 1969 and 1971 at Framingham.  In the ∼4 years following the characterization of lipids, coronary heart disease developed in 79 of the 1025 men and 63 of the 1445 women free of coronary heart diseases.  At these older ages the major potent lipid risk factor was HDL cholesterol.  This lipid was assocd. with each major manifestation of coronary heart disease.  Triglycerides were assocd. with the incidence of coronary heart disease only in women and then only when the level of other lipids was not taken into account.  At these ages total cholesterol was not assocd. with the risk of coronary heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd43DXOPo8vrVg90H21EOLACvtfcHk0ljtSBNZWYYUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVOhtbg%253D&md5=4627db810c609ea43992d8f508b7ec08</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2877%2990874-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252877%252990874-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DT.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DHjortland%26aufirst%3DM.%2BC.%26aulast%3DKannel%26aufirst%3DW.%2BB.%26aulast%3DDawber%26aufirst%3DT.%2BR.%26atitle%3DHigh%2520density%2520lipoprotein%2520as%2520a%2520protective%2520factor%2520against%2520coronary%2520heart%2520disease.%2520The%2520Framingham%2520Study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1977%26volume%3D62%26spage%3D707%26epage%3D714%26doi%3D10.1016%2F0002-9343%2877%2990874-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gordon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Probstfield, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neaton, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castelli, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoke, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, D. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bangdiwala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyroler, H. A.</span><span> </span><span class="NLM_article-title">High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1161/01.CIR.79.1.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2F01.CIR.79.1.8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1989&pages=8-15&author=D.+J.+Gordonauthor=J.+L.+Probstfieldauthor=R.+J.+Garrisonauthor=J.+D.+Neatonauthor=W.+P.+Castelliauthor=J.+D.+Knokeauthor=D.+R.+Jacobsauthor=S.+Bangdiwalaauthor=H.+A.+Tyroler&title=High-density+lipoprotein+cholesterol+and+cardiovascular+disease.+Four+prospective+American+studies&doi=10.1161%2F01.CIR.79.1.8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.79.1.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.79.1.8%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BJ.%26aulast%3DProbstfield%26aufirst%3DJ.%2BL.%26aulast%3DGarrison%26aufirst%3DR.%2BJ.%26aulast%3DNeaton%26aufirst%3DJ.%2BD.%26aulast%3DCastelli%26aufirst%3DW.%2BP.%26aulast%3DKnoke%26aufirst%3DJ.%2BD.%26aulast%3DJacobs%26aufirst%3DD.%2BR.%26aulast%3DBangdiwala%26aufirst%3DS.%26aulast%3DTyroler%26aufirst%3DH.%2BA.%26atitle%3DHigh-density%2520lipoprotein%2520cholesterol%2520and%2520cardiovascular%2520disease.%2520Four%2520prospective%2520American%2520studies%26jtitle%3DCirculation%26date%3D1989%26volume%3D79%26spage%3D8%26epage%3D15%26doi%3D10.1161%2F01.CIR.79.1.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis</span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">160</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1161/01.ATV.0000054658.91146.64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2F01.ATV.0000054658.91146.64" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=12588754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=160-167&author=P.+J.+Barterauthor=H.+B.+Brewerauthor=M.+J.+Chapmanauthor=C.+H.+Hennekensauthor=D.+J.+Raderauthor=A.+R.+Tall&title=Cholesteryl+ester+transfer+protein%3A+a+novel+target+for+raising+HDL+and+inhibiting+atherosclerosis&doi=10.1161%2F01.ATV.0000054658.91146.64"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein</span></div><div class="casAuthors">Barter, Philip J.; Brewer, H. Bryan; Chapman, M. John; Hennekens, Charles H.; Rader, Daniel J.; Tall, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">160-167</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)-contg. lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs.  A deficiency of CETP is assocd. with increased HDL levels and decreased LDL levels, a profile that is typically antiatherogenic.  Studies in rabbits, a species with naturally high levels of CETP, support the therapeutic potential of CETP inhibition as an approach to retarding atherogenesis.  Studies in mice, a species that lacks CETP activity, have provided mixed results.  Human subjects with heterozygous CETP deficiency and an HDL cholesterol level >60 mg/dL have a reduced risk of coronary heart disease.  Evidence that atherosclerosis may be increased in CETP-deficient subjects whose HDL levels are not increased is difficult to interpret and may reflect confounding or bias.  Small-mol. inhibitors of CETP have now been tested in human subjects and shown to increase the concn. of HDL cholesterol while decreasing that of LDL cholesterol and apoB.  Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacol. inhibition of CETP retards the development of atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBGX_CUbamrVg90H21EOLACvtfcHk0lhBfTiQDw5XrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptF2jsw%253D%253D&md5=1cf83327815b82a906915c61e355e891</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2F01.ATV.0000054658.91146.64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.ATV.0000054658.91146.64%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DChapman%26aufirst%3DM.%2BJ.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DTall%26aufirst%3DA.%2BR.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%253A%2520a%2520novel%2520target%2520for%2520raising%2520HDL%2520and%2520inhibiting%2520atherosclerosis%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D160%26epage%3D167%26doi%3D10.1161%2F01.ATV.0000054658.91146.64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Angelantonio, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarwar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erqou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleheen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dullaart, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keavney, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesh, J.</span><span> </span><span class="NLM_article-title">Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">2777</span><span class="NLM_x">–</span> <span class="NLM_lpage">2788</span><span class="refDoi"> DOI: 10.1001/jama.299.23.2777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1001%2Fjama.299.23.2777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18560005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Sktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2008&pages=2777-2788&author=A.+Thompsonauthor=E.+Di+Angelantonioauthor=N.+Sarwarauthor=S.+Erqouauthor=D.+Saleheenauthor=R.+P.+Dullaartauthor=B.+Keavneyauthor=Z.+Yeauthor=J.+Danesh&title=Association+of+cholesteryl+ester+transfer+protein+genotypes+with+CETP+mass+and+activity%2C+lipid+levels%2C+and+coronary+risk&doi=10.1001%2Fjama.299.23.2777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk</span></div><div class="casAuthors">Thompson, Alexander; Di Angelantonio, Emanuele; Sarwar, Nadeem; Erqou, Sebhat; Saleheen, Danish; Dullaart, Robin P. F.; Keavney, Bernard; Ye, Zheng; Danesh, John</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2777-2788</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The importance of the cholesteryl ester transfer protein (CETP) pathway in coronary disease is uncertain.  Study of CETP genotypes can help better understand the relevance of this pathway to lipid metab. and disease risk.  Objective was to assess assocns. of CETP genotypes with CETP phenotypes, lipid levels, and coronary risk.  Data Sources Studies published between Jan. 1970 and Jan. 1980 were identified through computer-based and manual searches using MEDLINE, EMBASE, BIOSIS, Science Citation Index, and the Chinese National Knowledge Infrastructure Database.  Previously unreported studies were sought through correspondence with investigators.  Selection Relevant studies related principally to 3 common (TaqlB[rs708272], I405V [rs5882], and - 629C > A[rs1800775]) and 3 uncommon (D442G[rs2303790], - 631C > A[rs1800776], and R451Q [rs1800777]) CETP polymorphisms.  Extn. Information on CETP genotypes, CETP Phenotypes, lipid levels, coronary disease, and study characteristics was abstracted from publications, supplied by investigators, or both.  Ninety-two studies had data on CETP phenotypes, lipid levels, or both in 113833 healthy participants, and 46 studies had data on 27 196 coronary cases and 55 338 controls.  For each A allele inherited, individuals with the TaqlB polymorphism had lower mean CETP mass (- 9.7%; 95% confidence interval [CI], - 11.7% tp - 7.8%), lower mean CETP activity (- 8.6%; 95% Cl, - 13.0% to - 4.1%), higher mean high-d. lipoprotein cholesterol (HDL-C) concns. (4.5%; 95% Cl, 3.8%-5.2%), and higher mean apolipoprotein A-I concns. (2.4%; 95% Cl, 1.6%-3.2%).  The pattern of findings was very similar with the I405V and - 629C > A polymorphisms.  The combined per-allele odds ratios (ORs) for coronary disease were 0.95 (95% Cl, 0.92-0.99) for TaqlB, 0.94 (95% Cl, 0.89-1.00) for I405V, and 0.95 (95% Cl, 0.91-1.00) for - 629C > A.  Three CETP genotypes that are assocd. with moderate inhibition of CETP activity (and, therefore, modestly higher HDL-C levels) show weakly inversely assocns. with coronary risk.  The ORs for coronary disease were compatible with the expected redns. in risk for equiv. increases in HDL-C concn. in available prospective studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBUEuoJ3vytLVg90H21EOLACvtfcHk0lhBfTiQDw5XrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Sktb4%253D&md5=f828480566c595b6e3aca85eeff05c41</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.299.23.2777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.299.23.2777%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DSarwar%26aufirst%3DN.%26aulast%3DErqou%26aufirst%3DS.%26aulast%3DSaleheen%26aufirst%3DD.%26aulast%3DDullaart%26aufirst%3DR.%2BP.%26aulast%3DKeavney%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DDanesh%26aufirst%3DJ.%26atitle%3DAssociation%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520genotypes%2520with%2520CETP%2520mass%2520and%2520activity%252C%2520lipid%2520levels%252C%2520and%2520coronary%2520risk%26jtitle%3DJAMA%26date%3D2008%26volume%3D299%26spage%3D2777%26epage%3D2788%26doi%3D10.1001%2Fjama.299.23.2777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Johannsen, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frikke-Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordestgaard, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tybjaerg-Hansen, A.</span><span> </span><span class="NLM_article-title">Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2048</span><span class="refDoi"> DOI: 10.1016/j.jacc.2012.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.jacc.2012.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=23083790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=2041-2048&author=T.+H.+Johannsenauthor=R.+Frikke-Schmidtauthor=J.+Schouauthor=B.+G.+Nordestgaardauthor=A.+Tybjaerg-Hansen&title=Genetic+inhibition+of+CETP%2C+ischemic+vascular+disease+and+mortality%2C+and+possible+adverse+effects&doi=10.1016%2Fj.jacc.2012.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects</span></div><div class="casAuthors">Johannsen, Trine Holm; Frikke-Schmidt, Ruth; Schou, Jesper; Nordestgaard, Borge G.; Tybjaerg-Hansen, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2041-2048</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objectives: This study tested whether genetic variation in the CETP gene is consistent with a protective effect of cholesteryl ester transfer protein (CETP) inhibition on risk of ischemic events and on total mortality, without the adverse effects reported for torcetrapib.  Background: Torcetrapib, an inhibitor of CETP, increased risk of death and ischemic cardiovascular disease of those randomized to the drug, despite improving the lipid profile.  Methods: The Copenhagen City Heart Study is a prospective cohort study of 10,261 individuals, aged 20 to 93 years, who were followed for up to 34 years (1976 to 2010).  Of these, 2,087 developed ischemic heart disease, 1,064 developed ischemic cerebrovascular disease, and 3,807 died during follow-up.  We selected 2 common genetic variants in CETP previously assocd. with redns. in CETP activity, thus mimicking the effect of pharmacol. CETP inhibition.  Results: In individuals carrying 4 vs. 0 high-d. lipoprotein cholesterol-increasing alleles, there was an increase in levels of high-d. lipoprotein cholesterol of up to 14% (0.2 mmol/l), and concomitant decreases in triglycerides, low-d. lipoprotein cholesterol, and non-high-d. lipoprotein cholesterol of, resp., 6% (0.1 mmol/l), 3% (0.1 mmol/l), and 4% (0.2 mmol/l) (p for trend 0.004 to <0.001).  Corresponding hazard ratios were 0.76 (95% confidence interval [CI]: 0.68 to 0.85) for any ischemic vascular event, 0.74 (95% CI: 0.65 to 0.85) for ischemic heart disease, 0.65 (95% CI: 0.54 to 0.79) for myocardial infarction, 0.77 (95% CI: 0.65 to 0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for ischemic stroke, and 0.88 (95% CI: 0.80 to 0.97) for total mortality.  CETP genotypes did not assoc. with variation in markers of possible side effects previously reported for torcetrapib.  Conclusions: Genetic CETP inhibition assocs. with redns. in risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a corresponding antiatherogenic lipid profile, and with increased longevity, without adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Pu5WBKmjErVg90H21EOLACvtfcHk0lhXYwLvY_h0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1OlurnM&md5=b9960b97887b3b10c1a3e5b3b4c92b5a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2012.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2012.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohannsen%26aufirst%3DT.%2BH.%26aulast%3DFrikke-Schmidt%26aufirst%3DR.%26aulast%3DSchou%26aufirst%3DJ.%26aulast%3DNordestgaard%26aufirst%3DB.%2BG.%26aulast%3DTybjaerg-Hansen%26aufirst%3DA.%26atitle%3DGenetic%2520inhibition%2520of%2520CETP%252C%2520ischemic%2520vascular%2520disease%2520and%2520mortality%252C%2520and%2520possible%2520adverse%2520effects%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2012%26volume%3D60%26spage%3D2041%26epage%3D2048%26doi%3D10.1016%2Fj.jacc.2012.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komajda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Sendon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waters, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shear, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revkin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhr, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, B.</span><span> </span><span class="NLM_article-title">Investigators, I. Effects of torcetrapib in patients at high risk for coronary events</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">2109</span><span class="NLM_x">–</span> <span class="NLM_lpage">2122</span><span class="refDoi"> DOI: 10.1056/NEJMoa0706628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa0706628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=17984165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2109-2122&author=P.+J.+Barterauthor=M.+Caulfieldauthor=M.+Erikssonauthor=S.+M.+Grundyauthor=J.+J.+Kasteleinauthor=M.+Komajdaauthor=J.+Lopez-Sendonauthor=L.+Moscaauthor=J.+C.+Tardifauthor=D.+D.+Watersauthor=C.+L.+Shearauthor=J.+H.+Revkinauthor=K.+A.+Buhrauthor=M.+R.+Fisherauthor=A.+R.+Tallauthor=B.+Brewer&title=Investigators%2C+I.+Effects+of+torcetrapib+in+patients+at+high+risk+for+coronary+events&doi=10.1056%2FNEJMoa0706628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of torcetrapib in patients at high risk for coronary events</span></div><div class="casAuthors">Barter, Philip J.; Caulfield, Mark; Eriksson, Mats; Grundy, Scott M.; Kastelein, John J. P.; Komajda, Michel; Lopez-Sendon, Jose; Mosca, Lori; Tardif, Jean-Claude; Waters, David D.; Shear, Charles L.; Revkin, James H.; Buhr, Kevin A.; Fisher, Marian R.; Tall, Alan R.; Brewer, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2109-2122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels.  We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events.  The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.  Methods: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk.  The patients received either torcetrapib plus atorvastatin or atorvastatin alone.  The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.  Results: At 12 mo in patients who received torcetrapib, there was an increase of 72.1% in high-d. lipoprotein cholesterol and a decrease of 24.9% in low-d. lipoprotein cholesterol, as compared with baseline (P < 0.001 for both comparisons), in addn. to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P < 0.001 for all comparisons).  There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P = 0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P = 0.006).  Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose redn. in potassium or increase in bicarbonate was greater than the median change.  Conclusions: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism.  Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrjJJlK3IwJbVg90H21EOLACvtfcHk0lhXYwLvY_h0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGns7bL&md5=36913112326b0998658eaf6ea95b3ff9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706628%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DCaulfield%26aufirst%3DM.%26aulast%3DEriksson%26aufirst%3DM.%26aulast%3DGrundy%26aufirst%3DS.%2BM.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%26aulast%3DMosca%26aufirst%3DL.%26aulast%3DTardif%26aufirst%3DJ.%2BC.%26aulast%3DWaters%26aufirst%3DD.%2BD.%26aulast%3DShear%26aufirst%3DC.%2BL.%26aulast%3DRevkin%26aufirst%3DJ.%2BH.%26aulast%3DBuhr%26aufirst%3DK.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BR.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DBrewer%26aufirst%3DB.%26atitle%3DInvestigators%252C%2520I.%2520Effects%2520of%2520torcetrapib%2520in%2520patients%2520at%2520high%2520risk%2520for%2520coronary%2520events%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2109%26epage%3D2122%26doi%3D10.1056%2FNEJMoa0706628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briscoe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumiskey, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrhart, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hershey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharif-Rodriguez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinclair, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparrow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woltmann, R. F.</span><span> </span><span class="NLM_article-title">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span><span class="refDoi"> DOI: 10.1038/bjp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fbjp.2008.229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18536749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1465-1473&author=M.+J.+Forrestauthor=D.+Bloomfieldauthor=R.+J.+Briscoeauthor=P.+N.+Brownauthor=A.+M.+Cumiskeyauthor=J.+Ehrhartauthor=J.+C.+Hersheyauthor=W.+J.+Kellerauthor=X.+Maauthor=H.+E.+McPhersonauthor=E.+Messinaauthor=L.+B.+Petersonauthor=W.+Sharif-Rodriguezauthor=P.+K.+Sieglauthor=P.+J.+Sinclairauthor=C.+P.+Sparrowauthor=A.+S.+Stevensonauthor=S.+Y.+Sunauthor=C.+Tsaiauthor=H.+Vargasauthor=M.+Walkerauthor=S.+H.+Westauthor=V.+Whiteauthor=R.+F.+Woltmann&title=Torcetrapib-induced+blood+pressure+elevation+is+independent+of+CETP+inhibition+and+is+accompanied+by+increased+circulating+levels+of+aldosterone&doi=10.1038%2Fbjp.2008.229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone</span></div><div class="casAuthors">Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1465-1473</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high d. lipoprotein (HDL) cholesterol levels but is assocd. with increased blood pressure.  In a phase 3 clin. study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib.  The studies reported herein sought to evaluate off-target effects of torcetrapib.  Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models.  Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was obsd. with anacetrapib.  The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists.  Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator.  Treatment with torcetrapib was assocd. with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells.  Increased adrenal steroid levels were not obsd. with anacetrapib.  Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats.  Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids.  The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEhvVtQh2IkLVg90H21EOLACvtfcHk0lhXYwLvY_h0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVajs7g%253D&md5=c24fd90f9cbd9e8c2ab9c7994f8b21c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DBloomfield%26aufirst%3DD.%26aulast%3DBriscoe%26aufirst%3DR.%2BJ.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DCumiskey%26aufirst%3DA.%2BM.%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DHershey%26aufirst%3DJ.%2BC.%26aulast%3DKeller%26aufirst%3DW.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DMcPherson%26aufirst%3DH.%2BE.%26aulast%3DMessina%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DSharif-Rodriguez%26aufirst%3DW.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DSinclair%26aufirst%3DP.%2BJ.%26aulast%3DSparrow%26aufirst%3DC.%2BP.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BY.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%2BH.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DWoltmann%26aufirst%3DR.%2BF.%26atitle%3DTorcetrapib-induced%2520blood%2520pressure%2520elevation%2520is%2520independent%2520of%2520CETP%2520inhibition%2520and%2520is%2520accompanied%2520by%2520increased%2520circulating%2520levels%2520of%2520aldosterone%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1465%26epage%3D1473%26doi%3D10.1038%2Fbjp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Stroes, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastelein, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benardeau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clerc, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niesor, E. J.</span><span> </span><span class="NLM_article-title">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">–</span> <span class="NLM_lpage">1770</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00460.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1111%2Fj.1476-5381.2009.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=19917065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1763-1770&author=E.+S.+Stroesauthor=J.+J.+Kasteleinauthor=A.+Benardeauauthor=O.+Kuhlmannauthor=D.+Blumauthor=L.+A.+Camposauthor=R.+G.+Clercauthor=E.+J.+Niesor&title=Dalcetrapib%3A+no+off-target+toxicity+on+blood+pressure+or+on+genes+related+to+the+renin-angiotensin-aldosterone+system+in+rats&doi=10.1111%2Fj.1476-5381.2009.00460.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats</span></div><div class="casAuthors">Stroes, E. S. G.; Kastelein, J. J. P.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1763-1770</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The assocn. between torcetrapib and its off-target effects on blood pressure suggested a possible class-specific effect.  The effects of dalcetrapib (RO4607381/JTT-705) and torcetrapib on haemodynamics and the renin-angiotensin-aldosterone system (RAAS) were therefore assessed in a rat model.  Arterial pressure (AP) and heart rate were measured by telemetry in normotensive and spontaneously hypertensive rats (SHR) receiving torcetrapib 10, 40, or 80 mg/kg-1/day-1; dalcetrapib 100, 300, or 500 mg-1/kg/day-1; or vehicle (placebo) for 5 days.  Expression of RAAS genes in adrenal gland, kidney, aorta and lung from normotensive rats following 5 days' treatment with torcetrapib 40 mg/kg-1/day-1, dalcetrapib 500 mg/kg-1/day-1 or vehicle was measured by quant. polymerase chain reaction.  Torcetrapib transiently increased mean AP in normotensive rats (+3.7 ± 0.1 mmHg), whereas treatment in SHR resulted in a dose-dependent and sustained increase [+6.5 ± 0.6 mmHg with 40 mg/kg-1/day-1 at day 1 (P < 0.05 vs. placebo)], which lasted over the treatment period.  No changes in AP or heart rate were obsd. with dalcetrapib.  Torcetrapib, but not dalcetrapib, increased RAAS-related mRNAs in adrenal glands and aortas.  In contrast to torcetrapib, dalcetrapib did not increase blood pressure or RAAS-related gene expression in rats, suggesting that the off-target effects of torcetrapib are not a common feature of all compds. acting on cholesteryl ester transfer protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SJRkg9vZAbVg90H21EOLACvtfcHk0ljQCGO-_uhbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Whtr%252FL&md5=f907da070f24a4fe86e1398869c86de8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DStroes%26aufirst%3DE.%2BS.%26aulast%3DKastelein%26aufirst%3DJ.%2BJ.%26aulast%3DBenardeau%26aufirst%3DA.%26aulast%3DKuhlmann%26aufirst%3DO.%26aulast%3DBlum%26aufirst%3DD.%26aulast%3DCampos%26aufirst%3DL.%2BA.%26aulast%3DClerc%26aufirst%3DR.%2BG.%26aulast%3DNiesor%26aufirst%3DE.%2BJ.%26atitle%3DDalcetrapib%253A%2520no%2520off-target%2520toxicity%2520on%2520blood%2520pressure%2520or%2520on%2520genes%2520related%2520to%2520the%2520renin-angiotensin-aldosterone%2520system%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1763%26epage%3D1770%26doi%3D10.1111%2Fj.1476-5381.2009.00460.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loging, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keiser, J.</span><span> </span><span class="NLM_article-title">Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">150</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1210/en.2008-1512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1210%2Fen.2008-1512" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2009&pages=2211-2219&author=X.+Huauthor=J.+D.+Dietzauthor=C.+Xiaauthor=D.+R.+Knightauthor=W.+T.+Logingauthor=A.+H.+Smithauthor=H.+Yuanauthor=D.+A.+Perryauthor=J.+Keiser&title=Torcetrapib+induces+aldosterone+and+cortisol+production+by+an+intracellular+calcium-mediated+mechanism+independently+of+cholesteryl+ester+transfer+protein+inhibition&doi=10.1210%2Fen.2008-1512"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1210%2Fen.2008-1512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2008-1512%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDietz%26aufirst%3DJ.%2BD.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DD.%2BR.%26aulast%3DLoging%26aufirst%3DW.%2BT.%26aulast%3DSmith%26aufirst%3DA.%2BH.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DKeiser%26aufirst%3DJ.%26atitle%3DTorcetrapib%2520induces%2520aldosterone%2520and%2520cortisol%2520production%2520by%2520an%2520intracellular%2520calcium-mediated%2520mechanism%2520independently%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%26jtitle%3DEndocrinology%26date%3D2009%26volume%3D150%26spage%3D2211%26epage%3D2219%26doi%3D10.1210%2Fen.2008-1512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Johns, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span> </span><span class="NLM_article-title">On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.2165/11599310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.2165%2F11599310-000000000-00000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=491-507&author=D.+G.+Johnsauthor=J.+Duffyauthor=T.+Fisherauthor=B.+K.+Hubbardauthor=M.+J.+Forrest&title=On-+and+off-target+pharmacology+of+torcetrapib%3A+current+understanding+and+implications+for+the+structure+activity+relationships+%28SAR%29%2C+discovery+and+development+of+cholesteryl+ester-transfer+protein+%28CETP%29+inhibitors&doi=10.2165%2F11599310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2165%2F11599310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11599310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DJohns%26aufirst%3DD.%2BG.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DT.%26aulast%3DHubbard%26aufirst%3DB.%2BK.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26atitle%3DOn-%2520and%2520off-target%2520pharmacology%2520of%2520torcetrapib%253A%2520current%2520understanding%2520and%2520implications%2520for%2520the%2520structure%2520activity%2520relationships%2520%2528SAR%2529%252C%2520discovery%2520and%2520development%2520of%2520cholesteryl%2520ester-transfer%2520protein%2520%2528CETP%2529%2520inhibitors%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D491%26epage%3D507%26doi%3D10.2165%2F11599310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Schwartz, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballantyne, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brumm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaitman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallend, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiter, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitersdorf, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mundl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tardif, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dal-OUTCOMES Investigators</span><span> </span><span class="NLM_article-title">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">367</span><span class="NLM_x">, </span> <span class="NLM_fpage">2089</span><span class="NLM_x">–</span> <span class="NLM_lpage">2099</span><span class="refDoi"> DOI: 10.1056/NEJMoa1206797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa1206797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=23126252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=2089-2099&author=G.+G.+Schwartzauthor=A.+G.+Olssonauthor=M.+Abtauthor=C.+M.+Ballantyneauthor=P.+J.+Barterauthor=J.+Brummauthor=B.+R.+Chaitmanauthor=I.+M.+Holmeauthor=D.+Kallendauthor=L.+A.+Leiterauthor=E.+Leitersdorfauthor=J.+J.+McMurrayauthor=H.+Mundlauthor=S.+J.+Nichollsauthor=P.+K.+Shahauthor=J.+C.+Tardifauthor=R.+S.+Wrightauthor=dal-OUTCOMES+Investigators&title=Effects+of+dalcetrapib+in+patients+with+a+recent+acute+coronary+syndrome&doi=10.1056%2FNEJMoa1206797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of dalcetrapib in patients with a recent acute coronary syndrome</span></div><div class="casAuthors">Schwartz, Gregory G.; Olsson, Anders G.; Abt, Markus; Ballantyne, Christie M.; Barter, Philip J.; Brumm, Jochen; Chaitman, Bernard R.; Holme, Ingar M.; Kallend, David; Leiter, Lawrence A.; Leitersdorf, Eran; McMurray, John J. V.; Mundl, Hardi; Nicholls, Stephen J.; Shah, Prediman K.; Tardif, Jean-Claude; Wright, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2089-2099</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BAckground: In observational analyses, higher levels of high-d. lipoprotein (HDL) cholesterol have been assocd. with a lower risk of coronary heart disease events.  However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain.  Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.  Methods: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addn. to the best available evidence-based care.  The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.  Results: At the time of randomization, the mean HDL cholesterol level was 42 mg per dL (1.1 mmol per L), and the mean low-d. lipoprotein (LDL) cholesterol level was 76 mg per dL (2.0 mmol per L).  Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group.  Dalcetrapib had a minimal effect on LDL cholesterol levels.  Patients were followed for a median of 31 mo.  At a prespecified interim anal. that included 1135 primary end-point events (71% of the projected total no.), the independent data and safety monitoring board recommended termination of the trial for futility.  As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, resp.; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality.  The median C-reactive protein level was 0.2 mg per L higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons).  Conclusions: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppAqt1S8zjbVg90H21EOLACvtfcHk0ljZZDbErIgHPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyltrvK&md5=a9bcd3b77461ed5ef7e14fdbd8101a7b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1206797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1206797%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BG.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DAbt%26aufirst%3DM.%26aulast%3DBallantyne%26aufirst%3DC.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrumm%26aufirst%3DJ.%26aulast%3DChaitman%26aufirst%3DB.%2BR.%26aulast%3DHolme%26aufirst%3DI.%2BM.%26aulast%3DKallend%26aufirst%3DD.%26aulast%3DLeiter%26aufirst%3DL.%2BA.%26aulast%3DLeitersdorf%26aufirst%3DE.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DMundl%26aufirst%3DH.%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DTardif%26aufirst%3DJ.%2BC.%26aulast%3DWright%26aufirst%3DR.%2BS.%26aulast%3D%26atitle%3DEffects%2520of%2520dalcetrapib%2520in%2520patients%2520with%2520a%2520recent%2520acute%2520coronary%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D2089%26epage%3D2099%26doi%3D10.1056%2FNEJMoa1206797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Nicholls, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lincoff, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grainger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalescot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McErlean, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riesmeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangerow, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruotolo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerakkody, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nissen, S. E.</span><span> </span><span class="NLM_article-title">Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1069</span><span class="refDoi"> DOI: 10.1016/j.ahj.2015.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.ahj.2015.09.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2015&pages=1061-1069&author=S.+J.+Nichollsauthor=A.+M.+Lincoffauthor=P.+J.+Barterauthor=H.+B.+Brewerauthor=K.+A.+Foxauthor=C.+M.+Gibsonauthor=C.+Graingerauthor=V.+Menonauthor=G.+Montalescotauthor=D.+Raderauthor=A.+R.+Tallauthor=E.+McErleanauthor=J.+Riesmeyerauthor=B.+Vangerowauthor=G.+Ruotoloauthor=G.+J.+Weerakkodyauthor=S.+E.+Nissen&title=Assessment+of+the+clinical+effects+of+cholesteryl+ester+transfer+protein+inhibition+with+evacetrapib+in+patients+at+high-risk+for+vascular+outcomes%3A+Rationale+and+design+of+the+ACCELERATE+trial&doi=10.1016%2Fj.ahj.2015.09.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2015.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2015.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DS.%2BJ.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DBrewer%26aufirst%3DH.%2BB.%26aulast%3DFox%26aufirst%3DK.%2BA.%26aulast%3DGibson%26aufirst%3DC.%2BM.%26aulast%3DGrainger%26aufirst%3DC.%26aulast%3DMenon%26aufirst%3DV.%26aulast%3DMontalescot%26aufirst%3DG.%26aulast%3DRader%26aufirst%3DD.%26aulast%3DTall%26aufirst%3DA.%2BR.%26aulast%3DMcErlean%26aufirst%3DE.%26aulast%3DRiesmeyer%26aufirst%3DJ.%26aulast%3DVangerow%26aufirst%3DB.%26aulast%3DRuotolo%26aufirst%3DG.%26aulast%3DWeerakkody%26aufirst%3DG.%2BJ.%26aulast%3DNissen%26aufirst%3DS.%2BE.%26atitle%3DAssessment%2520of%2520the%2520clinical%2520effects%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibition%2520with%2520evacetrapib%2520in%2520patients%2520at%2520high-risk%2520for%2520vascular%2520outcomes%253A%2520Rationale%2520and%2520design%2520of%2520the%2520ACCELERATE%2520trial%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2015%26volume%3D170%26spage%3D1061%26epage%3D1069%26doi%3D10.1016%2Fj.ahj.2015.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Barter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rye, K. A.</span><span> </span><span class="NLM_article-title">Cholesteryl ester transfer protein inhibition is not yet dead – <i>Pro</i></span> <span class="citation_source-journal">Arterioscler., Thromb., Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1161/ATVBAHA.115.306879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1161%2FATVBAHA.115.306879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26848159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVKlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=439-441&author=P.+J.+Barterauthor=K.+A.+Rye&title=Cholesteryl+ester+transfer+protein+inhibition+is+not+yet+dead+%E2%80%93+Pro&doi=10.1161%2FATVBAHA.115.306879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead-Pro</span></div><div class="casAuthors">Barter, Philip J.; Rye, Kerry-Anne</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">439-441</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from nonatherogenic high-d. lipoproteins to potentially proatherogenic non-high-d. lipoprotein fractions.  Human genetic studies and human cohort studies have concluded that CETP gene polymorphisms assocd. with decreased CETP activity are accompanied by a significantly lower risk of atherosclerotic cardiovascular disease.  Inhibition of CETP in rabbits reduces development of diet-induced atherosclerosis.  Inhibition of CETP in humans reduces non-high-d. lipoprotein cholesterol while increasing high-d. lipoproteins cholesterol, consistent with a reduced risk of having an atherosclerotic cardiovascular disease event.  The failure of randomized human clin. outcome trials with 3 different CETP inhibitors may have been the consequence of either off-target adverse effects of the drug used or problems with the design of the trials.  The hypothesis that CETP inhibition reduces atherosclerotic cardiovascular disease risk is still untested.  The future of CETP inhibition as a cardio-protective strategy will depend on the outcome of the ongoing Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial with the CETP inhibitor, anacetrapib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8ECU0zUIUsLVg90H21EOLACvtfcHk0ljZZDbErIgHPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVKlsr0%253D&md5=d7f9341fac058369561b5c706e4e5e1e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.115.306879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.115.306879%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DP.%2BJ.%26aulast%3DRye%26aufirst%3DK.%2BA.%26atitle%3DCholesteryl%2520ester%2520transfer%2520protein%2520inhibition%2520is%2520not%2520yet%2520dead%2520%25E2%2580%2593%2520Pro%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D439%26epage%3D441%26doi%3D10.1161%2FATVBAHA.115.306879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">HPS3/TIMI55-REVEAL Collaborative Group</span><span> </span><span class="NLM_article-title">Effects of anacetrapib in patients with atherosclerotic vascular disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span><span class="refDoi"> DOI: 10.1056/NEJMoa1706444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1056%2FNEJMoa1706444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=28847206" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1217-1227&author=HPS3%2FTIMI55-REVEAL+Collaborative+Group&title=Effects+of+anacetrapib+in+patients+with+atherosclerotic+vascular+disease&doi=10.1056%2FNEJMoa1706444"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706444%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEffects%2520of%2520anacetrapib%2520in%2520patients%2520with%2520atherosclerotic%2520vascular%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1217%26epage%3D1227%26doi%3D10.1056%2FNEJMoa1706444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffor, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, X.</span><span> </span><span class="NLM_article-title">Crystal structures of cholesteryl ester transfer protein in complex with inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">37321</span><span class="NLM_x">–</span> <span class="NLM_lpage">37329</span><span class="refDoi"> DOI: 10.1074/jbc.M112.380063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1074%2Fjbc.M112.380063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=22961980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=37321-37329&author=S.+Liuauthor=A.+Mistryauthor=J.+M.+Reynoldsauthor=D.+B.+Lloydauthor=M.+C.+Grifforauthor=D.+A.+Perryauthor=R.+B.+Ruggeriauthor=R.+W.+Clarkauthor=X.+Qiu&title=Crystal+structures+of+cholesteryl+ester+transfer+protein+in+complex+with+inhibitors&doi=10.1074%2Fjbc.M112.380063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors</span></div><div class="casAuthors">Liu, Shenping; Mistry, Anil; Reynolds, Jennifer M.; Lloyd, David B.; Griffor, Matthew C.; Perry, David A.; Ruggeri, Roger B.; Clark, Ronald W.; Qiu, Xiayang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">37321-37329</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human plasma cholesteryl ester transfer protein (CETP) transports cholesteryl ester from the antiatherogenic high-d. lipoproteins (HDL) to the proatherogenic low-d. and very low-d. lipoproteins (LDL and VLDL).  Inhibition of CETP has been shown to raise human plasma HDL cholesterol (HDL-C) levels and is potentially a novel approach for the prevention of cardiovascular diseases.  Here, we report the crystal structures of CETP in complex with torcetrapib, a CETP inhibitor that has been tested in phase 3 clin. trials, and compd. 2, an analog from a structurally distinct inhibitor series.  In both crystal structures, the inhibitors are buried deeply within the protein, shifting the bound cholesteryl ester in the N-terminal pocket of the long hydrophobic tunnel and displacing the phospholipid from that pocket.  The lipids in the C-terminal pocket of the hydrophobic tunnel remain unchanged.  The inhibitors are positioned near the narrowing neck of the hydrophobic tunnel of CETP and thus block the connection between the N- and C-terminal pockets.  These structures illuminate the unusual inhibition mechanism of these compds. and support the tunnel mechanism for neutral lipid transfer by CETP.  These highly lipophilic inhibitors bind mainly through extensive hydrophobic interactions with the protein and the shifted cholesteryl ester mol.  However, polar residues, such as Ser-230 and His-232, are also found in the inhibitor binding site.  An enhanced understanding of the inhibitor binding site may provide opportunities to design novel CETP inhibitors possessing more drug-like phys. properties, distinct modes of action, or alternative pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnCzSbL7tPrVg90H21EOLACvtfcHk0lgREeB0vkCS7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqs7zJ&md5=04e3f7a33d893f05fadada46ad6deb9d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.380063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.380063%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DLloyd%26aufirst%3DD.%2BB.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DQiu%26aufirst%3DX.%26atitle%3DCrystal%2520structures%2520of%2520cholesteryl%2520ester%2520transfer%2520protein%2520in%2520complex%2520with%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D37321%26epage%3D37329%26doi%3D10.1074%2Fjbc.M112.380063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panebianco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hoydonck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laethem, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez-Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilliard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Bortel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasseter, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Huniti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykstra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span> </span><span class="NLM_article-title">Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2009.03465.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1111%2Fj.1365-2125.2009.03465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=19843057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVyis73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=535-545&author=R.+Krishnaauthor=A.+Gargauthor=D.+Panebiancoauthor=J.+Coteauthor=A.+J.+Bergmanauthor=P.+Van+Hoydonckauthor=T.+Laethemauthor=K.+Van+Dyckauthor=J.+Chenauthor=C.+Chavez-Engauthor=L.+Archerauthor=R.+Lutzauthor=D.+Hilliardauthor=K.+Snyderauthor=B.+Jinauthor=L.+Van+Bortelauthor=K.+C.+Lasseterauthor=N.+Al-Hunitiauthor=K.+Dykstraauthor=K.+Gottesdienerauthor=J.+A.+Wagner&title=Single-dose+pharmacokinetics+and+pharmacodynamics+of+anacetrapib%2C+a+potent+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitor%2C+in+healthy+subjects&doi=10.1111%2Fj.1365-2125.2009.03465.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects</span></div><div class="casAuthors">Krishna, Rajesh; Garg, Amit; Panebianco, Deborah; Cote, Josee; Bergman, Arthur J.; Van Hoydonck, Pascale; Laethem, Tine; Van Dyck, Kristien; Chen, Jingjing; Chavez-Eng, Cynthia; Archer, Laura; Lutz, Ryan; Hilliard, Deborah; Snyder, Karen; Jin, Bo; Van Bortel, Luc; Lasseter, Kenneth C.; Al-Huniti, Nidal; Dykstra, Kevin; Gottesdiener, Keith; Wagner, John A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">535-545</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS Anacetrapib is an orally active and potent inhibitor of CETP in development for the treatment of dyslipidemia.  These studies endeavoured to establish the safety, tolerability, pharmacokinetics and pharmacodynamics of rising single doses of anacetrapib, administered in fasted or fed conditions, and to preliminarily assess the effect of food, age, gender and obesity on the single-dose pharmacokinetics and pharmacodynamics of anacetrapib.  METHODS Safety, tolerability, anacetrapib concns. and CETP activity were evaluated.  RESULTS Anacetrapib was rapidly absorbed, with peak concns. occurring at ∼4 h post-dose and an apparent terminal half-life ranging from ∼9 to 62 h in the fasted state and from ∼42 to ∼83 h in the fed state.  Plasma AUC and Cmax appeared to increase in a less than approx. dose-dependent manner in the fasted state, with an apparent plateau in absorption at higher doses.  Single doses of anacetrapib markedly and dose-dependently inhibited serum CETP activity with peak effects of ∼90% inhibition at tmax and ∼58% inhibition at 24 h post-dose.  An Emax model best described the plasma anacetrapib concn. vs CETP activity relationship with an EC50 of ∼22 nM.  Food increased exposure to anacetrapib; up to ∼two-three-fold with a low-fat meal and by up to ∼six-eight fold with a high-fat meal.  Anacetrapib pharmacokinetics and pharmacodynamics were similar in elderly vs young adults, women vs men, and obese vs non-obese young adults.  Anacetrapib was well tolerated and was not assocd. with any meaningful increase in blood pressure.  CONCLUSIONS Whereas food increased exposure to anacetrapib significantly, age, gender and obese status did not meaningfully influence anacetrapib pharmacokinetics and pharmacodynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCk8KUowPfKLVg90H21EOLACvtfcHk0lgREeB0vkCS7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVyis73J&md5=b8e576da068c883896816f910ef48549</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2009.03465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2009.03465.x%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DGarg%26aufirst%3DA.%26aulast%3DPanebianco%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DA.%2BJ.%26aulast%3DVan%2BHoydonck%26aufirst%3DP.%26aulast%3DLaethem%26aufirst%3DT.%26aulast%3DVan%2BDyck%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChavez-Eng%26aufirst%3DC.%26aulast%3DArcher%26aufirst%3DL.%26aulast%3DLutz%26aufirst%3DR.%26aulast%3DHilliard%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DK.%26aulast%3DJin%26aufirst%3DB.%26aulast%3DVan%2BBortel%26aufirst%3DL.%26aulast%3DLasseter%26aufirst%3DK.%2BC.%26aulast%3DAl-Huniti%26aufirst%3DN.%26aulast%3DDykstra%26aufirst%3DK.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26atitle%3DSingle-dose%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520anacetrapib%252C%2520a%2520potent%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitor%252C%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D68%26spage%3D535%26epage%3D545%26doi%3D10.1111%2Fj.1365-2125.2009.03465.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljiW-1FmCOXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljiW-1FmCOXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, C. D.</span><span> </span><span class="NLM_article-title">LogD: lipophilicity for ionisable compounds</span> <span class="citation_source-journal">Chemosphere</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1408</span><span class="refDoi"> DOI: 10.1016/j.chemosphere.2008.04.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.chemosphere.2008.04.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=18565570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=1401-1408&author=M.+Kahauthor=C.+D.+Brown&title=LogD%3A+lipophilicity+for+ionisable+compounds&doi=10.1016%2Fj.chemosphere.2008.04.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Log D: Lipophilicity for ionizable compounds</span></div><div class="casAuthors">Kah, Melanie; Brown, Colin D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemosphere</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1401-1408</span>CODEN:
                <span class="NLM_cas:coden">CMSHAF</span>;
        ISSN:<span class="NLM_cas:issn">0045-6535</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  The octanol/water partition coeff. (Kow) for org. compds. is widely used in predictive environmental studies.  A significant proportion of contaminants of surface and ground water are ionizable (e.g. many pesticides, pharmaceuticals, metabolites).  Such compds. may be partially ionized dependent on the pH.  Since the neutral and ionic species exhibit different polarities, the Kow value of ionizable pesticides is pH dependent.  It is therefore essential to det. Kow values over the full range of pH that occurs in the environment in order to get appropriate predictors.  Numerous methods are available to measure lipophilicity but only a few are appropriate for ionizable pesticides (e.g. pH metric and filter probe methods).  Parameters such as pH and ionic strength need to be carefully controlled when working with ionizable compds.  Variation of these factors probably explains why literature can yield Kow values that differ by more than one order of magnitude for some compds.  In this article, Kow values obtained for six acidic pesticides with three different methods are compared as well (data from the literature, measured by pH metric method and calcd. with five computer programs).  The values used in predictive regression equations needs to be either measured with a suitable method or selected from the literature with great care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovGJvDX2SsPrVg90H21EOLACvtfcHk0ljiW-1FmCOXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGmsLw%253D&md5=e35b5073cc61d6cdae39efb5881c8ad7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.chemosphere.2008.04.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chemosphere.2008.04.074%26sid%3Dliteratum%253Aachs%26aulast%3DKah%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26atitle%3DLogD%253A%2520lipophilicity%2520for%2520ionisable%2520compounds%26jtitle%3DChemosphere%26date%3D2008%26volume%3D72%26spage%3D1401%26epage%3D1408%26doi%3D10.1016%2Fj.chemosphere.2008.04.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Hirota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ieiri, I.</span><span> </span><span class="NLM_article-title">Drug-drug interactions that interfere with statin metabolism</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1435</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span><span class="refDoi"> DOI: 10.1517/17425255.2015.1056149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1517%2F17425255.2015.1056149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26058399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1435-1447&author=T.+Hirotaauthor=I.+Ieiri&title=Drug-drug+interactions+that+interfere+with+statin+metabolism&doi=10.1517%2F17425255.2015.1056149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-drug interactions that interfere with statin metabolism</span></div><div class="casAuthors">Hirota, Takeshi; Ieiri, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1435-1447</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Lipid-lowering drugs, esp. hydroxymethylglutaryl-CoA reductase inhibitors (statins), are widely used in the treatment and prevention of atherosclerotic diseases.  The benefits of statins are well documented.  However, myotoxic side effects, which can sometimes be severe, including myopathy or rhabdomyolysis, have been assocd. with the use of statins.  In some cases, this toxicity is assocd. with pharmacokinetic alterations.  Potent inhibitors of CYP 3A4 significantly increase plasma concns. of the active forms of simvastatin, lovastatin and atorvastatin.  Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin and pitavastatin are not susceptible to inhibition by any CYP.  This review discusses the pharmacokinetic aspects of the drug-drug interaction with statins and genetic polymorphisms in CYPs, which are involved in the metab. of statins, and highlights the importance of establishing a system utilizing electronic medical information practically to avoid adverse drug reactions.  An understanding of the mechanisms underlying statin interactions will help to minimize drug interactions and develop statins that are less prone to adverse interactions.  Quant. analyzed information for the low-d. lipoprotein cholesterol lowering effects of statin based on electronic medical records may be useful for avoiding the adverse effect of statins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-G_q1DYD7ALVg90H21EOLACvtfcHk0ljmpWp1GWXOGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2ntLvO&md5=9ec84303e67b64049feaaa0722fb6001</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F17425255.2015.1056149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2015.1056149%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DT.%26aulast%3DIeiri%26aufirst%3DI.%26atitle%3DDrug-drug%2520interactions%2520that%2520interfere%2520with%2520statin%2520metabolism%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2015%26volume%3D11%26spage%3D1435%26epage%3D1447%26doi%3D10.1517%2F17425255.2015.1056149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lewis, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lake, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, M.</span><span> </span><span class="NLM_article-title">Quantitative structure-activity relationships (QSars) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding</span> <span class="citation_source-journal">J. Enzyme Inhib. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1080/14756360500532747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1080%2F14756360500532747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=16789425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1ajtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=127-132&author=D.+F.+Lewisauthor=B.+G.+Lakeauthor=M.+Dickins&title=Quantitative+structure-activity+relationships+%28QSars%29+in+CYP3A4+inhibitors%3A+the+importance+of+lipophilic+character+and+hydrogen+bonding&doi=10.1080%2F14756360500532747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding</span></div><div class="casAuthors">Lewis, David F. V.; Lake, Brian G.; Dickins, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The results of Quant. Structure-Activity Relationship (QSAR) analyses on three series of CYP3A4 inhibitors are reported for enzyme inhibition expressed as Ki values.  These include a small series of structurally related statins and two larger groupings of structurally diverse compds., some of which display competitive inhibition of CYP3A4 whereas others act via heme iron ligation.  In all cases, however, it is apparent that there are lipophilicity relationships assocd. with CYP3A4 inhibitory activity in the total of 46 compds. investigated.  This is evidenced by linear correlations between inhibition of CYP3A4 and the octanol-water partition coeff. (P value) when expressed logarithmically (ie., log P).  In the case of the statins, however, the distribution coeff. (D) at pH 7 is used due to the effect of compd. ionization.  Conversion of equil. consts. (ie. Ki and P) to the corresponding free energy changes (ΔG values) facilitates exploration of the likely intermol. forces of interaction between the inhibitors and the active site region of CYP3A4.  In this respect, there appears to be good agreement between QSAR analyses and mol. modeling of the CYP3A4 enzyme itself, and both are consistent with the known mechanisms of inhibition displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMt4lAzR-aILVg90H21EOLACvtfcHk0ljmpWp1GWXOGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1ajtLc%253D&md5=07c8373b6900504588cb076f4c96644e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F14756360500532747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756360500532747%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BF.%26aulast%3DLake%26aufirst%3DB.%2BG.%26aulast%3DDickins%26aufirst%3DM.%26atitle%3DQuantitative%2520structure-activity%2520relationships%2520%2528QSars%2529%2520in%2520CYP3A4%2520inhibitors%253A%2520the%2520importance%2520of%2520lipophilic%2520character%2520and%2520hydrogen%2520bonding%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2006%26volume%3D21%26spage%3D127%26epage%3D132%26doi%3D10.1080%2F14756360500532747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Mogi, M.; Yamada, K.; Yasoshima, K.; Kawanami, T.; Umemura, I.; Iwaki, Y.; Qin, H.; Imase, H.</span><span> </span><span class="NLM_article-title">4-Benzylamino-1-carboxyacyl-piperidine Derivatives as CETP Inhibitors Useful for the Treatment of Diseases Such as Hyperlipidemia or Arteriosclerosis</span>. WIPO PCT WO 2009/059943A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=M.+Mogi&author=K.+Yamada&author=K.+Yasoshima&author=T.+Kawanami&author=I.+Umemura&author=Y.+Iwaki&author=H.+Qin&author=H.+Imase&title=4-Benzylamino-1-carboxyacyl-piperidine+Derivatives+as+CETP+Inhibitors+Useful+for+the+Treatment+of+Diseases+Such+as+Hyperlipidemia+or+Arteriosclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DM.%26atitle%3D4-Benzylamino-1-carboxyacyl-piperidine%2520Derivatives%2520as%2520CETP%2520Inhibitors%2520Useful%2520for%2520the%2520Treatment%2520of%2520Diseases%2520Such%2520as%2520Hyperlipidemia%2520or%2520Arteriosclerosis%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Trieselmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamprecht, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremonesi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streicher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luippold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span> </span><span class="NLM_article-title">Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1′-spiro-substituted hexahydrofuroquinoline derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8766</span><span class="NLM_x">–</span> <span class="NLM_lpage">8776</span><span class="refDoi"> DOI: 10.1021/jm500431d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500431d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8766-8776&author=T.+Trieselmannauthor=H.+Wagnerauthor=K.+Fuchsauthor=D.+Hamprechtauthor=D.+Bertaauthor=P.+Cremonesiauthor=R.+Streicherauthor=G.+Luippoldauthor=A.+Volzauthor=M.+Markertauthor=H.+Nar&title=Potent+cholesteryl+ester+transfer+protein+inhibitors+of+reduced+lipophilicity%3A+1%2C1%E2%80%B2-spiro-substituted+hexahydrofuroquinoline+derivatives&doi=10.1021%2Fjm500431d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm500431d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500431d%26sid%3Dliteratum%253Aachs%26aulast%3DTrieselmann%26aufirst%3DT.%26aulast%3DWagner%26aufirst%3DH.%26aulast%3DFuchs%26aufirst%3DK.%26aulast%3DHamprecht%26aufirst%3DD.%26aulast%3DBerta%26aufirst%3DD.%26aulast%3DCremonesi%26aufirst%3DP.%26aulast%3DStreicher%26aufirst%3DR.%26aulast%3DLuippold%26aufirst%3DG.%26aulast%3DVolz%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26atitle%3DPotent%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%2520of%2520reduced%2520lipophilicity%253A%25201%252C1%25E2%2580%25B2-spiro-substituted%2520hexahydrofuroquinoline%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8766%26epage%3D8776%26doi%3D10.1021%2Fjm500431d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Gotto, A. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansky, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DEFINE Investigators</span><span> </span><span class="NLM_article-title">Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease</span> <span class="citation_source-journal">Am. J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1016/j.amjcard.2013.08.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.amjcard.2013.08.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24188894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslajsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2014&pages=76-83&author=A.+M.+Gottoauthor=C.+P.+Cannonauthor=X.+S.+Liauthor=S.+Vaidyaauthor=U.+Kherauthor=E.+A.+Brintonauthor=M.+Davidsonauthor=J.+E.+Moonauthor=S.+Shahauthor=H.+M.+Danskyauthor=Y.+Mitchelauthor=P.+Barterauthor=DEFINE+Investigators&title=Evaluation+of+lipids%2C+drug+concentration%2C+and+safety+parameters+following+cessation+of+treatment+with+the+cholesteryl+ester+transfer+protein+inhibitor+anacetrapib+in+patients+with+or+at+high+risk+for+coronary+heart+disease&doi=10.1016%2Fj.amjcard.2013.08.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease</span></div><div class="casAuthors">Gotto, Antonio M.; Cannon, Christopher P.; Li, Xiujiang Susie; Vaidya, Sanskruti; Kher, Uma; Brinton, Eliot A.; Davidson, Michael; Moon, Jennifer E.; Shah, Sukrut; Dansky, Hayes M.; Mitchel, Yale; Barter, Philip</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">76-83</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this study was to assess the effects on lipids and safety during a 12-wk reversal period after 18 mo of treatment with anacetrapib.  The cholesteryl ester transfer protein inhibitor anacetrapib was previously shown to reduce low-d. lipoprotein cholesterol by 39.8% (estd. using the Friedewald equation) and increase high-d. lipoprotein (HDL) cholesterol by 138.1%, with an acceptable side-effect profile, in patients with or at high risk for coronary heart disease in the Detg. the Efficacy and Tolerability of CETP Inhibition With Anacetrapib (DEFINE) trial.  A total of 1,398 patients entered the 12-wk reversal-phase study, either after completion of the active-treatment phase or after early discontinuation of the study medication.  In patients allocated to anacetrapib, placebo-adjusted mean percentage decreases from baseline were obsd. at 12 wk off the study drug for Friedewald-calcd. low-d. lipoprotein cholesterol (18.6%), non-HDL cholesterol (17.6%), and apolipoprotein B (10.2%); placebo-adjusted mean percentage increases were obsd. for HDL cholesterol (73.0%) and apolipoprotein A-I (24.5%).  Residual plasma anacetrapib levels (about 40% of on-treatment apparent steady-state trough levels) were also detected 12 wk after cessation of anacetrapib.  No clin. important elevations in liver enzymes, blood pressure, electrolytes, or adverse experiences were obsd. during the reversal phase.  Preliminary data from a small cohort (n = 30) revealed the presence of low concns. of anacetrapib in plasma 2.5 to 4 years after the last anacetrapib dose.  In conclusion, after the cessation of active treatment, anacetrapib plasma lipid changes and drug levels decreased to approx. 40% of on-treatment trough levels at 12 wk after dosing, but modest HDL cholesterol elevations and low drug concns. were still detectable 2 to 4 years after the last dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iSQ6XmMyZbVg90H21EOLACvtfcHk0lgJc6QcdALgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslajsLzN&md5=fa70e20a5a463a78c9df31c4bf66f588</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2013.08.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2013.08.041%26sid%3Dliteratum%253Aachs%26aulast%3DGotto%26aufirst%3DA.%2BM.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%2BS.%26aulast%3DVaidya%26aufirst%3DS.%26aulast%3DKher%26aufirst%3DU.%26aulast%3DBrinton%26aufirst%3DE.%2BA.%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DMoon%26aufirst%3DJ.%2BE.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DDansky%26aufirst%3DH.%2BM.%26aulast%3DMitchel%26aufirst%3DY.%26aulast%3DBarter%26aufirst%3DP.%26aulast%3D%26atitle%3DEvaluation%2520of%2520lipids%252C%2520drug%2520concentration%252C%2520and%2520safety%2520parameters%2520following%2520cessation%2520of%2520treatment%2520with%2520the%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitor%2520anacetrapib%2520in%2520patients%2520with%2520or%2520at%2520high%2520risk%2520for%2520coronary%2520heart%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2014%26volume%3D113%26spage%3D76%26epage%3D83%26doi%3D10.1016%2Fj.amjcard.2013.08.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambler, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garigipati, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefker, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morehouse, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francone, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span> </span><span class="NLM_article-title">Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span><span class="refDoi"> DOI: 10.3109/00498254.2013.874611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.3109%2F00498254.2013.874611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=24380613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpt1Wjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=591-605&author=A.+S.+Kalgutkarauthor=K.+S.+Frederickauthor=H.+L.+Hatchauthor=C.+M.+Amblerauthor=D.+A.+Perryauthor=R.+S.+Garigipatiauthor=G.+C.+Changauthor=B.+A.+Lefkerauthor=R.+W.+Clarkauthor=L.+A.+Morehouseauthor=O.+Franconeauthor=X.+Hu&title=Identification+of+a+novel%2C+non-tetrahydroquinoline+variant+of+the+cholesteryl+ester+transfer+protein+%28CETP%29+inhibitor+torcetrapib%2C+with+improved+aqueous+solubility&doi=10.3109%2F00498254.2013.874611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility</span></div><div class="casAuthors">Kalgutkar, Amit S.; Frederick, Kosea S.; Hatch, Heather L.; Ambler, Catherine M.; Perry, David A.; Garigipati, Ravi S.; Chang, George C.; Lefker, Bruce A.; Clark, Ronald W.; Morehouse, Lee A.; Francone, Omar; Hu, Xiao</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">1. Elaborate studies of cholesteryl ester transfer protein (CETP) polymorphisms and genetic deficiency in humans suggest direct links between CETP, high-d. lipoprotein cholesterol (HDL-c) levels and coronary heart diseases.  The hypothesis that CETP inhibition by small mol. inhibitors raises HDL-c has been validated clin. with structurally-diverse CETP inhibitors such as torcetrapib, anacetrapib, dalcetrapib and evacetrapib.  2. Despite promising phase 2 results with respect to HDL-c elevation, torcetrapib was discontinued in phase 3 trials due to increased mortality rates in the cardiovascular outcomes study.  Emerging evidence for the adverse effects hints at off-target chemotype-specific cardiovascular toxicity, possibly related to the pressor effects of torcetrapib, since structurally diverse CETP inhibitors such as anacetrapib, evacetrapib and dalcetrapib are not assocd. with blood pressure increases in humans.  Nonclin. follow-up studies showed that torcetrapib induces aldosterone biosynthesis and secretion in vivo and in vitro, an effect which is not obsd. with other CETP inhibitors in clin. development.  3. As part of ongoing efforts to identify novel CETP inhibitors devoid of pressor effects, strategies were implemented towards the design of compds., which lack the 1,2,3,4-tetrahydroquinoline (THQ) scaffold present in torcetrapib.  In this article, we disclose results of structure-activity relationship studies for a series of novel non-THQ CETP inhibitors, which resulted in the identification of a novel isonipecotic acid deriv. 10 (also referred to as PF-04445597) with vastly improved oral pharmacokinetic properties mainly as a result of improved aq. soly.  This feature is attractive in that, it bypasses significant investments needed to develop compatible solubilizing formulation(s) for oral drug delivery of highly lipophilic and poorly sol. compds.; attributes, which are usually assocd. with small mol. CETP inhibitors.  PF-04445597 was also devoid of aldosterone secretion in human H295R adrenal carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigP90-90on7Vg90H21EOLACvtfcHk0lgJc6QcdALgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpt1Wjsbg%253D&md5=a6986b98ad2edf52eef2f33bb3fd366c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3109%2F00498254.2013.874611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2013.874611%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DHatch%26aufirst%3DH.%2BL.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DPerry%26aufirst%3DD.%2BA.%26aulast%3DGarigipati%26aufirst%3DR.%2BS.%26aulast%3DChang%26aufirst%3DG.%2BC.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DClark%26aufirst%3DR.%2BW.%26aulast%3DMorehouse%26aufirst%3DL.%2BA.%26aulast%3DFrancone%26aufirst%3DO.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DIdentification%2520of%2520a%2520novel%252C%2520non-tetrahydroquinoline%2520variant%2520of%2520the%2520cholesteryl%2520ester%2520transfer%2520protein%2520%2528CETP%2529%2520inhibitor%2520torcetrapib%252C%2520with%2520improved%2520aqueous%2520solubility%26jtitle%3DXenobiotica%26date%3D2014%26volume%3D44%26spage%3D591%26epage%3D605%26doi%3D10.3109%2F00498254.2013.874611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Borensztajn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rone, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlar, T. J.</span><span> </span><span class="NLM_article-title">The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span><span class="refDoi"> DOI: 10.1042/bj1560539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1042%2Fbj1560539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1976&pages=539-543&author=J.+Borensztajnauthor=M.+S.+Roneauthor=T.+J.+Kotlar&title=The+inhibition+in+vivo+of+lipoprotein+lipase+%28clearing-factor+lipase%29+activity+by+triton+WR-1339&doi=10.1042%2Fbj1560539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1042%2Fbj1560539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj1560539%26sid%3Dliteratum%253Aachs%26aulast%3DBorensztajn%26aufirst%3DJ.%26aulast%3DRone%26aufirst%3DM.%2BS.%26aulast%3DKotlar%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520inhibition%2520in%2520vivo%2520of%2520lipoprotein%2520lipase%2520%2528clearing-factor%2520lipase%2529%2520activity%2520by%2520triton%2520WR-1339%26jtitle%3DBiochem.%2520J.%26date%3D1976%26volume%3D156%26spage%3D539%26epage%3D543%26doi%3D10.1042%2Fbj1560539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ugawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakuta, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inagaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shikama, H.</span><span> </span><span class="NLM_article-title">YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">139</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0705229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1038%2Fsj.bjp.0705229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=12746232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Ghs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2003&pages=140-146&author=T.+Ugawaauthor=H.+Kakutaauthor=H.+Moritaniauthor=O.+Inagakiauthor=H.+Shikama&title=YM-53601%2C+a+novel+squalene+synthase+inhibitor%2C+suppresses+lipogenic+biosynthesis+and+lipid+secretion+in+rodents&doi=10.1038%2Fsj.bjp.0705229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents</span></div><div class="casAuthors">Ugawa, Tohru; Kakuta, Hirotoshi; Moritani, Hiroshi; Inagaki, Osamu; Shikama, Hisataka</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-146</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To better understand how it decreases plasma cholesterol and triglyceride levels, we evaluated the effect of (E)-2-[2-fluoro-2-(quinuclidin-3-ylidene)ethoxy]-9H-carbazole monohydrochloride (YM-53601) on lipogenic biosynthesis in the liver and lipid secretion from the liver in rats and hamsters.  Single administration of YM-53601 in cholestyramine-treated rats inhibited triglyceride and free fatty acid (FFA) biosynthesis at a similar dose range to that at which it inhibited cholesterol biosynthesis.  YM-53601 inhibited both triglyceride and FFA biosynthesis in hamsters treated with cholestyramine.  YM-53601 by single oral administration decreased the enhanced plasma triglyceride levels in hamsters induced by an injection of protamine sulfate, which inhibits lipoprotein lipase (LPL) and consequently increases plasma very low-d. lipoprotein (VLDL) triglyceride levels.  YM-53601 also decreased the enhanced plasma triglyceride and cholesterol levels in hamsters treated with Triton WR1339, which also inhibits the degrdn. of VLDL.  Plasma cholesterol was significantly decreased as soon as 1 h after single administration of YM-53601 in hamsters fed a normal diet.  This is the first report that a squalene synthase inhibitor suppresses lipogenic biosynthesis in the liver and cholesterol and triglyceride secretion from the liver in vivo.  We therefore suggest that the mechanism by which YM-53601 decreases plasma triglyceride might include these effects.  The finding that YM-53601 rapidly decreased plasma cholesterol suggests that this compd. may be effective in decreasing plasma cholesterol levels early in the course of treatment of hypercholesterolemia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrciODXXK8Q7LVg90H21EOLACvtfcHk0lgJc6QcdALgQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Ghs7o%253D&md5=6dfff3133d8723b6c2ac9c44982e78e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705229%26sid%3Dliteratum%253Aachs%26aulast%3DUgawa%26aufirst%3DT.%26aulast%3DKakuta%26aufirst%3DH.%26aulast%3DMoritani%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DO.%26aulast%3DShikama%26aufirst%3DH.%26atitle%3DYM-53601%252C%2520a%2520novel%2520squalene%2520synthase%2520inhibitor%252C%2520suppresses%2520lipogenic%2520biosynthesis%2520and%2520lipid%2520secretion%2520in%2520rodents%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D139%26spage%3D140%26epage%3D146%26doi%3D10.1038%2Fsj.bjp.0705229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Carroll, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kit, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shero, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mussolino, M. E.</span><span> </span><span class="NLM_article-title">Trends in lipids and lipoproteins in US adults, 1988–2010</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1545</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1001/jama.2012.13260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1001%2Fjama.2012.13260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=1545-1554&author=M.+D.+Carrollauthor=B.+K.+Kitauthor=D.+A.+Lacherauthor=S.+T.+Sheroauthor=M.+E.+Mussolino&title=Trends+in+lipids+and+lipoproteins+in+US+adults%2C+1988%E2%80%932010&doi=10.1001%2Fjama.2012.13260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjama.2012.13260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2012.13260%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DM.%2BD.%26aulast%3DKit%26aufirst%3DB.%2BK.%26aulast%3DLacher%26aufirst%3DD.%2BA.%26aulast%3DShero%26aufirst%3DS.%2BT.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26atitle%3DTrends%2520in%2520lipids%2520and%2520lipoproteins%2520in%2520US%2520adults%252C%25201988%25E2%2580%25932010%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D1545%26epage%3D1554%26doi%3D10.1001%2Fjama.2012.13260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yunoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span> </span><span class="NLM_article-title">Postprandial hyperlipidemia as a potential residual risk factor</span> <span class="citation_source-journal">J. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1016/j.jjcc.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.jjcc.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26744235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A280%3ADC%252BC28rotlCnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=335-339&author=K.+Nakamuraauthor=T.+Miyoshiauthor=K.+Yunokiauthor=H.+Ito&title=Postprandial+hyperlipidemia+as+a+potential+residual+risk+factor&doi=10.1016%2Fj.jjcc.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Postprandial hyperlipidemia as a potential residual risk factor</span></div><div class="casAuthors">Nakamura Kazufumi; Miyoshi Toru; Ito Hiroshi; Yunoki Kei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Statin therapy targeting reduction of low-density lipoprotein cholesterol (LDL-C) decreases the risk of coronary heart disease (CHD) and all-cause mortality.  However, a substantial number of cases of CHD are not prevented and residual risk factors remain unsettled.  A high triglyceride (TG) level is considered to be an important and residual risk factor.  Postprandial hyperlipidemia is a condition in which TG-rich chylomicron remnants are increased during the postprandial period and hypertriglycedemia is protracted.  Postprandial hyperlipidemia evokes atherogenesis during the postprandial period.  Several prospective studies have revealed that nonfasting serum TG levels predict the incidence of CHD.  Values of TG, remnant lipoprotein cholesterol, and remnant lipoprotein TG after fat loading were significantly higher in diabetes patients with insulin resistance than in diabetes patients without insulin resistance.  Endothelial dysfunction is an initial process of atherogenesis and it contributes to the pathogenesis of CHD.  Postprandial hyperlipidemia (postprandial hypertriglyceridemia) is involved in the production of proinflammatory cytokines, recruitment of neutrophils, and generation of oxidative stress, resulting in endothelial dysfunction in healthy subjects, hypertriglyceridemic patients, or type 2 diabetic patients.  Effective treatment has not been established till date.  Ezetimibe or omega-3 fatty acids significantly decrease postprandial TG elevation and postprandial endothelial dysfunction.  Ezetimibe or omega-3 fatty acids added to statin therapy reduce serum TG levels and result in good outcomes in patients with CHD.  In conclusion, postprandial hyperlipidemia is an important and residual risk factor especially in patients with insulin resistance syndrome (metabolic syndrome) and diabetes mellitus.  Further studies are needed to establish effective treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRN_Yn6hKKU5f3jf77P2BG3fW6udTcc2ebTTCOqjBbEf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rotlCnug%253D%253D&md5=84590c36e8a97aba740ef3d5dd89a156</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jjcc.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jjcc.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DYunoki%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPostprandial%2520hyperlipidemia%2520as%2520a%2520potential%2520residual%2520risk%2520factor%26jtitle%3DJ.%2520Cardiol.%26date%3D2016%26volume%3D67%26spage%3D335%26epage%3D339%26doi%3D10.1016%2Fj.jjcc.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Wojczynski, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parnell, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollin, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feitosa, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier-Wood, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslibekyan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Province, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiwari, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordovas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuldiner, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnett, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borecki, I. B.</span><span> </span><span class="NLM_article-title">Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)</span> <span class="citation_source-journal">Metab., Clin. Exp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1371</span><span class="refDoi"> DOI: 10.1016/j.metabol.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2Fj.metabol.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=26256467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12rs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1359-1371&author=M.+K.+Wojczynskiauthor=L.+D.+Parnellauthor=T.+I.+Pollinauthor=C.+Q.+Laiauthor=M.+F.+Feitosaauthor=J.+R.+O%E2%80%99Connellauthor=A.+C.+Frazier-Woodauthor=Q.+Gibsonauthor=S.+Aslibekyanauthor=K.+A.+Ryanauthor=M.+A.+Provinceauthor=H.+K.+Tiwariauthor=J.+M.+Ordovasauthor=A.+R.+Shuldinerauthor=D.+K.+Arnettauthor=I.+B.+Borecki&title=Genome-wide+association+study+of+triglyceride+response+to+a+high-fat+meal+among+participants+of+the+NHLBI+Genetics+of+Lipid+Lowering+Drugs+and+Diet+Network+%28GOLDN%29&doi=10.1016%2Fj.metabol.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)</span></div><div class="casAuthors">Wojczynski, Mary K.; Parnell, Laurence D.; Pollin, Toni I.; Lai, Chao Q.; Feitosa, Mary F.; O'Connell, Jeff R.; Frazier-Wood, Alexis C.; Gibson, Quince; Aslibekyan, Stella; Ryan, Kathy A.; Province, Michael A.; Tiwari, Hemant K.; Ordovas, Jose M.; Shuldiner, Alan R.; Arnett, Donna K.; Borecki, Ingrid B.</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1359-1371</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The triglyceride (TG) response to a high-fat meal (postprandial lipemia, PPL) affects cardiovascular disease risk and is influenced by genes and environment.  Genes involved in lipid metab. have dominated genetic studies of PPL TG response.  We sought to elucidate common genetic variants through a genome-wide assocn. (GWA) study in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN).  The GOLDN GWAS discovery sample consisted of 872 participants within families of European ancestry.  Genotypes for 2,543,887 variants were measured or imputed from HapMap.  Replication of our top results was performed in the Heredity and Phenotype Intervention (HAPI) Heart Study (n = 843).  PPL TG response phenotypes were constructed from plasma TG measured at baseline (fasting, 0 h), 3.5 and 6 h after a high-fat meal, using a random coeff. regression model.  Assocn. analyses were adjusted for covariates and principal components, as necessary, in a linear mixed model using the kinship matrix; addnl. models further adjusted for fasting TG were also performed.  Meta-anal. of the discovery and replication studies (n = 1715) was performed on the top SNPs from GOLDN.  GOLDN revealed 111 suggestive (p < 1E-05) assocns., with two SNPs meeting GWA significance level (p < 5E-08).  Of the two significant SNPs, rs964184 demonstrated evidence of replication (p = 1.20E-03) in the HAPI Heart Study and in a joint anal., was GWA significant (p = 1.26E-09).  Rs964184 has been assocd. with fasting lipids (TG and HDL) and is near ZPR1 (formerly ZNF259), close to the APOA1/C3/A4/A5 cluster.  This assocn. was attenuated upon addnl. adjustment for fasting TG.  This is the first report of a genome-wide significant assocn. with replication for a novel phenotype, namely PPL TG response.  Future investigation into response phenotypes is warranted using pathway analyses, or newer genetic technologies such as metabolomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiwAZ-D6B3tLVg90H21EOLACvtfcHk0lintBktFYE8jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12rs77L&md5=e33e07aa6ea324c40530a54a4d0dee09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWojczynski%26aufirst%3DM.%2BK.%26aulast%3DParnell%26aufirst%3DL.%2BD.%26aulast%3DPollin%26aufirst%3DT.%2BI.%26aulast%3DLai%26aufirst%3DC.%2BQ.%26aulast%3DFeitosa%26aufirst%3DM.%2BF.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BR.%26aulast%3DFrazier-Wood%26aufirst%3DA.%2BC.%26aulast%3DGibson%26aufirst%3DQ.%26aulast%3DAslibekyan%26aufirst%3DS.%26aulast%3DRyan%26aufirst%3DK.%2BA.%26aulast%3DProvince%26aufirst%3DM.%2BA.%26aulast%3DTiwari%26aufirst%3DH.%2BK.%26aulast%3DOrdovas%26aufirst%3DJ.%2BM.%26aulast%3DShuldiner%26aufirst%3DA.%2BR.%26aulast%3DArnett%26aufirst%3DD.%2BK.%26aulast%3DBorecki%26aufirst%3DI.%2BB.%26atitle%3DGenome-wide%2520association%2520study%2520of%2520triglyceride%2520response%2520to%2520a%2520high-fat%2520meal%2520among%2520participants%2520of%2520the%2520NHLBI%2520Genetics%2520of%2520Lipid%2520Lowering%2520Drugs%2520and%2520Diet%2520Network%2520%2528GOLDN%2529%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2015%26volume%3D64%26spage%3D1359%26epage%3D1371%26doi%3D10.1016%2Fj.metabol.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Comins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamunyon, D. H.</span><span> </span><span class="NLM_article-title">Preparation of 1-(tert-butoxycarbonyl)-2,6-dialkyl-2,3-dihydro-4-pyridones – a stereocontrolled synthesis of (±)-myrtine</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">5053</span><span class="NLM_x">–</span> <span class="NLM_lpage">5056</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)93445-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1016%2FS0040-4039%2801%2993445-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1989&pages=5053-5056&author=D.+L.+Cominsauthor=D.+H.+Lamunyon&title=Preparation+of+1-%28tert-butoxycarbonyl%29-2%2C6-dialkyl-2%2C3-dihydro-4-pyridones+%E2%80%93+a+stereocontrolled+synthesis+of+%28%C2%B1%29-myrtine&doi=10.1016%2FS0040-4039%2801%2993445-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2993445-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252993445-8%26sid%3Dliteratum%253Aachs%26aulast%3DComins%26aufirst%3DD.%2BL.%26aulast%3DLamunyon%26aufirst%3DD.%2BH.%26atitle%3DPreparation%2520of%25201-%2528tert-butoxycarbonyl%2529-2%252C6-dialkyl-2%252C3-dihydro-4-pyridones%2520%25E2%2580%2593%2520a%2520stereocontrolled%2520synthesis%2520of%2520%2528%25C2%25B1%2529-myrtine%26jtitle%3DTetrahedron%2520Lett.%26date%3D1989%26volume%3D30%26spage%3D5053%26epage%3D5056%26doi%3D10.1016%2FS0040-4039%2801%2993445-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients</span>. ClinicalTrials.gov; <span class="NLM_series">NCT01487460</span>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://clinicaltrials.gov/ct2/show/NCT01487460?term=tap311&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01487460?term=tap311&rank=1</a> (accessed Sep 22, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C+Tolerability%2C+Pharmacokinetics+and+Pharmacodynamics+of+TAP311+in+Healthy+Subjects+and+Dyslipidemic+Patients.+ClinicalTrials.gov%3B+NCT01487460%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2011%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01487460%3Fterm%3Dtap311%26rank%3D1+%28accessed+Sep+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520TAP311%2520in%2520Healthy%2520Subjects%2520and%2520Dyslipidemic%2520Patients%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Stiefl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindvall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiegel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buenemann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanazawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polyakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tommasi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Drie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totrov, M.</span><span> </span><span class="NLM_article-title">FOCUS--Development of a global communication and modeling platform for applied and computational medicinal chemists</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span><span class="refDoi"> DOI: 10.1021/ci500598e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500598e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVShtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=896-908&author=N.+Stieflauthor=P.+Gedeckauthor=D.+Chinauthor=P.+Huntauthor=M.+Lindvallauthor=K.+Spiegelauthor=C.+Springerauthor=S.+Billerauthor=C.+Buenemannauthor=T.+Kanazawaauthor=M.+Katoauthor=R.+Lewisauthor=E.+Martinauthor=V.+Polyakovauthor=R.+Tommasiauthor=J.+van+Drieauthor=B.+Vashauthor=L.+Whiteheadauthor=Y.+Xuauthor=R.+Abagyanauthor=E.+Raushauthor=M.+Totrov&title=FOCUS%2D%2DDevelopment+of+a+global+communication+and+modeling+platform+for+applied+and+computational+medicinal+chemists&doi=10.1021%2Fci500598e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">FOCUS - Development of a Global Communication and Modeling Platform for Applied and Computational Medicinal Chemists</span></div><div class="casAuthors">Stiefl, Nikolaus; Gedeck, Peter; Chin, Donovan; Hunt, Peter; Lindvall, Mika; Spiegel, Katrin; Springer, Clayton; Biller, Scott; Buenemann, Christoph; Kanazawa, Takanori; Kato, Mitsunori; Lewis, Richard; Martin, Eric; Polyakov, Valery; Tommasi, Ruben; van Drie, John; Vash, Brian; Whitehead, Lewis; Xu, Yongjin; Abagyan, Ruben; Raush, Eugene; Totrov, Max</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">896-908</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Communication of data and ideas within a medicinal chem. project on a global as well as local level is a crucial aspect in the drug design cycle.  Over a time frame of eight years, we built and optimized FOCUS, a platform to produce, visualize, and share information on various aspects of a drug discovery project such as cheminformatics, data anal., structural information, and design.  FOCUS is tightly integrated with internal services that involve-among others-data retrieval systems and in-silico models and provides easy access to automated modeling procedures such as pharmacophore searches, R-group anal., and similarity searches.  In addn., an interactive 3D editor was developed to assist users in the generation and docking of close analogs of a known lead.  In this paper, we will specifically conc. on issues we faced during development, deployment, and maintenance of the software and how we continually adapted the software in order to improve usability.  We will provide usage examples to highlight the functionality as well as limitations of FOCUS at the various stages of the development process.  We aim to make the discussion as independent of the software platform as possible, so that our experiences can be of more general value to the drug discovery community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozGiXPjxVBHrVg90H21EOLACvtfcHk0lhBpxm_ZEo9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVShtr8%253D&md5=00541e43a6212701678a400e36996caf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fci500598e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500598e%26sid%3Dliteratum%253Aachs%26aulast%3DStiefl%26aufirst%3DN.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DChin%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DLindvall%26aufirst%3DM.%26aulast%3DSpiegel%26aufirst%3DK.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DBuenemann%26aufirst%3DC.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DE.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3Dvan%2BDrie%26aufirst%3DJ.%26aulast%3DVash%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DRaush%26aufirst%3DE.%26aulast%3DTotrov%26aufirst%3DM.%26atitle%3DFOCUS--Development%2520of%2520a%2520global%2520communication%2520and%2520modeling%2520platform%2520for%2520applied%2520and%2520computational%2520medicinal%2520chemists%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2015%26volume%3D55%26spage%3D896%26epage%3D908%26doi%3D10.1021%2Fci500598e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original pKa prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span><span class="refDoi"> DOI: 10.1021/ci700018y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields&doi=10.1021%2Fci700018y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0lhBpxm_ZEo9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181%26doi%3D10.1021%2Fci700018y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wasan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassidy, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strobel, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. Y.</span><span> </span><span class="NLM_article-title">A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1023/A:1011951602894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;key=10.1023%2FA%3A1011951602894" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=165-169&author=K.+M.+Wasanauthor=S.+M.+Cassidyauthor=M.+Ramaswamyauthor=A.+Kennedyauthor=F.+W.+Strobelauthor=S.+P.+Ngauthor=T.+Y.+Lee&title=A+comparison+of+step-gradient+and+sequential+density+ultracentrifugation+and+the+use+of+lipoprotein+deficient+plasma+controls+in+determining+the+plasma+lipoprotein+distribution+of+lipid-associated+nystatin+and+cyclosporine&doi=10.1023%2FA%3A1011951602894"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011951602894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011951602894%26sid%3Dliteratum%253Aachs%26aulast%3DWasan%26aufirst%3DK.%2BM.%26aulast%3DCassidy%26aufirst%3DS.%2BM.%26aulast%3DRamaswamy%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DStrobel%26aufirst%3DF.%2BW.%26aulast%3DNg%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DT.%2BY.%26atitle%3DA%2520comparison%2520of%2520step-gradient%2520and%2520sequential%2520density%2520ultracentrifugation%2520and%2520the%2520use%2520of%2520lipoprotein%2520deficient%2520plasma%2520controls%2520in%2520determining%2520the%2520plasma%2520lipoprotein%2520distribution%2520of%2520lipid-associated%2520nystatin%2520and%2520cyclosporine%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D165%26epage%3D169%26doi%3D10.1023%2FA%3A1011951602894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i57"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00900">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_58576"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00900">10.1021/acs.jmedchem.7b00900</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Aldosterone and pressor effects of torcetrapib, anacetrapib, and compound <b>16</b>; single compound X-ray crystallography for the confirmation of relative stereochemistry of compound <b>16</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00900/suppl_file/jm7b00900_si_001.pdf">jm7b00900_si_001.pdf (495.35 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00900&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-20%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00900%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00900" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bf588f9d24c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
